Follow us on Twitter
twitter icon@FreshPatents


Diabetes patents

      

This page is updated frequently with new Diabetes-related patent applications.

new patent Location-based wireless diabetes management systems, methods and apparatus
embodiments provide systems, methods and apparatus for diabetes management using location-based reminders. Embodiments include requesting a user select a diabetes management related task to be reminded to perform; requesting the user select a location at which the user is to be reminded to perform the selected diabetes management related task; monitoring the user's location; detecting the user has entered the selected location; triggering the reminder in response to detecting the user has entered the selected location; and presenting the reminder to the user.
Ascensia Diabetes Care Holdings Ag


new patent System for improving diabetes testing and reducing counterfeiting
a diabetes test system for measuring blood glucose levels is provided, which includes a glucose meter, at least one diabetic test strip, and a container or pouch for storing the diabetes test strips and protecting them during transport. Methods of packaging diabetes test strips are also provided.

new patent Methods for treating diabetes
methods for treating diabetes by administering an inhibitor of gdf-8, or a related member of transforming growth factor-beta (tgf-β) superfamily of structurally-related growth factors (e.g., gdf-11) are disclosed. Also disclosed are methods for upregulating expression of hexose transporters, such as glut4 and glut 1, in a subject by administering an inhibitor of gdf-8.
Scidera, Inc.


new patent Inhibition of gliadin peptides
novel compounds and methods for the inhibition of biological barrier permeability and for the inhibition of peptide translocation across biological barriers are identified. Assays for determining modulators of biological barrier permeability and for peptide translocation across biological barriers are provided.
Alba Therapeutics Corporation


new patent Ethynyl derivatives
the present invention relates to positive allosteric modulators (pams) of metabotropic glutamate receptor 4 (mglur4) that may be used for the treatment of conditions such as parkinson's disease, anxiety, emesis, obsessive compulsive disorder, autism, neuroprotection, cancer, depression and diabetes type 2.. .
Hoffmann-la Roche Inc.


new patent Compositions and methods for treating diabetes, hypertension and hypercholesterolemia
the present invention provides a composition comprising a therapeutically effective amount of a polypeptide, peptide, or analog corresponding to one or more of seq id no(s) 1, 2, 3 or 4, and or more of a pharmaceutically acceptable carrier, pharmaceutically acceptable diluent, and/or pharmaceutically acceptable excipient. The polypeptide therapeutic of the present invention may be formulated for administration to a subject in need of treatment as an oral formulation, a parenteral formulation, a topical formulation, an aqueous formulation, a solid formulation, a lyophilized formulation, or a trans-dermal formulation.
Imagine Pharma


new patent Enrichment methods for preparing tannic acid compositions
methods for preparing tannic acid-containing compositions (e.g., pharmaceutical compositions, nutraceutical compositions or medical food compositions), particularly those having enriched tannic acid populations with superior potency, purity and safety profile. Also provide herein are the tannic acid-containing compositions for use in inhibiting d-amino acid oxidase and/or for treating cns disorder and obesity disorders including diabetes, hyperglycemia, hyperlipidemia or hypercholesterolemia..
Syneurx International (taiwan) Corp.


new patent Monoacylglycerols and fat-soluble nutrients for use in the treatment of nutrient deficiency from maldigestion
compositions comprising monoacylglycerols (mag), such as sn-1(3) mag, and further comprising fat-soluble nutrients such as fat-soluble vitamins and carotenoids, are administered to an individual having or at risk of a nutrient deficiency induced by maldigestion, such as maldigestion associated with chronic pancreatitis, cystic fibrosis, diabetes, pancreatic duct obstruction, a pancreatic tumor, or shwachman-diamondsyndrome (sds). The compositions and the methods of using the compositions enhance absorption of fatty acids and the fat-soluble nutrients to address nutritional deficiencies due to maldigestion..
Nestec S.a.


Blood glucose management device for calculating bolus insulin
a method of operating a glucose management device. The glucose management device includes one or more processing components, a housing, a user interface including a display and a user-input mechanism, and a memory.
Ascensia Diabetes Care Holdings Ag


A predicting the risk of incidence of chronic kidney diseases
the present invention relates to means and methods suitable for risk prediction of chronic kidney disease (ckd) using pro-enkephalin or fragments thereof as biomarker. The risk prediction methods of the invention are intended for healthy subjects and for subjects suffering from diseases such as hypertension, cardiovascular diseases and events, diabetes, metabolic syndrome, obesity, or autoimmune diseases.
Sphingotec Gmbh


Method for the prognosis and/or diagnosis of an illness based on a sample of adipose tissue, and a kit for said method

the invention relates to a method for the prognosis of adiposity and the prognosis and/or diagnosis of a disease selected from the group consisting of diabetes, cardiovascular diseases and metabolic syndrome.. .
Lipozyt Marker Ug

Cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide y receptors

z4, z7, z9, z11, z22, z23, z26, z30, z34, z35, p, m, n, q, and bridge are defined in the specification. The invention also relates to pharmaceutical compositions and methods for use thereof.

Novel cholesterol metabolite, 5-cholesten, 3beta-25-diol, disulfate (25hcds) for therapy of metabolic disorders, hyperlipidemia, diabetes, fatty livers diseases and atherosclerosis

5-cholesten, 3β,25-diol, disulfate (25hcds) has been found to be an authentic pparγ agonist and lxr antagonist, and is used for the therapy of lipid disorders and inflammatory diseases, including without limitation fatty liver, inflammatory bowel, and atherosclerotic diseases.. .
Virginia Commonwealth University

Epoxyazulene derivatives useful for treating cancer and diabetes

disclosed is a compound of formula (i) in which r1-r5 and x1 are as described herein. Also provided are methods of using a compound of formula (i), including a method of treating cancer and a method of treating diabetes..
Universitat Rovira I Virgili

Ethynyl derivatives

the compounds may be used for the treatment of parkinson's disease, anxiety, emesis, obsessive compulsive disorder, autism, neuroprotection, cancer, depression and diabetes type 2.. .

Eckol derivatives, methods of synthesis and uses thereof

provided herein are eckol derivatives, methods of synthesis thereof and pharmaceutical compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, alzheimer's disease, microbial infections, obesity, diabetes, cancer or inflammation using the compounds and pharmaceutical compositions disclosed herein..
Phloronol, Inc.

Novel compounds for treating diabetes

the present invention provides a class of novel aryl pseudo-c-glycoside compounds that are effective for treating diabetes. Also provided are methods for making such compounds and methods for treating diabetes by administering such compounds to patients who have been diagnosed with diabetes or are at risk of developing diabetes..
The Chinese University Of Hong Kong

Treating diabetes melitus using insulin injections administered with varying injection intervals

the present invention relates to methods for treatment of a condition or disease where administration of insulin will be of benefit, comprising administering, to a patient in need thereof, effective dosages of an insulin, insulin analogue or derivative thereof, which exhibits a prolonged profile of action, wherein said dosages are administered at intervals of varying length.. .
Novo Nordisk A/s

Insulin independence among patients with diabetes utilizing an optimized hamster reg3 gamma peptide

embodiments of the present invention provide for novel therapies, pharmaceutical compositions and methods for insulin independence utilizing a new optimized hamster reg3 gamma peptide, which is new to the art and has not previously been considered for development in the 30 year history since its discovery. Methods, pharmaceutical compositions and therapies novel to the prior art are utilized in this invention to render patients with recent onset and existing type 1 diabetes insulin independent by an optimized hamster reg3 gamma peptide and an immune tolerance agent for type 1 patients to become insulin independent and used alone without an immune tolerance agent for type 2 diabetes.

Probiotic compositions for improving metabolism and immunity

the application relates to methods based on modulating mammalian intestinal microbiota and related probiotic and prebiotic compositions. Specifically, the application relates to the use of novel bacterial genera ileibacterium and dubosiella, including their species i.
New York University

Compositions, methods of treatment and diagnostics for treatment of hepatic steatosis alone or in combination with a hepatitis c virus infection

the present invention is directed to pharmaceutical compositions and methods of treatment that relate to the inhibition, resolution and/or prevention of an array of the manifestations of metabolic syndromes, including type 2 diabetes, hyperlipidemia, weight gain, obesity, insulin resistance, hypertension, atherosclerosis, fatty liver diseases and certain chronic inflammatory states that lead to these manifestations, among others. In additional aspects, the present invention relates to compositions and methods which may be used to treat, inhibit or reduce the likelihood of hepatitis viral infections, including hepatitis b and hepatitis c viral infections, as well as the secondary disease states and/or conditions which are often associated with such viral infections, including hepatic steatosis (steatohepatitis), cirrhosis, fatty liver and hepatocellular cancer, among other disease states or conditions..
Volant Holdings Gmbh

Methods and formulations for modulating lyn kinase activity and treating related disorders

the present invention relates to compounds and pharmaceutically acceptable salts thereof and formulations comprising the compounds or a pharmaceutically acceptable salts thereof that are useful in modulating lyn kinase activity. In particular, the compounds or a pharmaceutically acceptable salts thereof are useful for treating or preventing a disease or disorder including cardiovascular disease, dyslipidemia, dyslipoproteinemia, a disorder of glucose metabolism, metabolic syndrome (i.e., syndrome x), a peroxisome proliferator activated receptor-associated disorder, septicemia, a thrombotic disorder, type ii diabetes, obesity, pancreatitis, hypertension, renal disease, inflammation, or impotence..
Melior Pharmaceuticals I, Inc.

Nitrated-fatty acids modulation of type ii diabetes

nitro oleic acid and related metabolites are agonists of ppar-γ. Surprisingly, nitro oleic acid is a more potent agonist of ppar-γ, relative to nitro linoleic acid.
University Of Pittsburgh - Of The Commonwealth System Of Higher Education

Induced expression of brain derived neurotrophic factor (bdnf) for treatment of neuromuscular, neurodegenerative, autoimmune, developmental and/or metabolic diseases

a method of treating a host of neuromuscular, neurodegenerative, developmental, autoimmune and metabolic diseases/disorders related to aging, such as traumatic injury, stroke, huntington's disease, epilepsy, multiple sclerosis (ms), lupus, type-1 and type-2 diabetes, maturity onset diabetes of the young (mody), myasthenia gravis (mg), rheumatoid arthritis (ra), graves' disease, guillain-barré syndrome (gb s), metabolic syndrome, muscular dystrophy or duchenne muscular dystrophy (dmd), severe burns, aging, amyotrophic lateral sclerosis (als), friedreich's ataxia, batten disease, alzheimer's disease, optic neuritis, leber's hereditary optic neuropathy (lhon), autism, rett syndrome, batten disease, angelman's syndrome, leigh disease, fragile-x syndrome, depression, parkinson's disease, mitochondrial diseases, developmental disorders, metabolic disease disorders and/or autoimmune disorders by inducing endogenous bdnf expression with dnp treatment to protect from neuromuscular dysfunction/disorders and/or neurodegeneration and/or muscle wasting. Dnp was administered to mice daily over a range of doses, and subsequently bdnf expression in the brain showed a dose dependent and non-linear increase in expression..
Mitochon Pharmaceuticals, Inc.

Gdanski Uniwersytet Medyczny

. .

Diabetes management therapy advisor

a method includes obtaining training data for a plurality of patients of a patient population. The training data includes training blood glucose history data including treatment doses of insulin administered by the patients of the patient population and one or more outcome attributes associated with each treatment dose.
Aseko, Inc.

Compositions and methods for diagnosing and treating autoimmune diseases

disclosed are compositions and methods for detecting, isolating, and/or characterizing a t cell or autoantibody associated with type i diabetes. The composition and methods comprise the use of a hybrid insulin peptide having an n-terminal amino acid sequence taken from the human insulin peptide and a c-terminal amino acid sequence taken from a secretory granule protein that are joined through a peptide bond to form an autoimmune antigen.
The Regents Of The University Of Colorado, A Body Corporate

Melanocortin receptor ligands modified with hydantoin

the present invention relates to peptide ligands of the melanocortin receptors, in particular the melancortin-4 receptor, and as such, are useful in the treatment of disorders responsive to the activation of this receptor, such as obesity, diabetes mellitus and sexual dysfunction.. .
Ipsen Pharma S.a.s.

Peptide with anti-obesity and anti-diabetes activity and use thereof

a peptide and a peptide complex of the present invention exhibit an anti-obesity effect by inhibiting fat accumulation and decomposing already accumulated fat, and exhibit an excellent effect with respect to diabetes by effectively reducing blood sugar. The peptide and the peptide complex of the present invention decrease the expression of pparγ, acc, and ap2, which are adipogenic markers, increase the expression of phsl, ampk-α1, cgi-58, and atgl, which are lipolytic factors, and reduce the size of fat cells and blood cholesterol values.
Caregen Co., Ltd.

Sk and ik channel agonists for treatment of heart failure

the present invention provides compounds that are improved potassium channel agonists. Pharmaceutical compositions including a pharmaceutically acceptable carrier and a compound of the present invention are also provided.
The Trustees Of Columbia University In The City Of New York

System for managing glucose levels in patients with diabetes or hyperglycemia

a blood glucose maintenance system for use by hyperglycemic individuals measures their blood glucose level and calculates an appropriate glucose or insulin dosage based on the measurement. Recheck intervals responsive to dosage history are determined.
Indiana University Health, Inc.

Porous silicon microparticle-based cancer vaccines and methods for potentiating anti-tumor immunity

porous silicon (psi) microparticles (psm) are disclosed, which provide an important advance in the area of cancer immunotherapeutics and molecular nanomedicine. In particular, potent psm-based adjuvants are disclosed for dendritic cell-based vaccines compositions, and methods for their use in a variety of cancer immunotherapies.
The Methodist Hospital

Therapeutic vaccine for treatment of diabetes type 1 in children, application of the cell sorter and the multiplying treg cells to produce therapeutic vaccine for treatment of diabetes type 1

treg cells cd3(+)cd4(+)cd25(high)cd127(−). Claimed too is the cell sorter used to produce the vaccine and the method of multiplying treg cells in vitro..

Tolerogenic dna vaccine

the present invention relates to plasmids useful for prevention and/or delay of e.g. Type 1 diabetes..
Novo Nordisk A/s

Insulin mimotopes and methods of using the same

methods for inhibiting an autoimmune disease by administering to a subject a therapeutically effective amount of a composition that induces conversion of naive t cells into foxp3+ regulatory t cells to induce immunosuppression in the subject. Methods for detecting in a subject an autoimmune disease or a predisposition to an autoimmune disease, and methods for assessing the efficacy of a therapy for an autoimmune disease, particularly type 1 diabetes..
National Jewish Health

Pharmaceutical compositions for combination therapy

the present application relates to a pharmaceutical composition comprising a combination of an fxr agonist and at least one additional therapeutic agent that lowers the glucose level in the blood, stimulates insulin secretion, and/or increases insulin sensitivity. The present application relates to use of the pharmaceutical composition for the treatment or prevention of a fxr mediated disease or condition, such as nafld and nash, a disease or condition related to an elevated level of glucose in the blood, decreased secretion of insulin, and/or decreased insulin sensitivity such as hyperglycemia, diabetes, obesity, and insulin resistance, or for lowering the glucose level in the blood, stimulating insulin secretion, and/or increasing insulin sensitivity..
Intercept Pharmaceuticals, Inc.

Combination therapy using enantiopure, oxy-substituted, deuterium-enriched 5-(benzyl)-5-deutero-thiazolidine-2,4-diones for treatment of medical disorders

the invention provides combination therapy using enantiopure deuterium-enriched pioglitazone, pharmaceutical compositions, and methods of treating nonalcoholic steatohepatitis, diabetes, fibrotic disorders, and other disorders using the combination therapy.. .
Deuterx, Llc

Modulators of farnesoid x receptor and methods for the use thereof

compounds, compositions and methods are provided for treating the fxr-mediated disease or process in a mammal, comprising administering to the mammal a therapeutically effective amount of a compound claimed, wherein the fxr-mediated disease or condition linked to chronic liver diseases such as nonalcoholic fatty liver disease and nonalcoholic steatohepatitis; gastrointestinal diseases; cardiovascular diseases; metabolic diseases such as diabetes and obesity; inflammation, or cancer etc.. .
Xiamen University

Methods of preventing and treating autoimmunity

methods of preventing, treating or ameliorating autoimmune diabetes by modulating the binding of mhc class ii molecules to antigenic peptides or fragments of antigenic peptides of the autoimmune disease by the administration of methyldopa. Pharmaceutical compositions containing therapeutically effective amounts of methyldopa in extended release formulations and methods of using the same are also provided..
The University Of Florida Research Foundation Incorporated

Computer-based diabetes management

a computer-based method includes receiving, from a computer-based user interface, user-specified information about one or more events influential on the user's blood glucose level, generating, with a computer-based processor, a plurality of estimated trajectories of the user's blood glucose level as influenced by the one or more events, receiving a set of data that represents actual blood glucose measurements for the user, and identifying, with the computer-based processor, which of the estimated trajectories represents a best fit to the set of data that represents the actual blood glucose measurements for the user. At least some of the actual blood glucose measurements occurred later in time than a start time of the one or more events influential on the user's blood glucose level.
Bigfoot Biomedical, Inc

Neural stem cell therapy for obesity and diabetes

methods are provided of treating obesity or an obesity comorbidity in a mammalian subject comprising administering to the subject an amount of an agent effective to treat obesity or the obesity comorbidity, which agent inhibits (i) iκb kinase (ikkβ) activation of nuclear factor kappa-light-chain-enhancer of activated b cells (nf-κb) or (ii) notch signaling, in a manner so as to permit the agent to enter the hypothalamus of the subject. Assays are also provided for identifying candidate agents for treating obesity’..
Albert Einstein College Of Medicine, Inc.

Analogs of glucagon exhibiting gip receptor activity

provided herein are glucagon analogs which exhibit potent activity at the gip receptor, and, as such are contemplated for use in treating diabetes and obesity. In exemplary embodiments, the glucagon analog of the present disclosures exhibit an ec50 at the gip receptor which is within the nanomolar or picomolar range..
Hoffmann-la Roche Inc.

Peptide analogs for treating diseases and disorders

provided herein are methods for the treatment of type i diabetes, type ii diabetes, metabolic syndrome, or obesity, or of appetite suppression, or for mitigating insulin resistance, or for reducing an undesirably high fasting serum glucose level, or for reducing an undesirably high peak serum glucose level, or for reducing an undesirably high peak serum insulin level, or for reducing an undesirably large response to a glucose tolerance test in synergistic combination with metformin. A peptide selected from sequences seq id no: 12, seq id no: 15 and seq id no: 17 are administered..
Keybioscience Ag

Novel cyclosporin derivatives and uses thereof

or pharmaceutically acceptable salt thereof, wherein the symbols are as defined in the specification; a pharmaceutical composition comprising the same, a method for treating or preventing viral infections, inflammation, dry eye, central nervous disorders, cardiovascular diseases, cancer, obesity, diabetes, muscular dystrophy, and hair loss.. .

Methods and compositions for inhibiting the interaction of menin with mll proteins

the present disclosure provides compositions and methods of use to inhibit the interaction of menin with mll1, mll2 and mll-fusion oncoproteins. The compositions and methods of use are useful for the treatment of leukemia, solid cancers, diabetes and other diseases dependent on activity of mll1, mll2, mll fusion proteins, and/or menin..
The Regents Of The University Of Michigan

Method and system for management of diabetes with a glucose monitor and infusion pump to provide feedback on bolus dosing

described and illustrated is a system for management of diabetes that includes an infusion pump, glucose sensor and controller with a method programmed into the controller. The infusion pump is configured to deliver insulin to a subject.
Lifescan, Inc.

Method and pharmaceutical composition for use in the treatment of diabetes

the present invention relates to an apj receptor agonist for use in the treatment or the prevention of diabetes.. .
Centre Hospitalier Universitaire De Toulouse

Zanthoxylum myriacanthum var. pubescens essential oil and application thereof in preparation of drug for treating diabetes

the invention relates to a pneumatic brake release apparatus used on an elevator traction machine. By means of the technical solution, the air films in the air cabin are pushed by using compressed air to drive the push rod to transfer a thrust force, so that the locking arms are unfolded, and the locking brake and the brake release are implemented in a pneumatic way.
Affiliated Xishuangbanna Tropical Botanical Garden Chines

Methods and pharmaceutical compositions comprising a sglt2 inhibitor for treating or improving erectile dysfunction

the invention relates to methods for improving glycemic control and for treating erectile dysfunction in a patient diagnosed with prediabetes, type 1 diabetes mellitus, type 2 diabetes mellitus or metabolic syndrome wherein a sglt2 inhibitor is administered to the patient. Furthermore the invention relates to a method for improving a treatment of erectile dysfunction in a male patient diagnosed with prediabetes, type 1 diabetes mellitus or type 2 diabetes mellitus characterized in that in addition to the treatment of erectile dysfunction a sglt2 inhibitor is administered to the patient.
Boehringer Ingelheim International Gmbh

Protein restriction for diabetes

treating a subject with at least one of diabetes, hyperinsulinemia, or glucose intolerance, can include: during a first low-protein time period of at least 4 consecutive days, administering nutrient material to the subject such that the subject has a bodily intake of protein of less than 20 grams per day and a bodily intake of carbohydrate of at least 40 percent of the subject's bodily intake of energy; and during a first normal-protein time period of at least 4 consecutive days that is after the low-protein period, administering to the subject a normal daily bodily intake of protein of at least 40 grams.. .

Btg International Limited

. .

Prodrug of 1,1'-(1,6-dioxo-1,6-hexanediyl)bis-d-proline

the present invention relates to the compound (2r,2′r)-bis(((((tetrahydro-2h-pyran-4-yl)oxy)carbonyl)oxy)methyl) 1,1′-adipoylbis(pyrrolidine-2-carboxylate), pharmaceutical compositions comprising the same and the use of the same for treatment of diseases or disorders wherein depletion of serum amyloid p component (sap) would be beneficial, including amyloidosis, alzheimer's disease, type 2 diabetes mellitus and osteoarthritis.. .
Glaxosmithkline Intellectual Property Development Limited

Diabetes treatment

methods and compositions for treating a patient who has recently developed diabetes are provided. The methods can include administering a tolerance-restoring agent to the patient and simultaneously administering intensive insulin therapy..
Beth Israel Deaconess Medical Center

Diagnostics and methods for treatment of non-alcoholic hepatic steatosis and hepatic steatohepatitis, and prevention of complications thereof

the present invention is directed to a system characterization of nash that combines modeling and biomarkers, enabling pharmaceutical compositions and methods of treatment that relate to the inhibition, resolution and/or prevention of non alcoholic fatty liver disease (nafld) and non alcoholic steatohepatitis (nash). Said conditions are liver related complications among the array of manifestations of metabolic syndromes, including type 2 diabetes, hyperlipidemia, weight gain, abdominal obesity, insulin resistance, hypertension, atherosclerosis, fatty liver diseases and certain chronic inflammatory states that lead to these manifestations, among others.
Volant Holdings Gmbh

Methods, tools and systems for the assessment, prevention, management and treatment selection for type 2 diabetes

the present invention provides a method of assessing type 2 diabetes susceptibility and/or predicting treatment responsiveness in a human subject, the method comprising determining the identity of at least one allele at each of three or more positions of single nucleotide polymorphism (snp) selected from the group consisting of: slc16a11—rs75493593; hnf1a—rs483353044; tcf7l2—rs7903146; cdkn2a/b—rs10811661; cdkal1—rs7756992; slc30a8—rs3802177; igf2bp2—rs4402960; fto—rs9936385; pparg—rs1801282; hhex/ide—rs1111875; adcy5—rs11717195; jazf1—rs849135; wsf1—rs4458523; ins—igf2—rs149483638; kcnq1—rs2237897; and kcnj11—rs5219, and/or an snp in linkage disequilibrium with any one of said snps at r2>0.8. Also provided are a genotyping tool and a type 2 diabetes risk assessment system for use in the method of the invention..
Patia Biopharmia, S.a. De C.v.

Acylated glucagon analogue

the invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel acylated glucagon analogue peptides effective in such methods.
Boehringer Ingelheim International Gmbh

Dipeptidyl peptidase-iv (dppiv), inhibitory peptide compound, composition containing the same, and production the same

a peptide compound having a dipeptidyl peptidase-iv (dppiv) inhibitory activity or a composition containing the peptide compound that can make a contribution to the prevention of the onset of pathology or the progression in diabetes mellitus patients or those at risk of diabetes mellitus can be provided according to the present invention by a simple method using, as a raw material, milt of a fishery product, which has been eaten for ages and has high safety. In the present invention, a peptide compound having a peptidyl peptidase-iv (dppiv) inhibitory activity obtained in a hydrolysate of a milt protein source obtained from a fishery product is used as an active component of a composition for inhibiting dppiv..
Maruha Nichiro Corporation

2-acylaminopropoanol-type glucosylceramide synthase inhibitors

or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by structural formula (i) or a pharmaceutically acceptable salt thereof.

Compositions and methods for treatment of insulin-dependent diabetes mellitus

this invention provides methods of treating insulin-dependent diabetes mellitus in a subject comprising administering to the subject a self-vector encoding human proinsulin. The invention also provides a pharmaceutical composition comprising a self-vector encoding human proinsulin, as well as treatment and maintenance regimens for administering the pharmaceutical composition to a subject..
Bayhill Therapeutics, Inc.

Treatment type 2 diabetes mellitus patients

a pharmaceutical combination for use in glycemic control in a type 2 diabetes mellitus patient, said combination comprising (i) lixisenatide or/and a pharmaceutically acceptable salt thereof, (ii) insulin glargine or/and a pharmaceutically acceptable salt thereof, and (iii) optionally metformin or/and a pharmaceutically acceptable salt thereof.. .
Sanofi-aventis Deutschland Gmbh

Use of human small leucine zipper protein in adipocyte differentiation procedure

the present invention relates to a use of a human small leucine zipper protein in the adipocyte differentiation procedure. More specifically, slzip binds with pparγ2 to induce the formation of a complex of hdac3 and pparγ2, thereby functioning as a corepressor to negatively inhibit the transcriptional activity of pparγ2 and suppress the differentiation to adipocytes, and thus can be used as a marker for treating diabetes and obesity and developing new medicines therefor..
Korea University Research And Business Foundation

Compositions containing tannic acids and uses thereof

compositions (e.g., pharmaceutical compositions, nutraceutical compositions or medical food compositions) comprising tannic acids, particularly tannic acids which are d-amino acid oxidase inhibitor with superior potency, purity and safety profile; and uses thereof for treating cns disorder and obesity disorders including diabetes, hyperglycemia, hyperlipidemia or hypercholesterolemia.. .
Syneurx International (taiwan) Corp.

Novel methods of use of tetrahydroberberine (thb)

tetrahydroberberine (thb), isolated from the chinese herb “corydalis ambigua”, exhibits a variety of pharmacological effects, although mechanisms of action are unclear or entirely unknown. Described herein are novel methods of using tetrahydroberberine (thb), thb analogs or derivatives, tetrahydroprotoberberines (thpb).
Dignity Health

Treating or preventing nephrogenic diabetes insipidus

in certain embodiments, the disclosure relates to methods of treating or preventing nephrogenic diabetes insipidus comprising administering an effective amount of a ampk activator to a subject in need thereof, wherein in certain embodiments, the ampk activator is metformin or salt thereof. In certain embodiments, the subject has been diagnosed with nephrogenic diabetes insipidus..
Emory University

Capsules with intracapsular microspheres for improved survival and function of encapsulated cells

provided is a microcapsule for increasing the survival and/or function of a cell, such as an islet cell, microcapsule can include an outer shell comprising a first polymer; an interior core comprising: at least one live cell; a second polymer; and at least one microsphere comprising a third polymer and a compound capable of improving survival of the at least one cell. The improved survival and/or function of the at least one live cell in the microcapsule is compared to a live cell in a microcapsule in the absence of the compound capable of improving survival of the at least one cell.
The Board Of Trustees Of The University Of Illinois

Anti-cxcr3 antibodies and methods of use thereof

the present disclosure provides anti-cxcr3 antibodies and methods of using the antibodies to diagnose and/or treat cxcr3-associated disorders such as diabetes mellitus type i (t1d), particularly new-onset t1d. In certain embodiments, disclosed herein are cxcr3 neutralizing antibodies..
Genzyme Corporation

Substituted 3-haloallylamine inhibitors of ssao and uses thereof

the invention also relates to methods of using compounds of formula i, or pharmaceutically acceptable salt or derivatives thereof, for the treatment of a variety of indications, e.g., inflammatory diseases, ocular diseases, fibrotic diseases, diabetes-induced diseases and cancer.. .

Use of long-acting glp-1 peptides

the invention relates to use of long-acting glp-1 peptides in certain dosage regimes for the treatment of type 2 diabetes, obesity, etc.. .
Novo Nordisk A/s

Use of tetraspanin-2 for treating diabetes and screening an anti-diabetic agent

there is provided a method for treating diabetes, the method comprising administering to a subject in need thereof an effective amount of a tetraspanin-2 (tspan2) protein expression or activity inhibitor. Further, there is provided a method for screening a diabetes therapeutic agent, the method comprising: (a) bringing a test material into contact with a cell expressing tspan2 gene; (b) determining the expression level of the tspan2 gene in the cell of (a) and in a control cell which is not in contact with the test material; and (c) selecting, as a diabetes therapeutic agent candidate, the test material reducing the expression level of the tspan2 gene in comparison with the control cell..
Korea Basic Science Institute

Methods for treating ocular diseases

the present invention is related to a method for treating an ocular disease, particularly a diabetes related ocular disease, comprising administering to a subject in need thereof an effective amount of a group of compounds having a structure of formula a1, wherein the ocular disease is selected from the group consisting of proliferative vitreoretinopathy (pvr), uveitis, glaucoma and age related macular degeneration (amd), and the diabetes related ocular disease is selected from the group consisting of diabetic retinopathy (dr) and diabetic macular edema (dme).. .
Springsky Biomed Company Limited

Sab as a biomarker for degenerative diseases and therapeutic sensitivity in cancers

the current invention pertains to a method of diagnosing a disease or identifying an increased likelihood of developing the disease in a subject. The method comprises determining the level of src homology 3 domain binding protein 5 (sh3bp5 or sab) or the rna encoding sab protein in a biological sample obtained from the subject and identifying the subject as having the disease or having an increased likelihood of developing the disease if the biological sample obtained from the subject has an altered level of sab protein or the rna encoding sab protein relative to a control sample.
The Florida International University Board Of Trustees

Method for decreasing the body fat content in a subject by administering an actriib protein

in certain aspects, the present invention provides compositions and methods for modulating (promoting or inhibiting) growth of a tissue, such as bone, cartilage, muscle, fat, brown fat and/or neuronal tissue and for treating metabolic disorders such as diabetes and obesity, as well as disorders associated with any of the foregoing tissue.. .
Acceleron Pharma Inc.

Growth differentiation factor 15 (gdf-15) constructs

constructs comprising gdf15, and mutants thereof are provided. In various embodiments the constructs comprising gdf15, and mutants thereof, can be of use in the treatment or ameliorating a metabolic disorder.
Amgen Inc.

. .

Treatment of diabetes using agonists of the mas-related gpcr d

methods of identifying agonists of mrgd for treating prediabetes, type-2 diabetes and cardiovascular diseases or disorders. Methods of treating prediabetes, type-2 diabetes and cardiovascular diseases or disorders comprising administering to a subject an agonist of mrgd..

Heteroaryl compounds and methods of use thereof

provided herein are heteroaryl compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. In one embodiment, the compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as cns disorders and metabolic disorders, including, but not limited to, e.g., neurological disorders, psychosis, schizophrenia, obesity, and diabetes..
Sunovion Pharmaceuticals Inc.

Therapeutic compounds

the invention provides compounds formula (i) and salts thereof: wherein the bond represented by ---- is a single bond or a double bond, and r1 has any of the values defined in the specification. The compounds are useful for treating conditions including alzheimer's disease, parkinson's disease, diabetes, cancer, and psychotic disorders such as schizophrenia..
Arizona Board Of Regents On Behalf Of Arizona State University

Fused heterocyclic compound

the present invention relates to a condensed heterocyclic compound that has an enteropeptidase inhibitory effect, and use of the compound as a medicament for the treatment or prevention of obesity, diabetes mellitus, or the like. Specifically, the present invention relates to a compound represented by the formula (i) or a salt thereof, and use of the compound as a medicament for the treatment or prevention of obesity, diabetes mellitus, or the like [in the formula, each symbol is as defined in the specification]..
Takeda Pharmaceutical Company Limited

Inhibitors of histone deacetylase

or a pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, wherein x1, x2, x3, x4, x5, w1, w2, w3, and w4 are as described herein. The present invention relates generally to inhibitors of histone deacetylase and to methods of making and using them.

Tolerogenic nanoparticles for treating diabetes mellitus

methods and compositions for increasing the number and/or activity of regulatory t cells (tregs) in vivo and in vitro, to induce tolerance to diabetogenic autoantigens.. .
The Brigham And Women`s Hospital, Inc.

Amylin analogues

the present invention relates to amylin analogues and to their use in the treatment or prevention of a variety of diseases, conditions or disorders, including obesity, excess food intake and associated metabolic diseases such as diabetes. The analogues have good physical and chemical stability, good solubility, and a long duration of action, and are well suited for use in the form of a liquid formulation..
Boehringer Ingelheim International Gmbh

Composition and preparation and uses thereof for preventing and treating diabetes

disclosed is a composition for use in the prevention, treatment, and management of diabetes in human and animal subjects that contains 2,3,5,4-tetrahydroxystilbene 2-o-b-glucopyranoside collected from one or more plants selected from the group consisting of fallopia genera of plants.. .

Carbazole-containing sulfonamides as cryptochrome modulators

the subject matter herein is directed to carbazole-containing sulfonamide derivatives and pharmaceutically acceptable salts or hydrates thereof of structural formula i wherein the variable r1, r2, r3, r4, r5, r6, r7, a, b, c′, d, e, f, g, h′, a, and b are accordingly described. Also provided are pharmaceutical compositions comprising the compounds of formula i to treat a cry-mediated disease or disorder, such as diabetes, obesity, metabolic syndrome, cushing's syndrome, and glaucoma..
Reset Therapeutics, Inc.

Methods and compositions for treating degenerative and ischemic disorders

model systems have shown that shifting a cell's reliance from oxidative phosphorylation (oxphos) to glycolysis can protect against cell death. Exploiting the therapeutic potential of this strategy, however, has been limited by the lack of clinically safe agents that remodel energy metabolism.
The General Hospital Corporation

Amelioration of neural deficits associated with diabetes

methods for treating non-systemic deficiencies associated with diabetes using 2-amino substituted nicotinamides or their pharmaceutically acceptable salts.. .
Neuralstem, Inc.

Tesofensine, beta blocker combination formulation

the present invention relates to a controlled release formulation comprising the active compounds tesofensine and a beta blocker, such as metoprolol or carvedilol, or a pharmaceutically acceptable salt thereof. The invention further relates to use of the controlled release formulation in a method of treatment of diabetes, obesity or an obesity associated disorder..
Saniona A/s

Antibodies against modified insulin for use in treatment of and assays for diabetes

the present invention provides a method of diagnosing type 1 diabetes (t1d) or latent autoimmune diabetes in adults (lada) in a subject comprising testing a sample from the subject for the presence or absence of antibodies against modified insulin, wherein the presence of antibodies against modified insulin in the sample is indicative of t1d or lada in the subject. The invention also provides a method of treating t1d or lada in a subject in need thereof.
Queen Mary University Of London

Identification of bitter ligands that specifically activate human t2r receptors and related assays for identifying human bitter taste modulators

the present invention relates to the discovery that specific human taste receptors in the t2r taste receptor family respond to particular bitter compounds. Also, the invention relates to the discovery of specific ht2r9 alleles and their disparate activity in functional assays with the same biter ligands.
Senomyx, Inc.

Antibodies and methods for wnt pathway-related diseases

the transmembrane e3 ubiquitin ligases znrf3 and rnf43 are negative regulators of β-catenin and the wnt signaling pathway in eukaryotic cells. The activity of znrf3 can be modulated by antibody binding to its extracellular domain, thus causing an increase in wnt signaling.
Novartis Ag

Indazole derivatives useful as glucagon receptor antagonists

the present invention is directed to indazole derivatives, pharmaceutical compositions containing them and their use in the treatment and/or prevention of disorders and conditions ameliorated by antagonizing one or more glucagon receptors, including for example metabolic diseases such as type ii diabetes mellitus and obesity.. .
Janssen Pharmaceutica Nv

Therapeutic compounds

the invention provides compounds formula (i) and salts thereof: wherein r1-r4 have any of the values defined in the specification. The compounds are useful for treating conditions including alzheimer's disease, parkinson's disease, diabetes, cancer, inflammation, hyperresponsiveness, allergic conditions, asthma, and psychotic disorders such as schizophrenia.
Arizona Board Of Regents On Behalf Of Arizona State University

Indazole derivatives useful as glucagon receptor antagonists

the present invention is directed to indazole derivatives, pharmaceutical compositions containing them and their use in the treatment and/or prevention of disorders and conditions ameliorated by antagonizing one or more glucagon receptors, including for example metabolic diseases such as type ii diabetes mellitus and obesity.. .
Janssen Pharmaceutica Nv

Tesofensine compositions

the present invention relates to tesofensine compositions, methods to prepare the same and uses thereof in preparing medicines for the prevention and treatment of overweight, obesity and type 2 diabetes mellitus.. .
Saniona A/s

Indole derivatives useful as glucagon receptor antagonists

the present invention is directed to indole derivatives, pharmaceutical compositions containing them and their use in the treatment and/or prevention of disorders and conditions ameliorated by antagonizing one or more glucagon receptors, including for example metabolic diseases such as type ii diabetes mellitus and obesity.. .
Janssen Pharmaceutica Nv

Agents useful for treating obesity, diabetes and related disorders

this invention provides methods of treatment diabetes and related conditions using idebenone and analogs thereof compounds 10, 11, 12 and df-1176-178.. .
The Regents Of The University Of California

Novel marker for gestational diabetes

the present invention relates to methods of typing a female subject as being at risk of developing gestational diabetes, comprising determining a level of expression of secreted frizzled-related protein 4 (sfrp4). The invention further relates to methods of treating of a subject being at risk of developing, gestational diabetes, comprising typing the subject according to the methods of the invention, and treating the subject with a dietary meal plan and/or physical activity.
Iq Products B.v.

Raav vector compositions, methods for targeting vascular endothelial cells and use in treatment of type i diabetes

disclosed are capsid-modified raav expression vectors, as well as infectious virions, compositions, and pharmaceutical formulations that include them. Also disclosed are methods of preparing and using novel capsid-protein-mutated raav vector constructs in a variety of diagnostic and therapeutic applications including, inter alia, as delivery agents for diagnosis, treatment, or amelioration of one or more diseases, disorders, or dysfunctions of the mammalian vascular system, and complications from type i diabetes.
University Of Florida Research Foundation, Inc.

Insulin analogues with a glucose-regulated conformational switch

a two-chain insulin analogue contains an a chain modified by (i) a monomeric glucose-binding element at or near its n terminus and (ii) a b chain modified by at or near its c terminus by an element that reversibly binds to the monomeric glucose-binding element such that this linkage is displaceable by glucose. The monomeric glucose-binding element may be phenylboronic acid derivative (optionally halogenated).
Case Western Reserve University

Traditional chinese medicine composition for preventing and treating externally diabetes and a using the same

the invention discloses a traditional chinese medicine composition and a method thereof for preventing and treating externally diabetes, which is characterized in that the traditional chinese medicine composition is composed of astragalus membranaceus, salvia miltiorrhiza, stigma maydis, cortex lycii radicis, wolfberry, prunella vulgaris, mulberry leaf, cornus officinalis, lycopodium clavatum, the root of bidentate achyranthes, rhizoma chuanxiong, chinese atractylodes, yam, puerarin, fructus arctii, cassia twig; the method of use is to put a 40-50 g/ml medicine bags of the chinese herbal medicine powder or decoction into a foot pot, brew with boiling water, and then steam more than 10 minutes with the traditional chinese medicine steam after stirring evenly. When the water is cooled to 40-42° c., soaking feet once a day before going to bed, a course for foot soaking being 20 days; the contents of blood glucose and symptom of polydipsia, polyuria and polyphagia of the patients can be effectively reduced and disappeared by the foot bath in traditional chinese medicine, thus improving the immunity of the body and activating the autoimmunity as well as promoting the self-healing ability for the disease; and also such diseases as diabetic peripheral neuropathy (dpn), diabetic foot, diabetic nephropathy (dn), uremia caused by renal insufficiency resulted from diabetes can be prevented..

Compositions and methods for increasing lifespan and health span

disclosed herein are compounds, extracts, and active fractions of the plant geum japonicum and methods for increasing longevity and survival potency or for preventing or treating various medical conditions, including diabetes, inflammation, wound healing, bed sores, and ocular disorders. The compounds provided herein can be formulated into pharmaceutical compositions and medicaments that are useful in the disclosed methods.
Generex Pharmaceuticals, Inc.

Pancreatic endocrine progenitor cell therapies for the treatment of obesity and type 2 diabetes (t2d)

provided herein are therapies, and methods using that therapy, in the treatment of one or more of type 2 diabetes (t2d), obesity, glucose intolerance and insulin resistance or to control weight gain in subjects. In particular, the subject may be candidates for treatment with one or more small molecule anti-diabetic drugs and the therapy may include implanting a population of pancreatic endocrine progenitor cells into the subject, where the cells are allowed to mature in vivo to produce a population..
The University Of British Columbia

Lanthionine synthetase c-like 2-based therapeutics

provided are compounds that target the lanthionine synthetase c-like protein 2 pathway. The compounds can be used to treat a number of conditions, including infectious disease, autoimmune disease, diabetes, and a chronic inflammatory disease..
Landos Biopharma, Inc.

Method for treating obesity, diabetes, cardiovascular and kidney diseases by regulating gpr30/gper activity

the current invention is in the field of molecular biology/pharmacology and provides methods of using compounds that modulate the effects of gpr30/gper for treating obesity and diabetes (preferably agonists) as well as disease states and/or conditions that result from excessive formation of reactive oxygen species (preferably antagonists). These compounds may function as agonists and/or antagonists of the disclosed estrogen receptor and/or modulate the expression/upregulation of nox and nox-associated reactive oxygen species (ros)..
Stc. Unm

Methods of preventing progression to type 2 diabetes mellitus

the present invention provides compositions and methods for delaying or preventing progression to type 2 diabetes mellitus in individuals with prediabetes and metabolic syndrome.. .
Vivus, Inc.

Low dosage serotonin 5-ht2a receptor agonist to suppress inflammation

activation of 5-ht2a receptors using agonists at surprisingly low concentrations was shown to potently inhibit tnf-α-induced inflammation in multiple cell types. Significantly, proinflammatory markers were also inhibited by the agonist, (r)-doi, even many hours after treatment with tnf-α.
Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College

Method, system and computer readable medium for predictive hypoglycemia detection for mild to moderate exercise

a system, method and non-transient computer readable medium for predicting hypoglycemic risk in patients with diabetes following moderate exercise. A system may include a digital processor; and an exercise module configured to generate a hypoglycemia risk signal with a hypoglycemia prediction algorithm and to determine a hypoglycemia risk state with a classifier algorithm that classifies the hypoglycemia risk signal to identify an actionable hypoglycemia risk state based on a predefined threshold..
University Of Virginia Patent Foundation

Smart messages and alerts for an infusion delivery and management system

method and system for providing diabetes management is provided.. .
Abbott Diabetes Care Inc.

Patient-based results display

a medical testing machine provides improved recall and display of the outcomes of tests performed by the machine. Test outcomes and other information are stored in mass storage directly accessible by the medical testing machine.
Bio-rad Laboratories, Inc.

Method for using probe based pcr detection to measure the levels of circulating demethylated beta cell derived dna as a measure of beta cell loss in diabetes

a method for measuring blood levels of β cell dna that is released upon β cell death by using a quantitative probe technology to detect amplified methylated and demethylated forms of the insulin gene dna, representing normal tissue and β cell specific origin, respectively. Using probes permits the sensitive and specific identification of demethylated insulin dna patterns that are present only in β cells.
Nyu Winthrop Hospital

Novel vista-ig constructs and the use of vista-ig for treatment of autoimmune, allergic and inflammatory disorders

the present invention relates to a fusion proteins comprising regulatory t cell protein, vista (v-domain immunoglobulin suppressor of t cell activation (pd-l3) and an immunoglobulin protein (ig), preferably also containing a flexible linker intervening the vista and ig fc polypeptide. The invention also provides the use of vista polypeptides, multimeric vista polypeptides, vista-conjugates (e.g., vista-ig), and vista antagonists for the treatment of autoimmune disease, allergy, and inflammatory conditions, especially lupus, multiple sclerosis, psoriasis, psoriatic arthritis, multiple sclerosis, crohn's disease, inflammatory bowel disease and type 1 or type 2 diabetes..
King's College London

Biomarkers

the invention provides binding agents and assays tor insulin signal peptide. The agents and assays are useful in methods tor predicting, diagnosing, assessing or monitoring acute cardiac disorders, glucose handling disorders and diabetes in a subject.
Otago Innovation Limited

Composition and treating metabolic disorders

bromocriptine citrate administered to a vertebrate, animal or human, can be used for any purpose including, e.g., the long-term modification and regulation of metabolic disorders, including prediabetes, obesity, insulin resistance, hyperinsulinemia, hyperglycemia and type 2 diabetes mellitus (t2dm) and/or, e.g., the treatment of other medical disorder(s) including immune or endocrine disorders or diseases. Bromocriptine citrate is administered over a limited or extended period at a time of day dependent on re-establishing the normal circadian rhythm of central dopaminergic activity of healthy members of a similar species and sex.
Veroscience Llc

Conjugate compounds of ursodeoxycholic, berberine or l-carnitine, and compositions and methods thereof

the invention provides novel conjugate compounds having at least one of a moiety derived from ursodeoxycholic acid, or eicosapentaenoic acid, or docosahexaenoic acid, or rhein, or r-(+)-α-lipoic acid, or ursolic acid, or corosolic acid, or hydroxycitric acid, or cinnamic acid, or cholic acid, or oleanolic acid, or salicylic acid, or betulinic acid, or chlorogenic acid, or caffeic acid, or bassic acid, or acetyl l-carnitine, or s-allyl cysteine sulphoxide, or s-methyl cysteine sulfoxide, or pantothenic acid, or ascorbic acid, or retinoic acid, or nicotinic acid, or biotin, or a derivative or analog thereof, and a moiety derived from berberine or l-carnitine or metformin or unsaturated fatty acid, or a derivative or analog thereof. The invention also relates to pharmaceutical compositions, methods of preparation and use of these conjugates in treating and/or preventing, for example, liver diseases or disorders, various diabetes, diabetic complications, dyslipidemia, obesity, metabolic syndromes, pre-diabetes, muscle atrophy, inflammation, and cancers.
Shenzhen Hjghtide-biopharmageutical, Ltd.

Summit Innovation Labs Llc

. .

Intrinsic chromosomal linkage and disease prediction

an improved method is the product of an exploration for ways in which to improve the success of genomic disease prediction and presents the elements of more successful prediction tools for the identification of genomic locations of disease based on: genomic labeling it loci as determined by correlated snp linkage as determined from several additional gwas (genome wide association studies) databases. The wellcome trust t2d (type 2, adult-onset, diabetes) has played a particularly important role in developing the new tools; additionally, the development of a wellness classifier, probably in part due to counter disease mutations has proven to be a powerful new tool and concept.

Use of mip-1beta inhibitors for improving angiogenesis to reduce tissue ischemia and rescue diabetic vascular disease in diabetes mellitus

the present invention relates to a use of mip-1β inhibitor for promoting angiogenesis in diabetes mellitus patients so as to improve tissue ischemia in damaged area and to prevent diabetic vasculopathy.. .
National Yang-ming University Taipei Veternas General Hospital

Substituted bridged urea analogs as sirtuin modulators

provided herein are novel substituted bridged urea and related analogs and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity.
Glaxosmithkline Llc

Compositions and methods for treating retinal degradation

the present disclosure relates to compounds, compositions, and methods useful for treating retinal damage and/or retinal degradation/retinal degeneration, for inhibiting inflammasome activation by alu rna associated with a cell, for reducing atp-induced permeability of a cell, for reducing an amount of mitochondrial reactive oxygen species in a cell, and for reducing an amount of mitochondrial reactive oxygen species in a cell. The present disclosure further relates to compounds, compositions, and methods for use in protecting an rpe cell and/or for treating, including prophylactic and therapeutic treatment, of conditions associated with retinal damage and/or degradation including, but not limited to, dry age related macular degeneration (amd) and wet amd, alzheimer disease, various forms of arthritis, atherosclerosis, diabetes mellitus, chronic obstructive pulmonary disease, inflammatory bowel disease, and duchenne muscular dystrophy..
University Of Kentucky Research Foundation

Vascular calcification prevention and treatment

the invention encompasses compositions and methods for effectively interfering, reducing and preventing conversion of vascular smooth muscle cells (vsmcs) and circulating stem cells to osteoblastic bone-like cells, thereby reducing and/or preventing vascular calcification (vc) or calcium mineral (hydroxyapatite) deposition in the vasculature. The severity and extent of calcification in the major arteries reflect atherosclerotic plaque burden and strongly predict cardiovascular morbidity and mortality.
Summit Innovation Labs Llc

Metabolic syndrome treatment

formulations and methods of providing an orally-active anti-metabolic disease fixed dose combinations (fdc) for use as personalized medicine to treat different components of the metabolic syndrome or insulin resistance syndrome such as type ii diabetes, hypertension, hyperlipidemia and obesity are disclosed. Pharmaceutical compositions of anti-inflammatory centric drug formulations and methods comprising of nsaids in general and selective cox-2 inhibitors in particular and one or more anti-t2dm or anti-hypertensive or anti-hyperlipidemic or anti-obesity drugs formulated to exhibit pre-determined modified release kinetics to achieve therapeutic as well as kinetic synergies are disclosed..
Arkay Therapeutics, Llc

Treatment and prevention of diabetes and obesity

since the present compositions are aimed toward normalizing metabolism and energy expenditure and managing oxidative stress and inflammation, they are also beneficial in relation to physical activity, in particular performance, endurance, fatigue and recovery during intensive and continuous exercise/exertion.. .

Ultrashort peptides as exogenous second harmonic probes for bioimaging applications

various aspects of the present invention relate to a peptide based biomaterial for visualization by shg microscopy. In particular the invention relates to the use of short peptides as a non-linear optical (nlo) material for second harmonic generation (shg) microscopy.
Suphatchatwong Innovation Co., Ltd.

Genetically modified mesenchymal stem cell expressing klotho

a genetically modified mesenchymal stem cell (msc) includes an exogenous nucleic acid that includes a klotho encoding region operably linked to a promoter or promoter/enhancer combination. The mscs can be used for the treatment of cancer, organ fibrosis, renal failure, age-related changes of organs or organ systems, arteriosclerosis, and neurodegenerative diseases, such as alzheimer's disease (ad), multiple sclerosis (ms), huntington's disease, amyotrophic lateral sclerosis (als), parkinson's disease, and schizophrenia, as well as dementia, diabetes mellitus, sepsis and autoimmune diseases and autoimmune-related diseases..
Apceth Gmbh & Co. Kg

Fiber-rich maltooligosaccharides having low glucose bioavailability, manufacture thereof and use thereof in human food and animal feed

the present invention relates to maltooligosaccharides, the content of α-1,4-glycosidic bonds of which is between 70% and 80% of the total number of 1,4-type glycosidic bonds. The invention also relates to the method for manufacturing these maltooligosaccharides.
Roquette Freres

Substituted quinolines as pde-10 inhibitors

provided herein are heteroaryl compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. In one embodiment, the compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as cns disorders and metabolic disorders, including, but not limited to, e.g., neurological disorders, psychosis, schizophrenia, obesity, and diabetes..
Sunovion Pharmaceuticals Inc.

Compounds and methods for inducing browning of white adipose tissue

the present invention provides a compound for inducing browning of white adipose tissue in vitro and in vivo of formula i, the preparation method thereof, as well as a composition comprising the same. Further, the present invention also relates to the use of the compound and the method to treat metabolic disorders, such as obesity and diabetes..
Guangzhou Institutes Of Biomedicine And Health, Chinese Academy Of Sciences

Dermatopontin as a therapeutic for metabolic disorders

the present disclosure describes to a method of treating a metabolic disease in a subject, wherein the method comprises administration of dermatopontin to a subject, wherein the dermatopontin is recombinant dermatopontin and the metabolic disease is selected from a group consisting of weight gain, diet-induced weight gain, obesity, morbid obesity, metabolic syndrome, glucose homeostasis, insulin resistance, type i diabetes, type if diabetes and cardiovascular disease. Disclosed herein is also a method of determining or making a prognosis of a subject's susceptibility to metabolic diseases and obesity, the method comprising measuring the level of circulating dermatopontin in a sample obtained from a subject; and comparing the level of circulating dermatopontin obtained with the level of dermatopontin previously determined in a control; and determining the susceptibility of the subject to metabolic disease and obesity based on the difference between the level of circulating dermatopontin and the level of dermatopontin in the control..
Agency For Science, Technology And Research

Method for treating hiv

the present invention provides novel processes for regulating immune responses in mammalian subjects, e.g., humans, afflicted with diseases such as cancers, infections, e.g., viral infections, bacterial infections, or immune dysfunctions, especially auto-immune disorders, e.g., diabetes, crohn's disease, rheumatoid arthritis, arteriosclerosis and ulcerative colitis. More particularly, this invention relates to generating elevated levels of an intermediary metabolite, e.g., lipids or conjugated biomolecules, e.g., glycolipids, lipoproteins and glycoproteins other than antibodies, cytokines or hormones.
Enzo Therapeutics, Inc.

A protecting against carbonyl stress induced ischemia-reperfusion injury in the diabetic brain via administration of n-acetylcysteine

a method for one of preventing and minimizing diabetes pathology in a mammal, comprising administering to the mammal an effective amount of n-acetylcysteine (nac).. .
Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College

No donors for the treatment of impaired tissue perfusion

a method for treatment of prophylaxis of a chronic disease or condition associated with impaired tissue or organ perfusion, comprising administering an amino-c2-c6-alkyl nitrate, an amino-c2-c4-alkyl nitrate, or a pharmaceutically acceptable salt thereof, to a patient in need thereof. The disease or condition is a micro- and/or macro-vascular disease selected from the group of diseases associated with impaired capillary function, impaired muscular function, impaired skin function, impaired cartilage function, impaired myocardial function, impaired retinal function or impaired organ function caused by impairment of tissue and organ perfusion or by impairment of the regeneration of capillaries, arterioles or other vascular tissue.
Mirandapharmaceuticals Ag

Active substances and cosmetic or dermatological preparations containing said active substances for the care of the skin of patients of diabetes mellitus

licochalcone a and/or plant extracts or microbiologically obtained extracts with an active content of licochalcone a or cosmetic or dermatological preparations containing licochalcone a and/or plant extracts or microbiologically obtained extracts with an active content of licochalcone a for the care of the skin of patients of diabetes mellitus.. .
Beiersdorf Ag

Aptamers and sensing technology used for detection of glycated hemoglobin in whole blood

high affinity dna aptamers seq id#1-8 for hba1c and thb were successfully selected using selex after 11 rounds of selection. The tested aptamers bind to hba1c with dissociation constants in the nanomolar range with the highest affinity aptamer, seq id#6, exhibiting a kd of 2.8 nm.
Alfaisal University

Devices for detection of antibodies against therapeutic drugs

devices for detection of antibodies against therapeutic drugs (adas), in which chimeric proteins facilitate immobilization and exposure of target epitopes, are described. Results can be obtained in minutes, enabling point of care testing and/or patient self-testing, and risk assessment.

Devices, solutions and methods for sample collection related applications, analysis and diagnosis

a solution is described for preserving cells and/or extra-cellular components in naturally expressed bodily fluids (e.g. Saliva, sputum, urine) for further downstream analysis and/or for diagnosis of a medical condition.
Abogen, Inc.

Diagnostic methods, therapeutic agents and uses thereof

the present invention provides a method for diagnosing a disease or disorder selected from the group consisting of insulin resistance, a metabolic disorder, diabetes and pre-diabetes in a subject. The method comprises the step of determining the level of a compound represented by structural formula (vi): or a salt thereof.
Metabolon, Inc.

Puma, a pro-apoptotic gene, as a novel molecular biomarker for tnfalpha-induced human islet damage

p53-upregulated modulator of apoptosis (puma) is a biomarker associated with islet cell health. If puma is low, islet cells are typically healthy.
Hitachi Chemical Co., Ltd.

Compositions and methods for treating fatty tissue buildup

the present disclosure is directed to the treatment of diseases or conditions involving the buildup of fatty tissues, such as obesity, metabolic syndrome, type ii diabetes, etc. A composition containing a monoclonal antibody directed against gastric inhibitory polypeptide is administered.
Mhs Care-innovation Llc

Apelin fusion proteins and uses thereof

the invention provides a fusion protein or polypeptide comprising an apelin peptide fused to a multimerizing component. The invention also provides a fusion protein or polypeptide comprising an apelin peptide fused to an fc domain, a fragment of an fc domain, or a variant of an fc domain.
Regeneron Pharmaceuticals, Inc.

Crystal form a of compound and preparation method thereof

the present invention relates to crystal form a of a compound. The present invention also discloses a preparation method and a pharmaceutical composition of the crystal form a.
Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences

Compounds and methods to suppress autoimmune response

a composition and method for treating autoimmune disease includes administering an effective amount of an aryl hydrocarbon receptor (ahr) ligand. The ahr ligand includes 11-cl-bbq, 10-cl-bbq, an analog of 11-cl-bbq, or combination thereof.
Oregon State University

Methods, compounds, and compositions for the treatment of angiotensin-related diseases

disclosed are small molecule non-peptidic compounds, as well as methods and compositions for the treatment of angiotensin-related diseases and disorders, including cardiovascular diseases, metabolic diseases, gastrointestinal diseases, renal diseases, inflammatory/autoimmune diseases, neurological diseases, bone marrow diseases and cancer. In particular, the invention provides compounds, methods and compositions for the treatment of metabolic diseases and disorders, such as diabetes mellitus, diabetes-related cardiovascular disorders, diabetes-related dermal ulcerations, diabetes related hypertension, and diabetes-related ophthalmic diseases..
University Of Southern California

Pyrazolyl substituted carbonic acid derivatives as modulators of the prostacyclin (pgi2) receptor useful for the treatment of disorders related thereto

pyrazole derivatives of formula ia and pharmaceutical compositions thereof that modulate the activity of the pgi2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (pah) and related disorders; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack; angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation in an angioplasty or coronary bypass surgery individual or in an individual suffering from atrial fibrillation; atherosclerosis; atherothrombosis; asthma or a symptom thereof; a diabetic-related disorder such as diabetic peripheral neuropathy, diabetic nephropathy or diabetic retinopathy; glaucoma or other disease of the eye with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (sle); ulcerative colitis; ischemia-reperfusion injury; restenosis; atherosclerosis; acne; type 1 diabetes; type 2 diabetes; sepsis; and chronic obstructive pulmonary disorder (copd)..
Arena Pharmaceuticals, Inc.

Compositions and methods for treating obesity and hyperphagia

the present disclosure is directed to the treatment of diseases or conditions characterized by the buildup of fatty tissue, or hyperphagia, such as prader-willi syndrome, obesity, metabolic syndrome, type ii diabetes, etc. A composition containing a monoclonal antibody directed against gastric inhibitory polypeptide is administered.
Mhs Care-innovation Llc

Compositions and methods to diagnose diabetes and/or to treat negative effects of diabetes

the present disclosure describes a genome-wide transcriptional analysis of differentially expressed genes in diabetic, non-diabetic, normal and wounded tissue. The analysis allowed development of compositions and methods to diagnose diabetes and/or to treat negative effects of diabetes, including delayed wound healing and reduced vision..
Wayne State University

Methods of preventing the occurrence of cardiovascular events

the present invention relates to pharmacological interventions with pemafibrate for cardiovascular diseases and adverse cardiovascular events. In addition, the invention relates to the use of pemafibrate to treat dyslipidemia and type 2 diabetes mellitus and thereby reduce the risk of cardiovascular disease and adverse cardiovascular events..
Kowa Company, Ltd.

Methods of preventing cardiovascular events in residual risk dyslipidemic populations

the present invention provides pharmacological interventions for the treatment of dyslipidemia, and to the reduction of residual risk of cardiovascular disease and adverse cardiovascular events in patients on intense statin use or with well-controlled ldl-c concentrations. In particular, the invention relates to the use of pemafibrate to prevent cardiovascular events in populations at-risk due to risk factors such as type 2 diabetes mellitus with dyslipidemia in spite of intense statin use or well-controlled ldl-c..
Kowa Company, Ltd.

New azabenzimidazole derivatives as agonists of the amp-activated protein kinase

the present invention relates to compounds of general formula i, wherein the group r1, x and y are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the amp-activated protein kinase (ampk) and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2..
Boehringer Ingelheim International Gmbh

Protein and lipid biomarkers providing consistent improvement to the prediction of type 2 diabetes

the invention relates to biomarkers associated with diabetes, including protein and lipid metabolite biomarkers, methods of using the biomarkers to determine the risk that an individual will develop diabetes, and methods of screening a population to identify persons at risk for developing diabetes and other pre-diabetic conditions.. .
True Health Ip Llc

Oligonucleotide sequences targeting transcription factortsc22d4 for the treatment of insulin resistance

the present invention relates to oligonucleotide inhibitors of the tsc22d4 activity or expression and their uses for the prevention, treatment, and/or regulation of insulin resistance, metabolic syndrome and/or diabetes and/or for improving insulin sensitivity in a mammal.. .
Deutsches Krebsforschungszentrum Stiftung Des öffentlichen Rechts

Glucagon antagonists

provided herein are compounds, including enantiomerically pure forms thereof, and pharmaceutically acceptable salts or co-crystals and prodrugs thereof which have glucagon receptor antagonist or inverse agonist activity. Further, provided herein are pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucagon receptor antagonist is indicated, including type i and ii diabetes, insulin resistance and hyperglycemia.
Metabasis Therapeutics, Inc.

Probes and methods for detecting amyloidogenic proteins

disclosed herein are novel photocontrollable probes and methods for detecting aggregated forms of amyloidogenic proteins in cells, tissues, or organs of a live subject. Results of such detection may be useful for making prognosis on the subject whether he/she suffers from a neurodegenerative disease and/or diabetes mellitus..
Academia Sinica

Nutritional approach to the control of anemia, diabetes and other diseases or conditions and prevention of associated comorbid states with the use of ergothioneine

nutritional products, compositions, pharmaceutical preparations and methods of use are disclosed for the prevention, suppression and treatment of anemia and/or diabetes and its various associated comorbidities. Uses of ergothioneine to neutralize free radicals and/or cytokines, reduce oxidative stress, prevent inflammation, stimulate red blood cell production with increased levels of hemoglobin, and/or stabilize iron in its normal 2+ charge for proper oxygen binding and carrying are further disclosed.
Entia Biosciences, Inc.

Bifidobacteria for treating diabetes and related conditions

this invention relates to new uses of bifidobacteria (particularly, although not exclusively, probiotic bifidobacteria), and to food products, feed products, dietary supplements and pharmaceutical formulations containing them. The bacteria are suitable for the treatment of diabetes (particularly type 2 diabetes), obesity and related conditions, metabolic syndrome, insulin resistance, and impaired glucose metabolism and consequences thereof, lowering tissue inflammation, treating hepatitis, myositis and cardiovascular conditions..
Dupont Nutrition Biosciences Aps

Heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders

compounds and methods are provided for the treatment of, inter alia, type ii diabetes and other diseases associated with poor glycemic control. The compounds of the invention are orally active..
Cymabay Therapeutics, Inc.

Flip - a selective molecular target of senescent cells

the present invention relates to modulators of flip protein and their method of use in the treatment and prevention of diseases and pathologies related to accumulation of senescent cells during aging, such as cancer, chronic obstructive pulmonary disease (copd), osteoarthritis, atherosclerosis, neurodegenerative diseases, diabetes, and many others. The present invention also relates to pharmaceutical compositions containing these compounds as well as various uses thereof..
Bioventures, Llc

Compositions comprising beta-hydroxybutyric acid and salt, and methods of using the same

β-hydroxybutyric acid in combination with β-hydroxybutyrate salts are useful to induce ketosis, achieving blood ketone levels of (0.5-6.0 mmol/l), with or without dietary restriction, and without inducing harmfully high mineral loads in the blood. The combination of β-hydroxybutyric acid and salt results in substantial improvements in metabolic biomarkers related to insulin resistance, diabetes, weight loss, and physical performance & endurance in a short period of time.
Savind, Inc.

Method, system and computer readable medium for assessing actionable glycemic risk

a system, method and non-transient computer readable medium for assessing the opportunity to address either hyperglycemic or hypoglycemic risk (or both) in patients with diabetes based on historical continuous glucose monitoring (cgm) data.. .
University Of Virginia Patent Foundation

Combination growth factor therapy and cell therapy for treatment of acute and chronic diseases of the organs

ischemia is treated to prevent or manage disease by delivering stem cells derived from cord blood and/or tissue. A patient suffering from disease caused in at least some part by ischemia is selected.

Acylated glucagon analogues

the present invention relates to novel peptide compounds which have an improved physical stability in solution and improved solubility at neutral ph, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of hyperglycemia, diabetes and obesity, as well as a variety of diseases or conditions associated with hyperglycemia, diabetes and obesity..
Novo Nordisk A/s

Novel fatty acid modified urocortin-2 analogs for the treatment of diabetes and chronic kidney disease

wherein the x1 denotes that the i residue is modified by either acetylation or methylation at the n-terminus; wherein x2 is l or t; wherein x3 is l or i; wherein x4 is q or e; and wherein a modified k residue (“k*”) at position 29 is modified through conjugation to the epsilon-amino group of the k-side chain with a group of the formula —x5—x6, wherein x5 is selected from the group consisting of one to four amino acids; one to four ([2-(2-amino-ethoxy)-ethoxy]-acetyl) moieties; and combinations of one to four amino acids and one to four ([2-(2-amino-ethoxy)-ethoxy]-acetyl) moieties; and x6 is a c14-c24 fatty acid. In some embodiments, the group of the formula —x5—x6 is ([2-(2-amino-ethoxy)-ethoxy]-acetyl)2-(γe)2-co—(ch2)x—co2h where x is 16 or 18..

Chemical ablation and treatment for various diseases

embodiments of the present invention provide a device and a method for treating at least one of hypertension, pulmonary arteries, diabetes, obesity, heart failure, end-stage renal disease, digestive disease, urological disease, cancers, tumors, pain, asthma or chronic obstructive pulmonary disease by delivering an effective amount of a formulation to a tissue, in embodiments of the present invention, the formulation may include at least one of a gas, a vapor, a liquid, a solution, an emulsion, or a suspensions of one or more ingredients. In embodiments of the present invention, amounts of the formulation and/or energy are effective to injure or damage tissue, nerves, and nerve endings in order to relieve disease symptoms..
Neurotronic, Inc.

Therapeutic homodimer and uses thereof

the invention relates to therapeutic peptides and uses thereof. In particular, the invention relates to disulphide-linked homodimers useful in the treatment or prevention of diseases and conditions in mammalian subjects (such as diabetes), via transmucosal administration..

Modulators of alpha-dicarbonyl detoxification and their use for the treatment of diabetic pathologies

in various embodiments compositions and methods are provided for ameliorating a pathology characterized by elevated α-dicarbonyl compounds or prophylactically slowing or stopping the onset of said pathology in a mammal. In certain embodiments the method comprises administering to the mammal an agent that activates trpa1 in an amount sufficient to activate trpa1, and/or to ameliorate one or more symptoms of the pathology (e.g., diabetes or a complication thereof), and/or to slow or stop the onset of the pathology, and/or to lower the level of α-dicarbonyl compounds in the mammal..
Buck Institute For Research On Aging

Devices and methods for managing insulin resistance

disclosed are devices and methods for mitigating insulin resistance in a human subject by contacting one or more regions of the neck, the supraclavicular, and the interscapular regions of the human subject with a part of a cooling device, wherein the part of the cooling device has a temperature at about 15 or less celsius degrees; cooling the one or more regions of the neck, the supraclavicular, and the interscapular regions of the human subject for a cooling period of at least 15 minutes; and performing previous two steps daily for about 14 or more days. The devices and methods may also be used to preventing, delaying or treating type 2 diabetes in a human subject or activating brown fat without incurring a sympathetic nerve-mediated cold feeling in a human subject..
Gludone Inc.

Cells genetically modified to comprise pancreatic islet glucokinase and uses thereof

the present invention relates generally to a population of cells genetically modified to produce insulin in a glucose responsive manner and uses thereof. More particularly, the present invention relates to a population of cells genetically modified to produce insulin in response to physiologically relevant levels of glucose and uses thereof.
University Of Technology, Sydney

Glucagon-receptor selective polypeptides and methods of use thereof

this invention relates to isolated polypeptides that are glucagon-receptor selective analogs and peptide derivatives thereof. These analogs are selective for human glucagon receptor with improved solubility, thermal stability, and physicochemical properties as compared to native endogenous glucagon.
Intarcia Therapeutics Inc.

Compositions and methods of using islet neogenesis peptides and analogs thereof

the invention provides peptides and analogs of ingap and hip peptides. The peptides and analogs can be used in methods for treating various diseases and conditions.
Shenzhen Hightide Biopharmaceutical, Ltd.

Method for preparing nanoprecipitates of low molecular weight peptide or protein

the present invention relates to a method for the non-denaturing preparation of peptide or protein nanoprecipitates, or of peptide or protein and metal ion nanocoprecipitales, in which said protein or said peptide has a molecular weight no higher than 20 kda, preferably no higher than 15 kda, advantageously no higher than 10 kda, and more advantageously no higher than 8 kda. Said method includes a step of preparing a mixture of an aqueous solution of peptides or proteins, a nonsolvent of the peptide or protein, and optionally a water-soluble metal salt.
Carlina Technologies

Isoquinoline derivatives as mgat2 inhibitors

the compounds of formula i act as mgat2 inhibitors and can be useful in preventing, treating or acting as a remedial agent for hyperlipidemia, diabetes mellitus and obesity.. .
Merck Sharp & Dohme Corp.

Chromenone inhibitors of monocarboxylate transporters

the invention provides compounds effective as inhibitors of monocarboxylate transporters such as mct1 and mct4, which can be used for treatment of medical conditions wherein treatment of the condition with a compound having an inhibitor effect on mct1, mct4, or both is medically indicated. Compounds of the invention can have antitumor, antidiabetes, anti-inflammatory, or immunosuppressive pharmacological effects, and can be effective for treatment of cancer and of type ii diabetes..
The Scripps Research Institute

Indication mechanism for an automatic applicator, particularly for insulin

the present disclosure concerns an indication mechanism for an automatic applicator, particularly for insulin or other liquid preparations, particularly for multiple injection administration of set doses of a medicine from an exchangeable container, for example for the self-application of insulin by diabetes patients. An indication mechanism for an automatic applicator, having an assembly of at least two barrels movably coupled to each other has an indication barrel mounted on the driving barrel contains only marking on its external surface and is co-axially connected to the pull-push control nut..
Copernicus Sp. Z O.o.

Prolonged anti-diabetic effect of fibroblast growth factor 1 (fgf1)

disclosed are compositions and methods for inducing sustained diabetes remission by single administration of fgf1 to the brain. The composition and methods described herein result in basal glucose clearance by using a dosage of fgf1 that is lower than that needed for systemic efficacy and is devoid of the risk of hypoglycemia and changes in body weight, food intake, hepatic glucose production, insulin secretion or insulin sensitivity..
University Of Washington

Health care

the treatment of type 2 diabetes involving the use of a regimen comprising: (a) one or more glucose-lowering drugs (g-lds) which function to lower the amount of glucose in the blood, preferably glyburide and metformin; (b) at least one non-steroidal anti-inflammatory drug (nsaid) selected from the group consisting of (1) magnesium salicylate tetrahydrate (hereafter “mg salicylate”); (2) naproxen; and (3) ibuprofen; and (c) acetaminophen. Also, a regimen for use in deterring the development in an individual of a cardiovascular disease or of alzheimer's and/or for treating individuals who are affected with such diseases, the regimen comprising aforementioned ingredients (b) and (c) above..

Pteridine dione monocarboxylate transporter inhibitors

the invention provides compounds effective as inhibitors of monocarboxylate transporters such as mct1 and mct4, which can be used for treatment of medical conditions wherein treatment of the condition with a compound having an inhibitor effect on mct1, mct4, or both is medically indicated. Compounds of the invention can have antitumor, antidiabetes, anti-inflammatory, or immunosuppressive pharmacological effects, and can be effective for treatment of cancer and of type ii diabetes..
The Scripps Research Institute

Medical condition management system and methods

a system ranks pharmaceutical and other regimens for the treatment of chronic diseases (e.g., diabetes) to optimize the patient, medical, financial, and operational aspects of drug therapy using a combination of data impossible for a human to consume and process within any useful period of time. A scoring algorithm balances estimated cost, intolerance, benefit, and efficacy, using information from the patient's medical history, personal preference, drug manufacturers, clinical trial data, and other sources (e.g., insurance payment data) for every possible therapy and combination of therapies.

Metabolite biomarkers predictive of renal disease in diabetic patients

the present invention relates to biomarkers that are predictive of renal disease in patients who have diabetes. The present invention also provides methods of using such biomarkers to predict the risk that a diabetic patient will develop renal disease, and/or to identify a patient who has diabetes as being in need of a therapy to prevent or delay the onset of a renal disease..
Joslin Diabetes Center

Fas and drs are novel molecular targets of senescent cells

the present invention relates to modulators of fas and drs and their method of use in the treatment and prevention of diseases and pathologies related to accumulation of senescent cells during aging, such as cancer, chronic obstructive pulmonary disease (copd), osteoarthritis, atherosclerosis, neurodegenerative diseases, diabetes, and many others. The present invention also relates to pharmaceutical compositions containing these compounds as well as various uses thereof..
Bioventures, Llc

New azabenzimidazole derivatives

the present invention relates to compounds of general formula (i), wherein r1, r2, r3, a1, a2, m and n are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the amp-activated protein kinase (ampk) and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2..
Boehringer Ingelheim International Gmbh

Heterocyclic inhibitors of monocarboxylate transporters

the invention provides compounds that inhibit monocarboxylate transporters, such as mct1 and mct4. Compounds of the invention can be used for treatment of a condition in a patient, wherein the condition is characterized by the heightened activity or by the high prevalence of mct1 and/or mct4, such as cancer or type ii diabetes..
The Scripps Research Institute

Ethynyl derivatives

the present invention relates to compounds that may be used for the treatment of parkinson's disease, anxiety, emesis, obsessive compulsive disorder, autism, neuroprotection, cancer, depression and diabetes type 2.. .
Hoffmann-la Roche Inc.

Dry powder drug delivery system and methods

a pulmonary drug delivery system is disclosed, including a breath-powered, dry powder inhaler, with or without a cartridge for delivering a dry powder formulation. The inhaler and cartridge can be provided with a drug delivery formulation comprising, for example, a diketopiperazine and an active ingredient, including, small organic molecules, peptides and proteins, including, hormones such as insulin and glucagon-like peptide 1 for the treatment of disease and disorders, for example, diseases and disorders, including endocrine disease such as diabetes and/or obesity..
Mannkind Corporation

Stable pharmaceutical solution formulation of glp-1r antibody fusion protein

disclosed is a stable pharmaceutical solution formulation of a glp-1r antibody fusion protein, comprising a therapeutically effective amount of the glp-1r antibody fusion protein, an amino acid, a surfactant and a buffer system. The final concentration of the amino acid is 1-500 mm, the final concentration of the surfactant is 0.01%-0.5%, and the ph value of the stable solution formulation is from 5.0 to 8.0.
Gmax Biopharm Llc.

Prevention of hypoglycaemia in diabetes mellitus type 2 patients

a method for the prevention of hypoglycaemia in diabetes mellitus type 2 comprising administering (a) despro36exendin-4(1-39)-lys6-nh2 or/and a pharmaceutically acceptable salt thereof, and (b) a sulfonyl urea or/and a pharmaceutically acceptable salt thereof, to a subject in need thereof.. .
Sanofi-aventis Deutschland Gmbh

Method of treating or ameliorating type 1 diabetes using fgf21

methods of treating metabolic diseases and disorders using a fgf21 polypeptide are provided. In various embodiments the metabolic disease or disorder is type 1 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels, diabetic nephropathy, neuropathy, retinopathy, ischemic heart disease, peripheral vascular disease and cerebrovascular disease.
Amgen Inc.

Disease prevention and alleviation by human myoblast transplantation

methods and materials are described for human genome prophylaxis and therapy of diseases using myoblast transfer. These methods result in gene transcript changes in multiple pathways.

Modified release compositions of epalrestat or a derivative thereof and methods for using the same

modified release pharmaceutical compositions of epalrestat are provided. Methods of manufacturing the tablets and treating various diseases and conditions, including diabetes and diabetic complications, by administering the modified release compositions to patients in need thereof are also provided..
Bionevia Pharmaceuticals Inc.

Intestinal fxr agonism enhances glp-1 signaling to restore pancreatic beta cell functions

disclosed are embodiments of a method of treating or preventing latent autoimmune diabetes of adults (lada) in a subject. Such embodiments include administering to a subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or farnesoid x receptor (fxr) agonist compounds, thereby activating fxr receptors in the intestines, and treating or preventing latent autoimmune diabetes of adults (lada) in the subject..
Salk Institute For Biological Studies

1,3-substituted 2-amino-indole derivatives and analogues useful in the treatment or prevention of diabetes mellitus, obesity, and inflammatory bowel disease

the present invention provides compounds of formula (i) and pharmaceutically acceptable salts thereof, wherein q, x4, x5, x6, x7, r1, r2, r3 and r8 are as defined in the specification, processes for the preparation of such compounds, pharmaceutical compositions containing them and the use of such compounds in therapy.. .
Takeda Pharmaceutical Company Limited

Ostreolysin, functionally related variant thereof, extract comprising ostreolysin and uses thereof

disclosed are methods for treating, preventing and alleviating obesity, fatty liver syndrome, diabetes, one or more metabolic syndrome conditions or complications and/or cancer comprising administering an effective amount of ostreolysin, its functionally related variant, or an extract or mushroom extract comprising the same to subjects in need thereof.. .
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.

Method for treatment of hyperglycemia and hyperlipidemia

provided is a method of treating metabolic diseases including type 2 diabetes, insulin resistance, hyperglycemia, hyperlipidemia, obesity, hepatic steatosis, and hyperinsulinemia in a subject in need, including the step of administering to the subject a therapeutically effective amount of antcin k. Also provided is a method of enhancing protein expression ratio of phospho-5′ adenosine monophosphate-activated protein kinase (phospho-ampk) to total ampk in skeletal muscle or liver of a subject, and a method of reducing blood leptin in a subject.

Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug

the present invention relates to the finding that certain dpp-4 inhibitors are particularly suitable for treating and/or preventing metabolic diseases, particularly diabetes, in patients with insufficient glycemic control despite a therapy with an oral and/or a non-oral antidiabetic drug.. .
Boehringer Ingelheim International Gmbh

Fusion polypeptide containing glp and immunoglobulin hybrid fc and use thereof

the present invention relates to a fusion polypeptide containing a glucagon-like peptide (glp) and an immunoglobulin hybrid fc, and more specifically, to a fusion polypeptide with an increased half-life and improved efficacy compared to the conventional fusion polypeptide based on the discovery of an immunoglobulin hybrid fc suitable for glp or analogs thereof, and a pharmaceutical composition for treating diabetes, inflammatory bowel disease, endoenteritis or diarrhea caused by anticancer chemotherapy, or short bowel syndrome, containing the fusion polypeptide. The fusion polypeptide of the present invention has an increased half-life and improved resistance to dpp-4 enzyme compared to those of glp-1 and glp-2, and it thus has improved drug efficacy in treating diabetes, inflammatory bowel disease, endoenteritis or diarrhea caused by anticancer chemotherapy, or short bowel syndrome, compared to those of the conventional drugs.
Genexine, Inc.

Substituted bridged urea analogs as sirtuin modulators

the present invention relates to novel substituted bridged urea analog compounds of formula (i) or pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions, processes for making and use of such compounds, alone or in combination with other therapeutic agents, as sirtuin modulators useful for increasing lifespan of a cell, and in treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity.. .
Glaxosmithkline Intellectual Property (no.2) Limited

Bicyclic compounds, compositions and medicinal applications thereof

these compounds are useful in the treatment, prevention, prophylaxis, management, or adjunct treatment of all medical conditions related to inhibition of retinoic acid-related orphan receptor gamma (rorγ) such as inflammatory and/or autoimmune disorder, rheumatoid arthritis, psoriasis, psoriatic arthritis, multiple sclerosis, inflammatory bowel disease, allergic diseases, asthma, copd, cancer, cell proliferation, type 1 diabetes, myasthenia gravis, hematopoetic disfunction, systemic lupus, erythematosus or other disorders.. .

2,3,4,5-tetrahydropyridin-6-amine and 3,4-dihydro-2h-pyrrol-5-amine compound inhibitors of beta-secretase

wherein the radicals are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which beta-secretase is involved, such as alzheimer's disease (ad), mild cognitive impairment, senility, dementia, dementia with lewy bodies, down's syndrome, dementia associated with stroke, dementia associated with parkinson's disease, dementia associated with beta-amyloid, age-related macular degeneration, type 2 diabetes or metabolic disorders..

Substituted benzothiophenyl derivatives as gpr40 agonists for the treatment of type ii diabetes

wherein r1, r2, r3, r5, r6, w, and a are defined herein.. .

Co-agonists of the glucagon and glp-1 receptors

described are peptide analogs of glucagon, which have been modified to be resistant to cleavage and inactivation by dipeptidyl peptidase iv (dpp-iv) and to increase in vivo half-life of the peptide analog while enabling the peptide analog to have relatively balanced agonist activity at the glucagon-like peptide 1 (glp-1) receptor and the glucagon (gcg) receptor, and the use of such glp-1 receptor/gcg receptor co-agonists for treatment of metabolic disorders such as diabetes, non-alcoholic fatty liver disease (nafld), non-alcoholic steatohepatitis (nash), and obesity. .
Merck Sharp & Dohme Corp.

Methods for the treatment of polycystic ovary syndrome

polycystic ovary syndrome (pcos) is a complex and heterogeneous endocrine syndrome associated with a high risk for the development of insulin resistance, type 2 diabetes (t2d), obesity, dyslipidemia, and cardiovascular disease. There are no known therapies for the 9-18% of women afflicted with pcos.
Center For Reproducitive Medicine, Shandong Provincial Hospital, Shandong University

Microsphere-based delivery and ex vivo manipulation of dendritic cells for autoimmune therapies

the present invention relates to tolerogenic mammalian dendritic cells (idcs) and methods for the production of tolerogenic dcs. In addition, the present invention provides methods for administration of tolerogenic dendritic cells as well as particles containing oligonucleotides to mammalian subjects.
University Of Pittsburgh - Of The Commonwealth System Of Higher Education

Compositions and methods for treating intestinal hyperpermeability

the present invention provides methods, compositions, and kits for treating intestinal hyperpermeability in a subject in need thereof, including conditions such as hyperglycemia and underlying diseases such as diabetes, autism, fibromyalgia, inflammatory bowel disease (ibd), graft versus host disease (gvhd), hiv/aids, multiple organ dysfunction syndrome, irritable bowel syndrome (ibs), celiac disease, eczema, psoriasis, acute pancreatitis, parkinson's disease, depression, chronic fatigue syndrome, asthma, multiple sclerosis, arthritis, ankylosing spondylitis, nonalcoholic fatty liver disease, alcoholic cirrhosis, environmental enteropathy, or kwashiorkor.. .

Modulators of the prostacyclin (pgi2) receptor useful for the treatment of disorders related thereto

the present invention relates to amide derivatives of formula (xiiia) and pharmaceutical compositions thereof that modulate the activity of the pgi2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (pah); idiopathic pah; familial pah; pah associated with a collagen vascular disease, a congenital heart disease, portal hypertension, hiv infection, ingestion of a drug or toxin, hereditary hemorrhagic telangiectasia, splenectomy, pulmonary veno-occlusive disease (pvod) or pulmonary capillary hemangiomatosis (pch); pah with significant venous or capillary involvement; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack, angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation in an angioplasty or coronary bypass surgery individual or in an individual suffering from atrial fibrillation; atherosclerosis; atherothrombosis; asthma or a symptom thereof; a diabetic-related disorder such as diabetic peripheral neuropathy, diabetic nephropathy or diabetic retinopathy; glaucoma or other disease of the eye with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (sle); ulcerative colitis; ischemia-reperfusion injury; restenosis; atherosclerosis; acne; type 1 diabetes; type 2 diabetes; sepsis; and chronic obstructive pulmonary disorder (copd)..
Arena Pharmaceuticals, Inc.

Procedure for the acquisition of data for the detection of angiogenesis in lower limbs

the invention relates to a method for obtaining useful data about the angiogenesis in a patient's lower limbs, and particularly in the lower limbs of patients with diabetes subjected to treatment.. .
Universidad De Córdoba

Rationale, methods, and assays for identifying human and non-human primate taste specific genes and use thereof in taste modulator and therapeutic screening assays

this invention relates to novel rationale and methods for identifying human and primate taste-specific genes, including genes involved in salty taste perception, especially human salty taste perception, but also genes involved in sweet, bitter, umami, and sour taste perception, and genes involved in other taste cell or taste receptor related activities such as digestive function and digestive related diseases, taste cell turnover, immunoregulation of the oral and digestive tract, and metabolic regulation such as in diabetes and obesity, the genes identified using these methods, and assays for identifying taste modulators (enhancers or blockers) and potential therapeutics using these genes. These compounds have potential application in modulating (enhancing or blocking) taste perception, especially salty taste perception and as potential therapeutics.
Senomyx, Inc.

Methods of reprogramming cells

the present invention provides methods of reprogramming cells, for example, directly reprogramming a somatic cell of a first cell type into a somatic cell of a second cell type, are described herein. In particular, the present invention generally relates to methods for reprogramming a cell of an endoderm origin to a cell having pancreatic β-cell characteristics.
President And Fellows Of Harvard College

Method of isolating cells from a tissue in a mammal

solutions and suspensions comprising polymerized hemoglobin derived from human blood are disclosed. The solutions and suspensions may comprise cell culture medium, an enzyme (such as a protease), and/or a buffer.
The Board Of Trustees Of The University Of Illinois

Peptides for modulating t-cell activity and uses therof

the present invention provides methods and materials for treating and preventing autoimmune diseases. In particular, the present invention relates to the discovery that small peptides are capable of interacting with cd40, thereby interfering with the ability of cd40 to interact with cd154, which is important in inflammation.
The Regents Of The University Of Colorado, A Body Corporate

Substituted bridged urea analogs as sirtuin modulators

the present invention relates to novel substituted bridged urea analog compounds of formula (i) or pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions, processes for making and use of such compounds, alone or in combination with other therapeutic agents, as sirtuin modulators useful for increasing lifespan of a cell, and for use in treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity.. .
Glaxosmithkline Intellectual Property (no.2) Limited

Substituted bridged urea analogs as sirtuin modulators

the present invention relates to novel substituted bridged urea compounds, corresponding related analogs, pharmaceutical compositions and methods of use thereof. Sirtuin-modulating compounds of the present invention may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity.
Glaxosmithkline Llc

Fibronectin based scaffold domain proteins that bind to myostatin

the present invention relates to fibronectin-based scaffold domain proteins that bind to myostatin. The invention also relates to the use of these proteins in therapeutic applications to treat muscular dystrophy, cachexia, sarcopenia, osteoarthritis, osteoporosis, diabetes, obesity, copd, chronic kidney disease, heart failure, myocardial infarction, and fibrosis.
Bristol-myers Squibb Company

Anti-obesity and anti-diabetic effects of angiopoietin-like 4 (angptl4) fibrinogen-like domain

angiopoietin-like 4 (angpt14) is a secreted protein that inhibits lipoprotein lipase (lpl) activity and promotes lipolysis in adipocytes. The present methods provides compositions comprising angptl4 fld and variants thereof of methods of using such compositions to protect a subject diet-induced obesity without affecting plasma tg levels, and, in an exemplary emobiment improve glucose homeostasis.
The Regents Of The University Of Califorina

Co-encapsulation of live cells with oxygen-generating particles

microcapsules are described that comprise (a) a liquid aqueous or hydrogel core; (b) a semipermeable membrane surrounding said core; (c) live animal cells (e.g., pancreatic cells) in the core; and (d) oxygen-generating particles in said core, said oxygen-generating particles included in said microcapsules in an amount sufficient to lengthen the duration of viability of said animal cells in said microcapsules. Compositions comprising such microcapsules and uses thereof, such as in treating diabetes, are also described..
Wake Forest University Health Sciences

Use of metformin in combination with a glucokinase activator and compositions comprising metformin and a glucokinase activator

the present invention provides uses of a glucokinase activator in combination with metformin. Uses include treating type 2 diabetes, lowering blood glucose, improving insulin sensitivity, enhancing phosphorylation of glucose, and improving the therapeutic effectiveness of metformin.
Vtv Therapeutics Llc

Methods and compositions for the treatment of pre-diabetes, diabetes and metabolic syndrome

the disclosure provides thiol-containing alkyl fatty acid and vitamin d compound formulations for intravenous, parenteral or oral administration. The compositions of the present technology have optimal controlled bioavailability and are useful for treating metabolic dysfunctions such as pre-diabetes, metabolic syndrome and diabetes.

Instituto Politécnico De Santarém

. .

Pairing and synchronizing a mobile phone application with a handheld glucose meter

a diabetes management system includes a handheld medical device, a mobile computing device, and a diabetes management application. The handheld medical device is configured to determine, in response to a port receiving a test strip, whether an auto-send feature is enabled on the handheld medical device, determine whether the handheld medical device is paired with a mobile computing device, and selectively instruct a wireless transceiver to establish a wireless connection and communicate a glucose measurement and identifying information to the mobile computing device.
Roche Diabetes Care, Inc.

Condensed heterocyclic compound

the present invention relates to a condensed heterocyclic compound that has an enteropeptidase inhibitory effect and is useful in the treatment or prevention of obesity, diabetes mellitus, or the like, and a medicament containing the same. Specifically, the present invention relates to a compound represented by the following formula (i) or a salt thereof, and a medicament containing the same [in the formula, each symbol is as defined in the specification]..
Takeda Pharmaceutical Company Limited

Biaryl derivative as gpr120 agonist

the present invention relates to a biaryl derivative expressed by the chemical formula 1, a method for producing the biaryl derivative, a pharmaceutical composition comprising same, and use of same, the biaryl derivative expressed by the chemical formula 1, as a gpr120 agonist, promoting glp-1 generation in the gastro-intestinal tract, reducing insulin resistance in the liver, muscles and the like from anti-inflammatory activity in the macrophage, pancreatic cells and the like, and allowing effective use in prevention or treatment of inflammation or metabolic diseases such as diabetes, complications from diabetes, obesity, non-alcoholic fatty liver disease, fatty liver disease, and osteoporosis.. .
Lg Chem, Ltd.

Risk-based control-to-range

methods and systems are disclosed for determining a basal rate adjustment of insulin based on risk associated with a glucose state of a person with diabetes. A method may include detecting a glucose state of the person based on a received glucose measurement signal and determining a current risk metric associated with the detected glucose state.
Roche Diabetes Care, Inc.

Control-to-range aggressiveness

a method and system of determining a basal rate adjustment of insulin in a continuous glucose monitoring system of a person with diabetes is provided. The method includes receiving, by at least one computing device, a signal representative of at least one glucose measurement; detecting, by the at least one computing device, a glucose state of the person based on the signal, the detected glucose state including a glucose level of the person and a rate of change of the glucose level; determining, by the at least one computing device, a current risk metric, the current risk metric indicating a risk of at least one of a hypoglycemic condition and a hyperglycemic condition of the person; and calculating, by the at least one computing device, an adjustment to a basal rate of a therapy delivery device based on the current risk metric and a control-to-range algorithm comprising at least one aggressiveness parameter..
Roche Diabetes Care, Inc.

Control-to-range failsafes

methods and systems are disclosed for determining a basal rate adjustment of insulin in a continuous glucose monitoring system of a person with diabetes. A method may include receiving, by at least one computing device, a signal representative of at least one glucose measurement and detecting, by the at least one computing device, a glucose state of the person based on the signal, the detected glucose state including a glucose level of the person and a rate of change of the glucose level.
Roche Diabetes Care, Inc.

Method for ameliorating and abating symptoms resulting from rheumatoid arthritis, fibromyalgia, and chronic pain of unknown origin

the present invention provides a composition and method for treating diseases associated with demyelination of the nerves, such as als, ra, tremors/parkinson's disease, and ms, alzheimer's disease, als, guillain-barre syndrome, atherosclerosis, schizophrenia, tremors/parkinson's disease, senile dementia, muscular dystrophy, attention deficit disorder, attention deficit hyperactivity disorder, complex regional pain syndrome, diabetes, neuropathic pain, spider arthritis west nile virus,, fibromyalgia, shingles, gout, migraine headaches, post polio syndrome, central virus deafness, asthma, chronic pain of unknown origin and hepatitis c and for treating non-viral based cancers. By administering measured doses of an immunity-provoking agent and a bacterial antigen activator, patients suffering from als, ra, ms, tremors/parkinson's disease, and prostate cancer and others realized immediate beneficial results with no side effects..
Honor C.w. M.d., Llc

Compositions and methods for decreasing blood glucagon levels

disclosed are improved compositions and methods for decreasing blood glucagon levels. As disclosed herein, l-glutamine is a selective stimulator of α-cell proliferation generated when glucagon signaling is interrupted.
Vanderbilt University

Use of helminthostachys zeylanica, ugonins or flavone-based compounds for the treatment or prevention of metabolic diseases

disclosed is a use of helminthostachys zeylanica, ugonins or compounds of formula (i) for the treatment or prevention of metabolic diseases comprising at least one selected from metabolic syndrome, excessive lipid accumulation, obesity, overweight, fatty liver, hepatic steatosis, hepatitis, cirrhosis, liver cancer, dyslipidemia, hyperlipidemia, hypertriglyceridemia, hyperlipoproteinemia, hypercholesterolemia, cardiovascular disease, hyperglycemia, hyperinsulinemia, diabetes mellitus type 2, insulin resistance, insulin disorder, impaired glucose tolerance and a combination thereof.. .
National Research Institute Of Chinese Medicine, Ministry Of Health And Welfare

Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes

the present invention is directed to compounds which are inhibitors of the dipeptidyl peptidase-iv enzyme (“dp-iv inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-iv enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-iv enzyme is involved..
Merck Sharp & Dohme Corp.

Method of treating liver fibrosis

a method of treating liver fibrosis with ccr2 antagonists is provided. The liver fibrosis may be associated with non-alcoholic steatohepatitis (nash), non-alcoholic fatty liver disease (nafld), emerging cirrhosis, non-cirrhotic hepatic fibrosis, type 2 diabetes mellitus (t2dm) or metabolic syndrome (ms)..
Chemocentryx, Inc.

Compositions containing omega-3 oil and uses thereof

the invention provides pharmaceutical compositions containing omega-3 oil and a non-hydrophilic co-solvent that have an increased absorption rate. The pharmaceutical compositions may further contain one or more pharmaceutical organic molecules.
Maine Natural Health Company, Inc.

System for adjusting pressure locally on the skin and subcutaneous tissue

the invention relates to a system for adjusting pressure locally acting on the skin. Said system includes a set of adjacent modules distributed so as to form a layer.
Ecole Polytechnique Federale De Lausanne (epfl)

Electrode assembly

the present invention relates to an electrode assembly (eg a nanoelectrode assembly), to an electrochemical glucose biosensor comprising the electrode assembly and to an apparatus for combating (eg management of) diabetes mellitus which comprises the electrochemical glucose biosensor.. .
Nanoflex Limited

System and assessing quantities or sizes of lipoprotein particles from lipoprotein particle compositions

this application discloses methods for assessing quantities of spherical or substantially spherical lipoprotein particles or portions thereof present in a biological sample based on the measurement of free cholesterol and/or phospholipid content in the lipoprotein particles. Methods of treating a subject at increased risk for cardiovascular disease and/or cardiodiabetes are also disclosed..
True Health Ip Llc

Hepatocyte based insulin gene therapy for diabetes

a method and vectors for controlling blood glucose levels in a mammal are disclosed. In one embodiment, the method comprises the steps of: treating the hepatocyte cells of a patient with a first, second or third vector, wherein the first vector comprises a promoter enhancer, glucose inducible regulatory elements, a liver-specific promoter, a gene encoding human insulin with modified peptidase and an albumin 3′utr and lacks an hgh intron, wherein the second vector comprises an hgh intron, glucose inducible regulatory elements, a liver-specific promoter, a gene encoding human insulin with modified peptidase site and an albumin 3′utr and lacks a promoter enhancer, wherein the third vector comprises an hgh intron, glucose inducible regulatory elements, a liver-specific promoter, a gene encoding human insulin with modified peptidase site, an albumin 3′utr and a promoter enhancer and observing the patient's insulin levels, wherein the patient's insulin levels are controlled..
Wisconsin Alumni Research Foundation

Use of microrna precursors as drugs for inducing cd34-positive adult stem cell expansion

this invention generally relates to a composition and its production method useful for developing drugs/vaccines and/or therapies against a variety of degenerative diseases in humans. Particularly, the present invention teaches the essential steps of production and purification processes necessary for producing small hairpin-like rna (shrna) compositions, such as microrna precursors (pre-mirna) and short interfering rnas (sirna), which are useful for treating human ageing related diseases, such as, but not limited, alzheimer's diseases, parkinson's diseases, osteoporosis, diabetes, and cancers.

Antibody therapy for modulating function of intestinal receptors and methods of treating diabetes and obesity

the present invention provides pharmaceutical compositions formulated for direct delivery to the gi tract of a patient comprising an antibody specific for a target apical intestinal receptor. The present invention further provides methods of treating diseases and conditions in a patient comprising administering directly to the gi tract of the patient, compositions of the present invention wherein modulation of the target apical intestinal receptor by the antibody treats the condition..
Circle 33 Llc

Methods and compositions to treat type-1 and type-2 diabetes

the present disclosure is directed to novel methods of treating type-1 or type-2 diabetes by inactivating tlr2 and tlr4 genes together in cells capable of producing insulin and/or regenerating β cells, and providing the cells to a subject in need thereof.. .
Cornell University

Pyrazino[2,3-b]pyrazine mtor kinase inhibitors for oncology indications and diseases associated with the mtor/pi3k/akt pathway

wherein r1-r4 are as defined herein, compositions comprising an effective amount of a heteroaryl compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, neurodegenerative diseases, diabetes, obesity, neurological disorders, age-related diseases, or cardiovascular conditions, comprising administering an effective amount of a heteroaryl compound to a patient in need thereof.. .

A multi-state ratchet mechanism for drug injection devices

the present invention relates in a first aspect to a multi-state ratchet mechanism for a drug injection device. The multi-state ratchet mechanism comprises a ratchet gear member and a cooperating ratchet pawl member.
Novo Nordisk A/s

Cell-based composition and use thereof for treatment of diabetes and associated metabolic disorders and for amelioration of insulin resistance in pre-diabetes

the present invention relates to a cell-based composition comprising a suspension of mesenchymal stem cells in crystalloid with a cellular concentration from 0.01 million to 3.0 million cells/ml. The cell-based composition is used in a form of medicament for treatment of diabetes and its associated metabolic disorders and complications..
Cytopeutics Sdn. Bhd.

Non-reducing end unsaturated mannuronic acid oligosaccharides and compositions containing same as active ingredient

disclosed is a non-reducing end unsaturated mannuronic acid oligosaccharide having a molecular weight of 100-3000 da, which is obtained by lysing polymannuronate as a substrate with alginate lyase, and provided are: a non-reducing end unsaturated mannuronic acid oligosaccharide; and pharmaceutical compositions for alleviating, preventing, or treating obesity, diabetes, and climacteric syndrome, and probiotics for promoting intestinal beneficial bacteria, the compositions and probiotics containing, as an active ingredient, the non-reducing end unsaturated mannuronic acid oligosaccharide, so that the antiobesity and antidiabetic effects, estrogen activity, and intestinal microflora controlling effect of the non-reducing end unsaturated mannuronic acid oligosaccharides are remarkably excellent as compared with non-reducing end saturated mannuronic acid oligosaccharides.. .
Industry Foundation Of Chonnam National University

Bromocriptine formulations

the present application describes pharmaceutical formulations of bromocriptine mesylate and methods of manufacturing and using such formulations. The formulations are useful for improving glycemic control in the treatment of type 2 diabetes..
Veroscience Llc

Alpha-cell re-generation combined with conversion to beta cells

the present invention relates to methods of generating a population of beta cells from a population of alpha cells, by contacting said population of alpha cells with gaba or a gaba receptor agonist, in combination with a monoclonal glucagon neutralizing antibody or other alpha cell mass regulating compounds, for an improved diabetes therapy.. .
Universite De Nice Sophia Antipolis-grand ChÂteau

Methods for identifying responders to dopaminergic neuronal enhancing therapies for the treatment of elevated heart rate and metabolic or cardiovascular conditions

methods for identifying responders to agents that increase brain dopaminergic neuronal activity for the treatment of metabolic and cardiovascular disease and for treating elevated heart rate and metabolic disease or dysglycemia in subjects with type 2 diabetes.. .
Veroscience Llc

Anti-acth antibodies and use thereof

the present invention is directed to antibodies and fragments thereof having binding specificity for acth. Another embodiment of this invention relates to the antibodies binding fragments thereof described herein, comprising the sequences of the vh, vl and/or cdr polypeptides described herein, and the polynucleotides encoding them.
Alder Biopharmaceuticals, Inc.

Thienopyranones as kinase and epigenetic inhibitors

the invention relates to methods of treating diseases including but not limited to, cancer, non-cancer proliferative disease, sepsis, autoimmune disease, viral infaction, atheroscleosis, type 1 or 2 diabetes, obesity, inflammatory disease, or myc-depenent disorder including by modulating biological processes by the inhibition of pi3 kinase and/or bromodomain protein binding to substrates comprising the administration of a compound(s) of formula i-ix (or pharmaceutically acceptable salts thereof) as defined herein.. .
Signalrx Pharmaceuticals, Inc.

New pyrazolopyrimidine derivatives as nik inhibitors

the present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of nf-κb-inducing kinase (nik—also known as map3k14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders..
Janssen Pharmaceutical Nv

New compounds as nik inhibitors

the present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of nf-κb-inducing kinase (nik—also known as map3k14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders..
Janssen Pharmaceutica Nv

New pyrazole derivatives as nik inhibitors

the present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of nf-κb-inducing kinase (nik—also known as map3k14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders..
Janssen Pharmaceutica Nv

Compounds and methods for activating the apoptotic arm of the unfolded protein response

n-substituted sulfonylphenyl-5-nitrofuranyl-2-carboxamide derived compounds, which selectively activate the apoptotic, but not the adaptive arm, of the unfolded protein response are provides as is their use in the treatment of diseases such as diabetes, alzheimer's, parkinson's, hemophilia, lysosomal storage diseases and cancer.. .
Sanford-burnham Medical Research Institute

Pyrazole compounds

this invention relates to pyrazole compounds or pharmaceutically acceptable salts thereof. Compounds of this invention are inhibitors of methionine aminopeptidase 2 (metap2) and dipeptidyl peptidase-4 (dpp-4).
Eli Lilly And Company

Novel mitochondrial uncouplers for treatment of metabolic diseases and cancer

the present disclosure relates to benzamide compounds, prodrugs of the compounds, pharmaceutical compositions containing the compounds and/or the prodrugs and methods of using the compounds, prodrugs and pharmaceutical compositions in the treatment of diseases related to lipid metabolism including diabetes, non-alcholic fatty liver disease (nafld), non-alcholic steathohepatitis (nash), diseases caused by abnormal cell proliferation including cancer, psoriasis, and infectious diseases.. .

Novel approach to treatment of hyperglycemia using a nanoparticle encapsulated peptide

the present invention relates to compositions and methods for treating or preventing hyperglycemia and diseases associated with hyperglycemia. In certain embodiments, the composition comprises a peptide having the amino acid sequence krscyk wherein the peptide consists of d-amino acids is useful in treating or preventing diabetes.
University Of Rochester

Methods for treating and/or limiting development of diabetes

the present invention provides methods for identifying candidate compounds for limiting development of and/or treating diabetes, and methods for limiting development of and/or treating diabetes.. .
Biocrine Ab

Pharmaceutical composition, methods for treating and uses thereof

the present invention relates to certain sglt-2 inhibitors for treating, preventing, protecting against and/or delaying the progression of chronic kidney disease in patients, for example patients with prediabetes, type 1 or type 2 diabetes mellitus.. .
Boehringer Ingelheim International Gmbh

Salts and compositions useful for treating disease

the invention provides a combination or salt of lipoic acid and a compound of formula (i): the combinations and salts are useful for treating diabetes.. .
Regents Of The University Of Minnesota

Therapeutic compound and its application in repairing diabetes-related cardiac injuries

the present invention is related to a therapeutic compound and its application in repairing diabetes-related cardiac injuries, particularly with providing a therapeutic composition containing the epigallocatechin gallate (egcg) of green tea and the adipose-derived stem cells. The epigallocatechin gallate (egcg) of green tea can enhance the ability of the adipose-derived stem cells to repaired damaged tissue.
Numen Biotech Co., Ltd

Method of treating hyperglycemia

disclosed herein are methods for treating conditions and/or disorders related to hyperglycemia. Such conditions and/or disorders related to hyperglycemia include, but are not limited to, type i, ii diabetes mellitus, gestational diabetes, other forms diabetes, and disorders related thereto.
Center Laboratories, Inc.

Methods and systems for treating diabetes and related diseases and disorders

systems, device and methods treat target tissue to provide a therapeutic benefit to the patient. A tissue treatment device comprises a tissue treatment element constructed and arranged to treat target tissue, such as duodenal mucosa tissue..
Fractyl Laboratories, Inc.

Method for treating diabetes and other glucose regulation disorders using stem cells

various embodiments of the invention provide methods of treating diabetes and other glucose regulation disorders. In one embodiment, the method comprises removing l-cells from a donor, obtaining stem cells from a patient, and culturing the l-cells in the presence of the stem cells under conditions such that the stem cells differentiate into stem cell-derived l-cells (scdlc).
Incube Labs, Llc

Composition to induce bone marrow stem cell mobilization

a pharmaceutical composition to induce bone marrow stem cell mobilization from the bone marrow to peripheral blood in patients suffering from pathological conditions, such as diabetes, or subjected to treatments that impair cell mobilization, or in patients suffering from the so called “poor mobilizer” condition, includes at least one therapeutic agent that inhibits production and/or action of the human cytokine oncostatin m (osm), a macrophage derived factor, that prevents mobilization of stem cells.. .
Universitá Degli Studi Di Padova

Omefibrates for treating dyslipidemia and cardiovascular disease

the present invention relates to the fibric acid derivatives of omega-3 fatty acids and their use in treating type2 diabetes, obesity, hypertriglyceridemia, cardiovascular diseases, metabolic syndrome, cancer, alzheimer's disease; and their use for modulating activity of peroxisome proliferator-activated receptors (ppars).. .
Jiva Pharma, Inc.

Satiation peptides for weight loss and altered taste sensitivity

the present application provides methods and compositions for aav-mediated delivery of pyy and glucagon-like peptide 1 or an analog thereof (e.g., exendin-4) to a subject (e.g., the saliva of a subject). In some embodiments, compositions and methods for topical delivery of ex-4 and pyy peptides also are provided.
University Of Florida Research Foundation, Inc.

Use of caspase-2 inhibitors to treat and prevent the metabolic syndrome

methods and compositions for treatment of obesity, insulin resistance, hyperinsulinemia, type 2 diabetes mellitus, dyslipidemia, and nonalcoholic fatty liver disease are discloses. The methods and compositions relate to inhibition of caspase-2..
Duke University

Treatment of mild and moderate alzheimer's disease

the present invention relates to methods of treatment using [3-(4-{2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl}-phenoxy)-propyl]-diethyl amine (“compound i”) or a pharmaceutically acceptable salt thereof. In various embodiments, the methods of treatment include treatment of mild-to-moderate dementia of alzheimer's type, diabetes, insomnia, and other indications.
Vtv Therapeutics Llc

Methods for detecting gestational diabetes mellitus

the present invention relates to methods for diagnosing gestational diabetes mellitus (gdm) in a pregnant female.. .
Kantonsspital Aarau Ag

Methods and compositions for diagnosis and management of diabetes and metabolic syndrome

described herein are assays, methods, and devices for diagnosing/prognosing diabetes, metabolic syndrome, pre-diabetic state and/or the early-onset of diabetes in a subject. The assays, methods, and devices described herein can be configured to detect one or more long-coding rnas in a sample from a subject..
The U.s. Government As Represented By The Departme Nt Of Veterans Affairs Office Of General Counsel

Alpha/beta-polypeptide analogs of glucagon-like peptide 1

described herein are peptide analogs of glucagon-like peptide 1 (glp-1) that retain agonist activity, but are more resistant to proteolytic degradation than native glp-1. In the analogs, at least one α-amino acid found in the native glp-1 is replaced with a β-amino acid residue, which may or may not be cyclically constrained.
President And Fellows Of Harvard College

Derivatives of 2-(1,2,4-triazol-3-ylsulfanyl)-n-1,3,4-thiadiazol-2-yl acetamide which are useful for the treatment of inter alia diabetes

disclosed are compounds, pharmaceutical compositions and methods for modulating aquaporin 9.. .
Apoglyx Ab

Novel heterocyclic derivatives and their use in the treatment of neurological disorders

in which all of the variables are as defined in the specification, pharmaceutical compositions thereof, combinations thereof, and their use as medicaments, particularly for the treatment of alzheimer's disease or diabetes via inhibition of bace-1 or bace-2.. .

Novel pentadienoyl piperidine derivative and use thereof

the present invention relates to a novel pentadienoyl piperidine derivative, a pharmaceutical composition containing the same for prevention or treatment of metabolic diseases, and a functional food composition using the same for improvement or relief of metabolic diseases. The pentadienoyl piperidine derivative of the present invention inhibits the differentiation of preadipocytes, reduces body weight, visceral fat, blood lipid levels, and blood glucose levels, improves a blood liver function index, and suppresses metabolic inflammation responses.
Snu R&db Foundation

Synergistic compositions

the present invention describes a synergistic composition comprising of one or more statins, or one or more dipeptidyl peptidase iv (dpp iv) inhibitor or one or more biguanide antihyperglycaemic agent and a ppar agonist of formula (1a) for the treatment of diabetes, especially non-insulin dependent diabetes or type 2 diabetes and conditions associated with diabetes mellitus and to compositions suitable for use in such method. The invention also describes the preparation of such compositions.
Cadila Healthcare Limited

Dosing regimen

the present invention relates to a long acting insulin analogue for use in reducing the risk of hypoglycaemia in a patient suffering from diabetes and requiring high amounts of delivered insulin, wherein the long acting insulin analogue is administered to said patient and in an amount of greater than 80 u/administration.. .
Novo Nordisk A/s

A dietary fibre composition

the invention provides a composition comprising glucomannan, carrageenan, xanthan gum and a monovalent or divalent cation salt. The composition is suitable for use in managing weight, combating obesity, combating metabolic syndrome, promoting satiety, reducing appetite, combating diabetes, lowering blood cholesterol, lowering blood pressure, reducing postpranial glycaemia, or increasing insulin sensitivity..
Inqpharm Group Sdn Bhd

Aldose reductase inhibitors and uses thereof

the present invention relates to novel compounds and pharmaceutical compositions thereof, and methods for promoting healthy aging of skin, the treatment of skin disorders, the treatment of cardiovascular disorders, the treatment of renal disorders, the treatment of angiogenesis disorders, such as cancer, treatment of tissue damage, such as non-cardiac tissue damage, the treatment of evolving myocardial infarction, and the treatment of various other disorders, such as complications arising from diabetes with the compounds and compositions of the invention. Other disorders can include, but are not limited to, atherosclerosis, coronary artery disease, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, infections of the skin, peripheral vascular disease, stroke, and the like..
The Trustees Of Columbia University In The City Of New York

Composition

the present invention relates to compositions for use and formulation as weight management products and in particular fermented dairy foodstuffs. The compositions generally comprise two or more of the following components: a) a microbiome modifying component; b) a satiety modifying component; and c) a metabolic modifying 5 component and at least one of the following: d) streptococcus thermophilus cbs 139100 and lactobacillus delbrueckii subsp.
Optibiotix Limited

Integrated medicament delivery device for use with continuous analyte sensor

an integrated system for the monitoring and treating diabetes is provided, including an integrated receiver/hand-held medicament injection pen, including electronics, for use with a continuous glucose sensor. In some embodiments, the receiver is configured to receive continuous glucose sensor data, to calculate a medicament therapy (e.g., via the integrated system electronics) and to automatically set a bolus dose of the integrated hand-held medicament injection pen, whereby the user can manually inject the bolus dose of medicament into the host.

Optical biomodule for detection of diseases at an early onset

additionally, chemical compositions and targeted, passive and programmable/active delivery (in near real-time/real-time) of bioactive compounds and/or bioactive molecules for lowering the risks of alzheimer's, cardiovascular and type-2 diabetes diseases are disclosed.. .

Method for determining risk of diabetes

a method of determining risk of diabetes is provided. In one embodiment, the method comprises: a) measuring the levels of a plurality of biomarkers in a blood samples obtained from a patient, wherein the plurality of biomarkers comprises at least five of the following biomarkers: glucose, adiponectin, crp, il2ra, ferritin, insulin and hba1c; b) calculating a diabetes risk score for the patients using the levels and, optionally, patient age and/or gender.

Methods of treating acute myeloid leukemia with antibodies to bone marrow stromal antigen 1

the invention provides antibodies which bind to the adp-ribosyl cyclase 2. Nucleic acid molecules encoding the antibodies, expression vectors, host cells and methods for expressing the antibodies are also provided.

System and relieving high blood sugar factor of diabetes

a system and method for relieving high blood sugar factor of diabetes includes an energy wave generator with an energy wave's frequency control mode. The energy wave's frequency control mode includes multiple controls for controlling and generating energy waves with corresponding energy densities to effect on diabetic patient's body, so as to reduce and eliminate the high blood sugar factors of the diabetic patient..

Compositions and methods for treatment of prediabetes

the invention provides compositions and methods to treat prediabetes. In particular, the inventor has discovered that particular combinations of diverse types of antioxidants have synergistic and surprising effects for use against prediabetes.

Methods and compositions for in vivo induction of pancreatic beta cell formation

embodiments of the invention stimulate three levels of beta cell physiology: (i) glucose metabolism, (ii) membrane receptor function, and (iii) transcriptional factors that result in the in vivo formation of beta cells in the pancreas for the purpose of treating diabetes. In certain aspects, the methods include the integration of three levels of cellular physiology: metabolism, membrane receptor function, and gene transcription.

Use of nitrite salts in chronic ischemia

methods of treating a subject who has chronic tissue ischemia are disclosed. The methods can include administering to the subject a pharmaceutical composition comprising inorganic nitrite or a pharmaceutically acceptable salt thereof, for a time and in an amount sufficient to result in blood vessel growth in the ischemic tissue.

Dpp iv inhibitor formulations

the present invention relates to pharmaceutical compositions of dpp iv inhibitors with an amino group, their preparation and their use to treat diabetes mellitus.. .

Substituted naphthyridine and quinoline compounds as mao inhibitors

wherein r1, r2, r3, y, and n have any of the values described herein and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies, detection and imaging techniques, and radioactive treatments; and therapies, including inhibiting mao, and mao-b selectively, enhancing neuronal plasticity, treating neurological disorders, providing neuroprotection, treating a cognitive impairment associated with a cns disorder, enhancing the efficiency of cognitive and motor training, providing neurorecovery and neurorehabilitation, enhancing the efficiency of non-human animal training protocols, and treating peripheral disorders (including obesity, diabetes, and cardiometabolic disorders) and their associated co-morbidities.. .

Interference rejection membranes comprising crosslinked poly(vinyl alcohol) matrices for implantable glucose sensors

embodiments of the invention provide amperometric analyte sensors having optimized elements such as interference rejection membranes as well as methods for making and using such sensors. The amperometric analyte sensor apparatus comprises: a base layer; a conductive layer disposed on the base layer and comprising a working electrode; an interference rejection membrane disposed on an electroactive surface of the working electrode, wherein the interference rejection membrane comprises poly(vinyl alcohol) (pva) polymers crosslinked by an acid crosslinker, wherein the crosslinker is a dicarboxylic acid type monomer or a polymer comprising a carboxylic acid group; and an analyte sensing layer.

Yeast screens for treatment of human disease

screening methods for identifying substances that provide therapeutic value for various diseases associated with protein misfolding are provided. Genetic and chemical screening methods are provided using a yeast system.
The University Of Chicago

Alk7 binding proteins and uses thereof

this disclosure provides alk7-binding proteins such as anti-alk7 antibodies, and compositions and methods for making the alk7-binding proteins. In certain embodiments the alk7-binding proteins inhibit, or antagonize alk7 activity.
Adimab, Llc

Methods for reducing cd36 expression

the invention provides a method for treating one or more complications of diabetes in a mammal. The method comprises administering to a mammal in need thereof an effective amount of an aromatic-cationic peptide having at least one net positive charge; a minimum of four amino acids; a maximum of about twenty amino acids; a relationship between the minimum number of net positive charges (pm) and the total number of amino acid residues (r) wherein 3 pm is the largest number that is less than or equal to r+1; and a relationship between the minimum number of aromatic groups (a) and the total number of net positive charges (pt) wherein 2a is the largest number that is less than or equal to pt+1, except that when a is 1, pt may also be 1..
Cornell Research Foundation, Inc.

Pharmaceutical composition, methods for treating and uses thereof

the invention relates to a pharmaceutical composition according to the claim 1 comprising an sglt2 inhibitor and a glp-1 receptor agonist which is suitable in the treatment or prevention of diabetes mellitus, impaired glucose tolerance, hyperglycemia or other conditions. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions..
Boehringer Ingelheim International Gmbh

Composition and treating metabolic disorders

bromocriptine citrate administered to a vertebrate, animal or human, can be used for any purpose including, e.g., the long-term modification and regulation of metabolic disorders, including prediabetes, obesity, insulin resistance, hyperinsulinemia, hyperglycemia and type 2 diabetes mellitus (t2dm) and/or, e.g., the treatment of other medical disorder(s) including immune or endocrine disorders or diseases. Bromocriptine citrate is administered over a limited or extended period at a time of day dependent on re-establishing the normal circadian rhythm of central dopaminergic activity of healthy members of a similar species and sex.
Veroscience Llc

Methods for treatment of disease using galvanic vestibular stimulation

methods are provided for treating diseases by altering body mass composition in a human subject through application of galvanic vestibular stimulation (gvs) using electrodes placed in electrical contact with the subject's scalp at a location corresponding to each of the subject's left and right vestibular systems. The methods may be used to treat obesity-related diseases such as diabetes, hypertension, type 2 diabetes mellitus and osteoporosis.
The Regents Of The University Of California

Hydrogel prodrug for treatment

aspects of the invention described herein include a hydrogel prodrug and methods of making a hydrogel prodrug for drug delivery. Also contemplated are methods of treating, inhibiting, ameliorating or inhibiting a disease or disorder.
Viking Scientific, Inc.

Method for treating hyperglycemia with glp-1

a method for treating hyperglycemia and/or diabetes in a subject is provided. In particular, the method is directed for the treatment of patients with type 2 diabetes mellitus who have a fasting blood glucose concentration greater than about 8 mm, wherein the patient is administered a formulation comprising a glp-1 molecule and a diketopiperazine by pulmonary inhalation with a dry powder inhalation system..
Mannkind Corporation

Use of low dose il-2 for treating autoimmune – related or inflammatory disorders

the present invention relates to novel therapies for treating autoimmune and inflammatory diseases. More specifically, the present invention relates to a use of low dose interleukin-2 for the treatment of type i diabetes and other autoimmune and/or inflammatory diseases..
Universite Pierre Et Marie Curie (paris 6)

Methods for increasing the selective efficacy of gene therapy using car peptide and heparan sulfate mediated macropinocytosis

disclosed are compositions and methods for triggering disease selective macropinocytosis. The compositions can serve as a marker of disease activity and as a trigger of enhanced macropinocytosis in tissues undergoing disease remodeling such as wound healing, cancer, pah, inflammation, diabetes, crohn's disease, ulcerative colitis, ankylosing spondylitis, diseases of the endometrium, psoriasis, irritable bowel syndrome, arthritis, fibrotic disorders, interstitial cystitis, autoimmune diseases, asthma, acute lung injury, and adult respiratory distress syndrome.
Vascular Biosciences

Selective nav1.7 inhibitors for the treatment of diabetes

provided herein are methods for treating or preventing prediabetes or diabetes, or maintaining or lowering blood or plasma glucose or maintaining or lowering blood or plasma glycated hemoglobin comprising administering to a subject in need thereof a therapeutically effective amount of a compound selectively inhibiting nav1.7. In particular, provided herein are processes for the preparation of and intermediates used in the preparation of compounds selectively inhibiting nav 1.7, such as the compounds of formula i or compounds of formula i′:.
Chromocell Corporation

Sglt-2 inhibitors for treating metabolic disorders in patients with renal impairment or chronic kidney disease

the present invention relates to certain sglt-2 inhibitors, such as ertugliflozin or a co-crystal or a pharmaceutically acceptable salt thereof, for treating and/or preventing metabolic disorders, such as type 1 or type 2 diabetes mellitus or pre-diabetes, in patients with renal impairment or chronic kidney disease (ckd). The present invention also relates to methods for preventing neuronal damage following the incidence of ischemic stroke and close-head traumatic brain injury in animals comprising the step of administering to an animal, in need of such treatment, a therapeutically effective amount of ertugliflozin or a co-crystal or a pharmaceutically acceptable salt thereof..
Pfizer Inc.

Delicious garlic shakes and smoothies

these delicious shakes or smoothies, has the active compound called allicin, which comes from the garlic. Allicin is the key ingredient for helping to lower our metabolic risk factors.

Systems and methods for health management

described herein are systems and methods of diabetes management and prediabetes prevention. The method includes rendering a graphical user interface including a first plurality of hexagonal tiles arranged in a honeycomb pattern, the first plurality of hexagonal tiles together displaying tracked data for a plurality of datatypes; receiving a tracked data input for a first datatype; adding the input data to a new or an existing hexagonal tile representing a tracked data point of the first datatype; dynamically rearranging the first'plurality of hexagonal tiles to maintain a time-ordered sequence of tracked data; receiving a user selection of a tile of a second datatype; and displaying a plurality of icons representing selectable user options corresponding to the user-selected tile.

Use of cd5 antigen-like as a biomarker for diabetic nephropathy

biomarkers for pre-diabetes, diabetes and/or a diabetes related conditions, and methods of their use, including the biomarkers in tables 1 and 2 such as peroxiredoxin-2, complement c1q subcomponent subunit b, sulfhydryl oxidase 1 and apolipoprotein a-iv.. .

Phosphorylation of histones and uses thereof

phosphorylation of histones was observed at certain tyrosine residues which have not been associated with epigenetic modification. These sites include h2b tyr37, h4 tyr88 and tyr 51 and h3 tyr99.

Modulators of ror-gamma receptors, composition and use thereof

the present invention provides novel methods to treat disease by modulating retinoid-related orphan receptor gamma (ror-gamma) in vitro and in vivo with ursolic acid analogs, and compositions thereof. The methods and compounds disclosed herein are useful for inhibiting the differentiation of a population of t cells, or treating a disease related to th17 cell responses in a subject.

Brain permeant peptidomimetic beta-secretase 1 inhibitors for the treatment or prophylaxis of neurological disorders or conditions

the present application presents novel peptidomimetic substituted hydroxyethylene compounds, which are inhibitors of beta amyloid cleavage enzyme, capable to permeate the brain and to achieve therapeutic concentrations in the target organ, the brain. These compounds are incorporated in pharmaceutical compositions and applied in the treatment or prophylaxis of neurological disorders or conditions and also other disorders or conditions including down's syndrome and diabetes..

Differentiation of pluripotent stem cells to intestinal midgut endoderm cells

cell populations of intestinal midgut endoderm cells and methods of generating the cells expressing markers characteristic of intestinal endoderm lineage are disclosed. Methods of treating conditions such as diabetes are also disclosed..

Composite preparation, containing novel 3-(4--(benzyloxy)phenyl)hex-4-inoic acid derivative and another active ingredient, for preventing or treating metabolic diseases

the present invention relates to a pharmaceutical composition for preventing or treating metabolic diseases, in which a novel 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative and at least another active ingredient, which is selected from the group consisting of dipeptidyl peptidase-4 (dppiv) inhibitor-based, sulfonylurea-based, thiazolidinedione (tzd)-based, biguanide-based, and sodium/glucose cotransporter 2 (sglt2) inhibitor-based drugs, may be administered in combination or in the form of a composite preparation. The use of the composition of the present invention can provide a remarkably excellent blood sugar reducing effect in various animal diabetic disease models, and the composition of the present invention can be favorably used as a pharmaceutical composition for preventing or treating metabolic diseases, such as obesity, diabetes type i, diabetes type ii, glucose intolerance symptoms, insulin resistance symptoms, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, dyslipidemia, and syndrome x..

Selective agonists of beta-adrenergic type 3 receptors (bar3) and use thereof

object of the present invention is the use of selective agonists of beta-adrenergic type 3 receptors (bar3) in the treatment of nephrogenic diabetes insipidus (ndi), in particular of x-linked nephrogenic diabetes insipidus (x-ndi).. .

Improved sugar-depleted fruit or vegetable juice and juice-retaining fruit or vegetable derived matter, methods of producing the same and the use thereof to maintain health and to treat and prevent medical ailments

the present invention provides a sugar-depleted fruit or vegetable juice product, wherein said juice product is a fruit or vegetable juice or juice-retaining fruit or vegetable derived matter, wherein said juice product contains at least about 5 g/l gluconic acid and said juice product contains any two or three, of (i) at least about 0.5 g/l ca2+, (iii) at least about 1 g/l k+, and (iii) at least about 0.1 g/l mg2+. Also provided are methods of producing the same and the use thereof to assist in maintaining the health and well-being of a subject and in the treatment and prevention of medical ailments, specifically those associated with the over-consumption of glucose and/or sucrose or inappropriate metabolism of glucose, e.g.

Mapping sympathetic nerve distribution for renal ablation and catheters for same

this invention provides methods for mapping and ablating renal nerves to treat disease caused by systemic renal nerve hyperactivity, e.g. Hypertension, heart failure, renal failure and diabetes.

Industry-academic Cooperation Foundation, Yonsei University

. .

Proteins increasing pancreatic beta cell number and methods of use

disclosed herein are bacterial proteins that increase pancreatic beta (β) cell number and/or proliferation, methods of increasing β cell number and/or proliferation using such proteins, and methods of treating or inhibiting diabetes in a subject by administering such proteins to the subject. In some embodiments, the protein has at least 80% sequence identity to the amino acid sequence set forth as any one of seq id nos: 1-7, or fragments thereof.
University Of Oregon

Growth differentiation factor 15 (gdf-15) polypeptides

gdf15 polypeptides, constructs comprising gdf15, and mutants thereof are provided. In various embodiments the gdf15 polypeptides, constructs comprising gdf15, and mutants thereof, can be of use in the treatment or ameliorating a metabolic disorder.
Amgen Inc.

Substituted benzothiophenyl derivatives as gpr40 agonists for the treatment of type ii diabetes

wherein u1, u2, u3, r1, r2, z, and w are defined herein.. .

Adeno-associated viral vectors for the gene therapy of metabolic diseases

the present invention discloses adeno-associated viral vectors useful in gene therapy methods for the treatment of obesity, insulin resistance, type 2 diabetes, liver cirrhosis and non-alcoholic fatty liver disease (nafld)/non-alcoholic steatohepatitis (nash). The invention also relates to polynucleotides, plasmids, vectors and methods for the production of such adeno-associated viral vectors.
Universitat Autonoma De Barcelona

Oral spray containing ixeris dentata nakai extract as active ingredient for preventing or treating xerostomia caused by diabetes

when the ixeris dentata nakai extract is administered using the formulation of the present invention, the ixeris dentata nakai extract is sublingually sprayed through the spray formulation, and thus can be directly locally administered to a salivary gland tissue having an activity to induce secretion of saliva. Therefore, saliva secretion can be induced by rapid absorption of the active ingredient of the ixeris dentata nakai extract in the salivary gland tissue without any absorption process through the digestive system, resulting in minimized side effects..

Method and composition for treatment or prevention of type 2 diabetes and hyperlipidemia

the present invention provides a method of treating or preventing type 2 diabetes and hyperlipidemia in a subject in need thereof, comprising administrating to the subject a therapeutically effective amount of a compound of formula i. The present invention also provides a pharmaceutical composition for treatment or prevention of type 2 diabetes and hyperlipidemia, comprising a compound of formula i and a pharmaceutically acceptable carrier.

Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with serm

novel methods for prevention, reduction or elimination of the incidence of male androgen deficiency symptoms or diseases including male hypogonadism-associated symptoms and diseases associated with low serum testosterone and/or low dhea or low total androgens in susceptible warm-blooded animals including humans involving administration of an amount of a sex steroid precursor, particularly dehydroepiandrosterone (dhea) and a selective estrogen receptor modulator (serm) (particularly acolbifene), an antiestrogen or a prodrug of the two. The symptoms or diseases are loss of libido, erectile dysfunction, tiredness, loss of energy, depression, bone loss, muscle loss, muscle weakness, fat accumulation, memory loss, cognition loss, alzheimer's disease, dementia, loss of body hair, fertility problems, insomnia, gynecomastia, anemia, hot flushes, sweats, decreased sense of well-being, obesity, osteoporosis, hypercholesterolemia, hyperlipidemia, atherosclerosis, hypertension, insulin resistance, cardiovascular disease and type 2 diabetes.
Endorecherche, Inc.

Method of using dihydro-resveratrol or its stilbenoid derivatives and/or chemical variants in treatments of fibrotic and diabetic conditions

the present invention relates to a polyphenol derivative of the stilbenoid family, namely trans-3,5,4′-trihydroxybibenzyl, also known as dihydro-resveratrol, as a remedial agent. In particular, the present invention presents the usage of dihydro-resveratrol as an anti-fibrotic agent in suppressing the activation of pancreatic stellate cells (pscs).
Hong Kong Baptist University

Peptides having reduced toxicity that stimulate cholesterol efflux

the present invention provides a family of non-naturally occurring polypeptides having cholesterol efflux activity that parallels that of full-length apolipoproteins (e.g., apo ai and apo e), and having high selectivity for abca1 that parallels that of full-length apolipoproteins. Further, the peptides of the invention have little or no toxicity when administered at therapeutic and higher doses.
The Regents Of The University Of California

Compounds and methods for kinase modulation, and indications therefor

in certain aspects and embodiments, the described compounds or salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof are active on one or more of fms, kit, flt3, trka, trkb and trkc kinase protein. Also described are methods of use thereof to treat diseases and conditions, including diseases and conditions associated with activity of one or more of fms, kit, flt3, trka, trkb and trkc, including rheumatoid arthritis, osteoarthritis, osteoporosis, peri-prosthetic osteolysis, systemic sclerosis, demyelinating disorders, multiple sclerosis, charcot marie tooth syndrome, amyotrophic lateral sclerosis, alzheimer's disease, parkinson's disease, global ischemia, ulcerative colitis, crohn's disease, immune thrombocytopenic purpura, atherosclerosis, systemic lupus erythematosis, myelopreparation for autologous transplantation, transplant rejection, glomerulonephritis, interstitial nephritis, lupus nephritis, tubular necrosis, diabetic nephropathy, renal hypertrophy, type i diabetes, acute pain, inflammatory pain, neuropathic pain, acute myeloid leukemia, melanoma, multiple myeloma, breast cancer, prostate cancer, pancreatic cancer, lung cancer, ovarian cancer, gliomas, glioblastoma, neurofibromatosis, osteolytic bone metastases, brain metastases, gastrointestinal stromal tumors, and giant cell tumors..

Indole derivatives for the prevention and/or treatment of diabetes and associated metabolic disorders

the invention relates to substituted heterocyclic indole derivatives of formula (i), which act as activators of the amp-activated protein kinase (ampk) and to the use of them for the treatment and prevention of diseases or disorders regulated by ampk. As a result, these compounds can be used for the treatment of inflammatory, autoimmune, cardiovascular, neurological diseases and cancer..
Centro De Investigacion Biomedica En Red (ciber)

Methods for treating and/or limiting development of diabetes in subjects with amyotrophic lateral sclerosis

methods for treating and/or limiting development of diabetes in a subject with amyotrophic lateral sclerosis (als) by inhibiting igg-mediated activation of voltage-gated calcium channels (vgccs) in cells of the subject, by one or more of removing igg from blood of the subject, blocking igg from activating vgccs in the subject; or blocking vgccs in the subject are described, as are methods for identifying als patients at risk of developing diabetes.. .
Biocrine Ab

Multi-cbv vaccine for preventing or treating type i diabetes

the invention is directed to a vaccine comprising: i) coxsackie b virus cbv1 and cbv2, and ii) at least one coxsackie b virus selected from cbv3, cbv4, cbv5 and cbv6. The cbvs are present in the vaccine in inactivated form, in the form of a component of the virus or as an antibody against the virus.
Vactech Oy

Peptide conjugates of glp-1 receptor agonists and gastrin and their use

the present invention relates, inter alia, to certain peptide conjugates, and to the use of the conjugates in the treatment of a variety of diseases or disorders, including diabetes (type 1 and/or type 2) and diabetes related diseases or disorders.. .
Zealand Pharma A/s

Pharmaceutical compositions and methods for the treatment of diabetes

this invention relates to compositions and methods for treating type i diabetes. Compositions of the invention include active compounds such as harmine, indy, or derivatives thereof to induce reproduction of beta cells.
University Of Limerick

Smart logging for management of health-related issues

a system managing health-related issues (e.g., diabetes) includes a measurement device to measure a health characteristic and a processing device communicatively coupled to the measurement device. The processing device receives the measurement from the measurement device.
Ascensia Diabetes Care Holdings Ag

Elisa for vegf

the vascular endothelial growth factor (vegf) activity in a patient's bloodstream or other biological sample can serve as a diagnostic and prognostic index for cancer, diabetes, heart conditions, and other pathologies. Antibody-sandwich elisa methods and kits for vegf as an antigen are provided to detect types of vegf levels in biological samples from animal models and human patients and can be used as a diagnostic/prognostic index..
Genentech, Inc.

Methods of preserving and protecting pancreatic beta cells and treating or preventing diabetes by inhibiting nox-1

methods of preserving and/or protecting pancreatic beta cells by inhibiting nox-1. In a further aspect, nox-1 inhibitors are administered to a subject in order to preserve and/or protect beta cells in the prevention or treatment of diabetes.
Eastern Virginia Medical School

Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists

methods of treating metabolic diseases and disorders using an antigen binding protein specific for the gipr polypeptide are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.
Amgen Inc.

Isoquinoline derivatives useful as inhibitors of diacylglyceride o-acyltransferase 2

the present invention relates to a compound represented by formula i: and pharmaceutically acceptable salts thereof. The compounds of formula i are inhibitors of diacylglyceride o-acyltransferase 2 (“dgat2”) and may be useful in the treatment, prevention and suppression of diseases mediated by dgat2.
Merck Sharp & Dohme Corp.

Small lipopeptidomimetic inhibitors of ghrelin o-acyl transferase

compositions and methods are disclosed that relate to small molecule lipopeptidomimetic inhibitors of mammalian ghrelin o-acyl transferase (goat). Compounds of general formula (i) and substructures thereof, i.e., formulae (ii), (iia), (iia1), (iia2), (iib), (iib1), (iib2), (iic) and (iii), are shown to exhibit potent inhibition of the octanoylation of ghrelin peptide, where the resulting non-octanoylated (des-acyl) form of ghrelin lacks ghsr ligand activity that is associated with weight gain and insulin resistance.
The Regents Of The University Of California

Novel antagonists of the glucagon receptor

the present invention provides for novel compounds of formula (i) and pharmaceutically acceptable salts and co-crystals thereof which have glucagon receptor antagonist or inverse agonist activity. The present invention further provides for pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucagon receptor antagonist is indicated, including type i and ii diabetes, insulin resistance and hyperglycemia.
Metabasis Therapeutics, Inc.

Polymeric stabilizing formulations

the present invention provides compositions of a therapeutic agent and a polymeric stabilizing agent for stabilizing the reservoir of an implantable drug delivery system. The present invention also includes an implantable drug delivery system incorporating the composition of the present invention, as well as methods of treating diabetes using the compositions and implantable drug delivery system of the present invention..
Nano Precision Medical, Inc.

Tetrahydroisoquinoline derivatives useful as inhibitors of diacylglyceride o-acyltransferase 2

the present invention relates to a compound represented by formula i:and pharmaceutically acceptable salts thereof. The compounds of formula i are inhibitors of diacylglyceride o-acyltransferase 2 (“dgat2”) and may be useful in the treatment, prevention and suppression of diseases mediated by dgat2.
Merck Sharp & Dohme Corp.

Tetrahydroisoquinoline derivatives useful as inhibitors of diacylglyceride o-acyltransferase 2

the present invention relates to a compound represented by formula (i): and pharmaceutically acceptable salts thereof. The compounds of formula (i) are inhibitors of diacylglyceride o-acyltransferase 2 (“dgat2”) and may be useful in the treatment, prevention and suppression of diseases mediated by dgat2.
Merck Sharp & Dohme Corp.

Use of flavonoids in manufacturing compositions for wound healing

disclosed is a method for wound healing comprising administering a subject in need thereof a therapeutically effective amount of a flavonoid compound, wherein the compound is preferably nonglycosylated flavone. Specifically, the present invention can be used for treating skin symptoms of a trauma, a burn, a scald and a chronic wound, and can be particularly used for healing a wound of a diabetes patient..
Oneness Biotech Co., Ltd

Thermometer device

a device for measuring the temperature of a lower extremity of a subject in need of such monitoring. The device is especially suited for monitoring the foot temperature of a subject with diabetes or another condition that could lead to lower blood circulation and temperature in the lower extremities of the subject.
Jackson State University

Prodrug of 1,1'-(1,6-dioxo-1,6-hexanediyl)bis-d-proline

the present invention relates to the compound (2r,2′r)-bis(((((tetrahydro-2h-pyran-4-yl)oxy)carbonyl)oxy)methyl) 1,1′-adipoylbis(pyrrolidine-2-carboxylate), pharmaceutical compositions comprising the same and the use of the same for treatment of diseases or disorders wherein depletion of serum amyloid p component (sap) would be beneficial, including amyloidosis, alzheimer's disease, type 2 diabetes mellitus and osteoarthritis.. .
Glaxosmithkline Intellectual Property Development Limited

Negative hydrogen ion intellegrnt filtration system for curing cancer, cardiovascular disease, diabetes, hypertension, nephrotic syndrome, gout, dysautonomia and atopic dermatitis

a negative hydrogen ion intelligent filtration system includes a housing; a filtering mechanism disposed in the housing and comprising a first filter, a second filter connected to the first filter, a third filter connected to second filter, a fourth filter connected to the third filter, a fifth filter connected to the fourth filter, a sixth filter connected to the fifth filter, a seventh filter connected to the sixth filter, an eighth filter connected to the seventh filter, a ninth filter connected to the eighth filter, a tenth filter connected to the ninth filter, a eleventh filter connected to the tenth filter and a twelfth filter connected to the eleventh filter; an inflow port connected to the first filter and extending out of the housing; an outflow port connected to the twelfth filter and extending out of the housing; and a flow rate control mechanism disposed in the housing, located between the first filter and the inflow port and connecting the first filter and the inflow port.. .
Mega Sun Biomedical Corp.

Compositions and methods for producing elevated and sustained ketosis

beta-hydroxybutyrate mineral salts in combination with medium chain fatty acids or an ester thereof such as medium chain triglycerides were used to induce ketosis, achieving blood ketone levels of (2-7 mmol/l), with or without dietary restriction. The combination results in substantial improvements in metabolic biomarkers related to insulin resistance, diabetes, weight loss, and physical performance in a short period of time.
University Of South Florida

Compositions and methods for diagnosis and treatment of metabolic syndrome

compositions including an odd chain fatty acid, and salts and derivatives thereof, and methods for metabolic syndrome treatment and prophylaxis are provided, including compositions and methods for treating diabetes, obesity, hyperferritinemia, elevated insulin, glucose intolerance, dyslipidemia and related conditions. Methods for the diagnosis and monitoring of metabolic syndrome are also provided..
United States Of America, As Represented By The Secretary Of The Navy

Diabetes testing kit and methods for its use

methods and apparatuses for use in screening for and assessing neuropathies, such as severe diabetic neuropathies of the feet, also known as loss of protective sensation (“lops”). The methods and apparatuses described herein employ a kit including one or more of an insert having at least one testing instrument attached thereto, the at least one testing instrument comprising at least a holder and a monofilament; an enclosure including inner compartments for holding and securing the insert; a folder having one or more pockets for securing the insert and one or more of a mirror, a packet and other material, such as instructions.
Medical Monofilament Manufacturing Llc

Process for preparation of a grifola frondosa polysaccharide f2 and its hypoglycemic activity

a grifola frondosa polysaccharide f2 with hypoglycemic activity, process for preparation and use thereof. The process for preparation of grifola frondosa polysaccharide f2 is as follows: the fruit bodies of grifola frondosa were homogenized to a fine powder and extracted with hot water.
Guangdong Yuewei Edible Fungi Technology Co.,ltd.

Stabilized insulinotropic peptides and methods of use

the present invention provides stably crosslinked insulinotropic polypeptides having superior and unexpected benefits in the treatment of conditions involving abnormal glucose homeostasis, e.g., type 2 diabetes and conditions relating to type 2 diabetes. Such benefits include, but are not limited to, extended polypeptide half-life, enhanced alpha-helicity, improved thermal stability and protease resistance, increased functional activity and pharmacologic properties, improved bioavailability when administered by any route, and improved bioavailability and gastrointestinal absorption when delivered orally, as compared to the corresponding unmodified polypeptides.
Dana-farber Cancer Institute, Inc.

Treatment of diabetes, toll-like receptor 4 modulators and methods for using the same

the present invention relates to treatment of diabetes, toll-like receptor 4 (tlr-4) modulators and methods for using the same. Particularly, the present invention provides an isolated peptide from pneumolysin (ply peptide) which is effective in treatment of diabetes.
Kemyth Biotech Co., Ltd.

Fgf-8 for use in treating diseases or disorders of energy homeostasis

the present invention relates to polypeptides for use in treating diseases or disorders of energy homeostasis such as obesity, dyslipidemia, diabetes, insulin resistance, hyperglycemia or the metabolic syndrome. The invention also relates to polynucleotides encoding said polypeptides for use in treating diseases or disorders of energy homeostasis.
Technische Universität München

Amine polymers for use as bile acid sequestrants

the present invention provides crosslinked amine polymers effective for binding and removing bile salts from the gastrointestinal tract. These bile acid binding polymers or pharmaceutical compositions thereof can be administered to subjects to treat various conditions, including hypercholesteremia, diabetes, pruritus, irritable bowel syndrome-diarrhea (ibs-d), bile acid malabsorption, and the like..
Relypsa, Inc.

Corticosteroid formulations and methods for the treatment of joint pain in patients with diabetes

this invention relates to the use of corticosteroids in patients with diabetes, including patients with type 2 diabetes, to treat pain, including pain caused by inflammatory diseases such as osteoarthritis or rheumatoid arthritis without increasing or otherwise significantly impacting blood glucose concentrations in diabetic patients, and to slow, arrest or reverse structural damage to tissues caused by an inflammatory disease, for example damage to articular and/or periarticular tissues caused by osteoarthritis or rheumatoid arthritis without increasing or otherwise impacting blood glucose concentrations. More specifically, a formulation of triamcinolone acetonide (tca) is administered locally to diabetes patients, including type 2 diabetes patients, as a sustained release dosage form (with or without an immediate release component) that results in efficacy levels accompanied by clinically insignificant or no measurable effect on blood glucose levels..
Flexion Therapeutics, Inc.

Fatty acid cysteamine conjugates and their use as activators of autophagy

the invention relates to (i) 6-membered heteroaryl substituted fatty acid cystamine conjugates, compositions thereof, methods of treating diseases involving dysregulation of autophagy, such as cystic fibrosis, idiopathic pulmonary fibrosis (ipf), a neurodegenerative disease, inflammatory disease, liver disease, muscle disease, infection and immune disease with this compound, or (ii) a method of treating idiopathic pulmonary fibrosis, mitochondrial diseases, leigh syndrome, diabetes mellitus and deafness (dad), leber's hereditary optic neuropathy, neuropathy-ataxia-retinis pigmentosa and ptosis (narp), myoneurogenic gastrointestinal encephalopathy (mng1e), myoclonic epilepsy with ragged red fibers (merrf), or mitochondrial myopathy-encephalomy-opathy-lactic acidosis stroke like symptoms (melas), comprising administering to a patient the fatty acid cysteamine conjugate, (4z, 7z. 10z, 13z, 16z, 19z)—n-(2-mercaptoethyl) docosa-4,7,10,13,16,19-hexaenamide or (5z, 8z, 11z, 14z, 17z)—n-(2-mercaptoethyl) icosa-5,8,11,14,17-pentaenamide..
Catabasis Pharmaceuticals, Inc.

Diabetes control using postprandial feedback

disclosed is a postprandial glucose-measuring device for preventing the development of or reversing t2d. Included are methods for using the device as well as better use for invasive and noninvasive glucose meters.

Rapid screening and evaluation of diabetes and prediabetes by glycated hemoglobin mass spectrometry

the method describes rapid screening of whole blood samples, pin prick and blood spot cards, subjected to maldi-tof mass spectrometry. The spectra is generated and compared to those from normal healthy controls.
Map Ip Holding Limited

Method for detecting and purifying pancreatic beta cells

the invention is based, in part, on the discovery that a polypeptide, referred to herein as betacam, is selectively expressed on the surface of pancreatic islet cells. Thus, in one aspect, the invention is directed to compositions comprising betacam or that can be used to detect betacam.
The Regent Of The University Of Colorado, A Body Corporate

Method for screening drug-saccharide conjugates

methods for identifying drug-saccharide conjugates that bind the mannose receptor, c type 1, (mrc1) and may be taken up by cells expressing mrc1, and the use of such drug-saccharide conjugates for treatment of particular diseases are described. In particular, the methods for identifying insulin-saccharide conjugates that bind the mrc1 receptor and may be taken up by cells expressing the mrc1 and use of such conjugates for treatment of diabetes are described..
Merck Sharp & Dohme Corp.

2-alkyloxy benzene formyl arylamine compound and pharmaceutical use thereof

2-alkoxy benzene formyl arylamine compounds and their pharmaceutical salts are disclosed. The compounds can act as sphingomyelin synthase (sms) inhibitors to treat diseases caused by abnormal increasing of sphingomyelin (sm).
Fudan University

Probability based controller gain

methods and systems are disclosed for estimating a glucose level of a person having diabetes and selecting automatically open-loop and closed-loop control for a connected therapy delivery device. The method may comprise analyzing measured glucose results and corresponding impedance values received from a glucose sensor coupled to the person with a probability analysis tool implemented by a microcontroller to determine a total quality score that is based on the minimum constraint of a probability of glucose sensor accuracy determined measured glucose results and a probability of sensing quality determined from the impedance values.
Roche Diabetes Care, Inc.

Compounds against ralstonia pickettii for use in the treatment of insulin resistance, and diagnosis of insulin resistance

compounds disclosed herein are effective against ralstonia pickettii for treating or preventing insulin resistance, obesity or type ii diabetes of a subject, and include an antibiotic effective against ralstonia pickettii, an immunogenic compound producing a protective immune response, or an antibody which specifically binds to ralstonia pickettii or a fragment thereof. In vitro methods for diagnosis or prediction of insulin resistance, obesity or type ii diabetes include determining the presence of ralstonia pickettii or of an antibody which specifically binds to ralstonia pickettii in a test sample.
Wageningen Universiteit

Extract of toona sinensis from supercritical fluid extraction for treating diabetes and metabolic disease, the preparation method and the use thereof

the toona sinensis extract of the present invention is prepared using supercritical fluid technique, wherein the method includes steps of: (a) drying the leaves of t. Sinensis; (b) pulverizing the leaves as particles; and (c) extracting the particles with supercritical carbon dioxide to obtain the t.
Kaohsiung Medical University

Probiotic bifidobacterium adolescentis strains

the present invention relates to novel isolated strains of bifidobacterium adolescentis which are capable of i) increasing the trans-epithelial electrical resistance (ter) of a caco-2 cell monolayer after 10 h treatment to more than 120% of ter at treatment start, ii) inducing secretion of >200 pg/ml of il-10, and/or iii) inducing an il-10:il-12 ratio>1 when co-incubated with human pbmc derived dendritic cells. The strains may have one, two or all three of these capabilities.
Chr. Hansen A/s

Patient diabetes monitoring system with clustering of unsupervised daily cgm profiles (or insulin profiles) and method thereof

a patient diabetes monitoring system with an efficient unsupervised daily monitoring profile clustering algorithm, a method, and a computer product thereof are disclosed. The system may include a physiological data input device or sensor which receives a plurality of physiological measurements to generate a dataset, a memory which stores a clustering algorithm, and a processor.
Roche Diabetes Care, Inc.

Method for screening drug-saccharide conjugates

methods for identifying drug-saccharide conjugates that bind the mannose receptor, c type 1, (mrc1) and may be taken up by cells expressing mrc1, and the use of such drug-saccharide conjugates for treatment of particular diseases are described. In particular, the methods for identifying insulin-saccharide conjugates that bind the mrc1 receptor and may be taken up by cells expressing the mrc1 and use of such conjugates for treatment of diabetes are described..
Merck Sharp & Dohme Corp.

Anti-tnf antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes

the present invention relates to compositions and methods utilizing anti-tnf antibodies having a heavy chain (hc) comprising seq id no:36 and a light chain (lc) comprising seq id no:37 for use in the treatment or prevention of type i diabetes (t1d).. .
Janssen Biotech, Inc.

Metformin derivatives

the present invention relates to novel biguanide derivatives including their pharmaceutically acceptable salts. The invention also relates processes for the preparation of, intermediates used in the preparation of, pharmaceutical compositions containing and the uses of such compounds in treating disorders such as diabetes..
Biopharma Works Llc

Novel amino-phenyl-sulfonyl-acetate derivatives and use thereof

the present invention relates to a novel amino-phenyl-sulfonyl-acetate derivative or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition for preventing or treating diabetes comprising the same as an active ingredient.. .
Cj Healthcare Corporation

Methods for treating type 1 diabetes using glucagon receptor antagonistic antibodies

the present disclosure relates to methods for treating type 1 diabetes (t1d) using a glucagon receptor blocking agent. More specifically, the present disclosure relates to methods for treating t1d using substantially lower doses of insulin supple-mentation, or even in the absence of insulin supplementation, using antigen binding and antagonizing proteins, e.g., fully human antibodies that specifically bind to and antagonize the function of the human glucagon receptor..
Remd Biotherapeutics, Inc

Blood glucose lowering compound

the present invention relates to the field of medicine and the treatment of diabetes or hyperglycemia within that field. More particularly, the invention relates to a compound that lowers blood glucose, pharmaceutical compositions containing such a compound, and therapeutic uses of such a compound..
Amunix Operating Inc.

Peptide for treatment of type 2 diabetes mellitus and its complications

the invention relates to biotechnology. The exenatide analogue with the formula h-his-gly-glu-gly-thr-phe-thr-ser-as-leu-ser-lys-gln-glu-glu-glu-glu-ala-val-arg-leu-phe-ile-glu-trp-leu-lys-asn-gly-gly-pro-ser-ser-gly-ala- pro-pro-pro-ser-d-arg-d-arg-d-arg-d-arg-d-arg-d-arg-d-arg-d-arg-gly-oh is presented.
Daphot Enterprises Limited

Modulating gamma-c-cytokine activity

peptide antagonists of γc-family cytokines, which is associated with important human diseases, such as leukemia, autoimmune diseases, collagen diseases, diabetes mellitus, skin diseases, degenerative neuronal diseases and graft-versus-host disease (gvhd). Thus, inhibitors of γc-cytokine activity are valuable therapeutic and cosmetic agents as well as research tools.
Bioniz, Llc

Compositions and methods for regulating glucose homeostasis and insulin action

the present invention encompasses the use of compounds for a novel approach to treat and prevent diseases, conditions, and disorders such as diabetes and ischemic reperfusion injury. Compounds of the invention, including but not limited to bam15 ((2-fluorophenyl){6-[(2-fluorophenyl)amino](1,2,5-oxadiazolo[3,4-e]pyrazin-5-yl)}amine), a mitochondrial uncoupler, can improve glucose tolerance, increases cellular oxygen consumption, treat or prevent kidney ischemia reperfusion injury reverse insulin resistance, reverse or treat hyperinsulinemia, and reverse or treat hyperlipidemia.
University Of Virginia Patent Foundation

Soluble epoxide hydrolase inhibitors and uses thereof

the present invention features compounds having soluble epoxide hydrolase inhibitory activity. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing various medical conditions, such as cardiovascular diseases, respiratory diseases, inflammation, and diabetes..
X-chem, Inc.

Composition for promoting anti-diabetic and anti-obesity effects, comprising herbal extract

the present invention relates to a composition for improving anti-diabetic and anti-obesity effects, including an extract extracted from any one selected from the group consisting of lonicera japonica (lonicerae flos), scutellaria baicalensis (scutellariae radix), and houttuynia cordata (houttuyniae herba). According to the present invention, it was confirmed that co-administration of the extract of the present invention and metformin, a representative anti-diabetic drug, increases an anti-diabetic effect and reduces side effects caused by metformin, and at the same time, exhibits an anti-obesity effect by suppressing fat accumulation.
Dongguk University Gyeongju Campus Industry- Academy Cooperation Foundation

Treating a bacterial skin infection with a whole, leech saliva extract

methods are also provided for isolating and using a whole-saliva leech extract in the treatment of a bacterial skin infection. The methods can include feeding a phagostimulatory agent to a leech; inducing a regurgitation in the leech, the inducing including placing the leech in an environment having a temperature of less than about 0° c.; and, collecting an unrefined, whole saliva in the regurgitation of the cooled leech.
Biopep Solutions, Inc.

Pyrroloquinoline derivatives as 5-ht6 antagonists, preparation method and use thereof

this invention concerns pyrroloquinoline derivatives as antagonists of 5-ht6 receptors, to methods for the preparation of these compounds and to novel intermediates useful for their synthesis. The invention also relates to the uses of such compounds and compositions, particularly their use in administering them to patients to achieve a therapeutic effect in schizophrenia, anxiety, depression, maniac depression, epilepsy, obsessive compulsive disorders, mood disorders, migraine, alzheimer's disease, age related cognitive decline, mild cognitive impairment, sleep disorders, eating disorders, anorexia, bulimia, panic attacks, attention deficit hyperactivity disorder, attention deficit disorder, parkinson's disease, huntington's disease, withdrawal from abuse of cocaine, ethanol, nicotine or benzodiazepines, pain, obesity and type-2 diabetes, functional bowel disorder, irritable bowel syndrome.
Universite De Montpellier

Telemonitoring system !

disclosed is a telemonitoring system and associated methods. A doctor creates a care plan for a patient with a chronic condition, such as diabetes.
Esvyda!, Inc.

Protein and protein conjugate for diabetes treatment, and applications thereof

the present invention relates to the field of biopharmaceuticals, and in particular to a protein, a protein conjugate, a pharmaceutical composition and its use for treating diabetes. The fusion protein of the present invention is obtained by linking two polypeptides, wherein one polypeptide is an interleukin-1 receptor antagonistic protein or an analogue thereof, and another polypeptide is glp-1 receptor binding polypeptide or an analogue thereof, or an insulin receptor binding polypeptide or an analogue thereof, or a gip receptor binding polypeptide or an analogue thereof.
Adda Biotech Inc.

Cyclic polypeptides for the treatment of heart failure

or an amide, an ester or a salt thereof, or a bioconjugate thereof, wherein x1, x3, x4, x7, x8, x9, x10, x11, x12 and x13 are defined herein. The polypeptides are agonist of the apj receptor.

Adjusting insulin delivery rates

a method may include displaying to a user an interface at which the user inputs a fear of hypoglycemia index (fhi), the fhi corresponding to an acceptable probability of a blood glucose level being below a threshold blood glucose level. The method may also include receiving blood glucose data for a person with diabetes (pwd).
Bigfoot Biomedical, Inc.

Soluble mediator

the present disclosure relates to a soluble cd52 glycoprotein and its use in treating diseases regulated by effector t-cells, for example autoimmune diseases such as type 1 diabetes. The present disclosure also relates to fusion proteins comprising the soluble glycoprotein, to cells expressing high levels of cd52, and to diagnostic methods based on the detection of cd52 expression levels in a subject..
The Walter And Eliza Hall Institute Of Medical Research

Pharmaceutical compositions of water soluble peptides with poor solubility in isotonic conditions and methods for their use

the present invention provides compositions comprising water soluble peptides with poor solubility in isotonic solutions which exhibit enhanced bioavailability with reduced adverse effects including injection site reactions. Methods are also disclosed for using such compositions for the treatment of diseases including, but not limited to, cancer, type 2 diabetes, acromegaly, metabolic disorders, endocrine disorders, exocrine tumors, and hormone-related tumors.
Strongbridge Biopharma Plc

Drug combinations and methods to stimulate embryonic-like regeneration to treat diabetes and other diseases

stem cell-based therapies can potentially reverse organ dysfunction and diseases but the removal of impaired tissue and reactivation of the program leading to organ regeneration pose major challenges. In mice, a four-day fasting mimicking diet (fmd) induces a step-wise expression of sox17 and pdx-1, resembling that observed during pancreatic development and followed by ngn3-driven generation of insulin-producing β-cells.
University Of Southern California

Cafestol for treating diabetes

a method is provided of treating, preventing or ameliorating type 2 diabetes and/or a clinical condition associated with type 2 diabetes, which method comprises administering an effective amount of cafestol or a derivative thereof including esters and salts thereof to a person in need thereof. Further provided are compositions comprising cafestol and at least one additional agent suitable for treating, preventing or ameliorating diabetes and/or a clinical condition associated with diabetes.
Region Midtjylland

Method for treating a neurovascular complication of diabetes mellitus

a method of preventing and/or treating a disease caused by diabetes complications includes administering to a patient in need thereof, an effective amount of thymoquinone or a pharmaceutically acceptable salt thereof, either singly or in combination with a pharmaceutically acceptable carrier, diluent or excipient. The disease can be at least one of retinopathy, nephropathy, neuropathy, and neurological disorder..
King Saud University

Apparatus, chronic disease monitoring

an apparatus, system, and method for monitoring a person suffering from a chronic medical condition predicts and assesses physiological changes which could affect the care of that subject. Examples of such chronic diseases include (but are not limited to) heart failure, chronic obstructive pulmonary disease, asthma, and diabetes.
Resmed Sensor Technologies Limited

Pig model for diabetes

the present invention relates to a transgenic pig comprising a mutated iapp gene and displaying a phenotype associated with diabetes. The invention also relates to a transgenic blastocyst, embryo, fetus, donor cell and/or cell nucleusderived from said transgenic pig.
Aarhus Universitet

Electronic phenotyping technique for diagnosing chronic kidney disease

an example method of diagnosing chronic kidney disease (ckd) includes obtaining an electronic medical record for a patient having medical data. The medical data includes an indication if the patient had been previously diagnosed with ckd, an indication if the patient had previously undergone a kidney transplant, an indication if the patient had previously undergone a renal dialysis procedure, an indication if the patient had previously been diagnosed with another type of kidney disease, one or more glomerular filtration rate (gfr) measurements associated with the patient, an indication if the patient has type 2 diabetes, and/or an indication if the patient has hypertension.
Icahn School Of Medicine At Mount Sinai

Insulinotropic peptide derivative with modified n-terminal charge

the present invention relates to an insulinotropic peptide derivative with a modified n-terminal charge and a pharmaceutical composition including the same. Specifically, the insulinotropic peptide derivative is characterized in that the n-terminal positive charge of the insulinotropic peptide is modified to a neutral or net negative charge at neutral ph.
Hanmi Pharm. Co., Ltd.

Chemical compounds and use thereof for improving muscular quality

chemical compounds and the therapeutic use thereof, in particular for improving muscular quality in mammals. More particularly, a method of improving muscular quality in sarcopenic mammals and treating and/or preventing sarcopenia using the chemical compounds and, in particular, sarcopenic obesity and the associated complications and/or pathologies thereof, such as loss of strength, muscle mass, performance and of physical and movement capacity.
Universite Paris 6 Pierre Et Marie Curie

N-(5-((aryl or heteroaryl)methyloxy)pentyl)-substituted iminosugars as inhibitors of glucosylceramide synthase

deoxynojirimycin and deoxygalactonojirimycin derivatives according to the present invention are n-alkylated d-galacto, d-gluco- or l-ido-deoxynojirimycin with a linear methyloxypentyl group bearing various sidegroups and a non-fused bicyclic aromatic group (“x”) on the methyloxy-carbon. These compounds display an increased inhibitory potency towards gcs, and/or an increased inhibitory potency towards gba2, and/or a decreased inhibitory potency towards gba1, relative to known deoxynojirimycin derivatives of the same (d-gluco, l-ido or d-galacto) configuration.
Universiteit Leiden

Device for attachment to a portable liquid injection device

the invention refers to a device for attachment to a portable liquid injection device, wherein said device is designed to enclose the drug reservoir of the injection device completely. Further, said device has at least two flat conductive electrodes enabling an electrical field to be applied across the entire volume of the drug reservoir of the injection device.
Valtronic Technologies (holding) Sa

Method of preventing and treating retinal microvasculature inflammation using c-met signaling pathway inhibition

the present invention provides methods for preventing retinal microvasculature inflammation in patients with diabetes who are highly susceptible to developing diabetic retinopathy and/or diabetic macular edema. The methods comprise inhibiting c-met signaling pathway by administering a c-met inhibitor alone or in combination with anti-vegf or steroid medications to diabetic patients.

Nutritional support health issues

a method of improving the outcome or recovery for depression, diabetes, cardiovascular disease, alzheimers progression, or breast cancer. This method consists of administering a food which includes transfer factor, lactic acid generating bacteria, and/or glucans in appropriate combinations and dosage levels.
Cortcontrol

Phospholipid-containing marine extracts for treatment of cardiovascular diseases

the present invention relates to a method of treatment and/or prevention of cardiovascular disease, rheumatoid arthritis, skin cancer, premenstrual syndrome, diabetes and transdermal transport enhancement. The method comprises the administration of a therapeutically effective amount of krill and/or marine oil to a patient.
Neptune Technologies & Bioressources, Inc.

Aromatic farnesyl compound and application thereof

aromatic farnesyl compound and application of a pharmaceutical salt thereof as an inhibitor of α-glucosidase, dipeptidyl peptidase-4, aldose reductase, protein tyrosine phosphatase-1b or hmg-coa reductase, or use thereof in preparing medicine and functional healthcare products having a liver protective function and/or for treating and/or preventing type ii diabetes, diabetic retinopathy, diabetic foot disease, and hyperlipidemia.. .
Institute Of Microbiology, Chinese Academy Of Sciences

Specialized flour for nutrition meals for diabetes and preparation method and use thereof

disclosed are specialized flour for nutrition meals for diabetes and a preparation method and use thereof. The flour is based on cereal meal as a basic material and is added to a defatted soybean vegetable protein powder and a soybean tissue isolated dietary fiber power, wherein in the dry flour base, the content of protein is 20-26 weight %, the content of the dietary fiber is 4-10 weight %, the content of carbohydrate is no more than 65 weight %, and the content of fat is no more than 4% of the weight.

System and decision support using lifestyle factors

systems and methods are provided relating to open loop decision-making for management of diabetes. People with diabetes face many problems in controlling their glucose because of the complex interactions between food, insulin, exercise, stress, activity, and other physiological and environmental conditions.
Dexcom, Inc.

System and decision support using lifestyle factors

systems and methods are provided relating to open loop decision-making for management of diabetes. People with diabetes face many problems in controlling their glucose because of the complex interactions between food, insulin, exercise, stress, activity, and other physiological and environmental conditions.
Dexcom, Inc.

Composition and using mir-302 precursors as drugs for treating alzheimer's diseases

this invention generally relates to a composition and method of using recombinant micrornas (mirna) and their hairpin-like precursors (pre-mirna) as therapeutic drugs for treating alzheimer's diseases (ad). More specifically, the present invention relates to the use of man-made mirna mir-302 precursors (pre-mir-302) for ad therapy in humans.
Mello Biotechnology, Inc.

Compositions and methods for measuring nmu and for treatment using anti-nmu agents

the inventors have produced two high specificity and high affinity monoclonal antibodies that bind to human neuromedin u (nmu). Methods and compositions are provided for treating an individual in need thereof (e.g., an individual who is obese and/or has diabetes) by administering an anti-nmu/nmur agent (e.g., an anti-nmu antibody).
The Board Of Trustees Of The Leland Stanford Junior University

Humanized antibodies specific for hsp65-derived peptide-6, methods and uses thereof

the present invention relates to humanized antibodies that specifically bind a polypeptide comprising peptide-6 as denoted by seq id no. 15, that is an hsp65 derived peptide.
Protab Ltd.

Novel 3-amino-pyrrolo[3,4-c]pyrazole-5(1h, 4h,6h) carbaldehyde derivatives

wherein a, b, r1, r2, r3, r4, r5, r6, r7, r8, r9 and r10 are as defined above. The invention further relates to pharmaceutical compositions comprising the compounds and pharmaceutically acceptable salts and to methods of treating diabetes mellitus and its complications, cancer, ischemia, inflammation, central nervous system disorders, cardiovascular disease, alzheimer's disease and dermatological disase pression, virus diseases, inflammatory disorders, or diseases in which the liver is a target organ..

Amlexanox analogs

provided herein are amlexanox analogs and methods for the treatment and/or prevention of diabetes, impaired insulin signaling, obesity, or other related diseases and conditions therewith.. .
The Regents Of The University Of Michigan

[7,6]-fused bicyclic antidiabetic compounds

novel compounds of the structural formula (i), and the pharmaceutically acceptable salts thereof, are agonists of g-protein coupled receptor 40 (gpr40) and may be useful in the treatment, prevention and suppression of diseases mediated by the g-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia..
Merck Sharp & Dohme Corp.

Pyrrolidine gpr40 modulators for the treatment of diseases such as diabetes

the present invention provides compounds of formula (i) or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, or a solvate thereof, wherein all of the variables are as defined herein. These compounds are gpr40 g protein-coupled receptor modulators which may be used as medicaments..
Bristol-meyers Squibb Company

Antidiabetic bicyclic compounds

novel compounds of the structural formula (i), and the pharmaceutically acceptable salts thereof, are agonists of g-protein coupled receptor 40 (gpr40) and may be useful in the treatment, prevention and suppression of diseases mediated by the g-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia..
Merck Sharp & Dohme Corp.

Antidiabetic bicyclic compounds

novel compounds of the structural formula (i), and the pharmaceutically acceptable salts thereof are agonists of g-protein coupled receptor 40 (gpr40) and may be useful in the treatment, prevention and suppression of diseases mediated by the g-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia..
Merck Sharp & Dohme Corp.

Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders

also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the treatment of s1p1 receptor-associated disorders, for example, psoriasis, rheumatoid arthritis, crohn's disease, transplant rejection, multiple sclerosis, systemic lupus erythematosus, ulcerative colitis, type i diabetes, acne, microbial infections or diseases and viral infections or diseases.. .

Swallowable capsule and stimulating incretin production within the intestinal tract

embodiments of the invention provide apparatus and methods for stimulating l cells in the intestinal tract to produce incretins for the treatment of conditions including diabetes and obesity. Many embodiments provide a method and apparatus for the treatment of diabetes by electrically stimulating l-cells to secrete incretins to stimulate or otherwise modulate the production of insulin.
Incube Labs, Llc

Dry powder inhaler

a dry powder inhaler including replaceable cartridges containing a dry powder for local or systemic delivery through the pulmonary tract and lungs is disclosed. The inhalers are used with inhalable dry powders, including medicament formulations comprising active agents for local or systemic delivery and for the treatment of diseases such as, pulmonary hypertension, cardiovascular disease, anaphylaxis, diabetes, obesity, cancer, and other diseases, or symptoms associated with these and other diseases, such as nausea, vomiting, pain and inflammation..
Mannkind Corporation

System and decision support using lifestyle factors

systems and methods are provided relating to open loop decision-making for management of diabetes. People with diabetes face many problems in controlling their glucose because of the complex interactions between food, insulin, exercise, stress, activity, and other physiological and environmental conditions.
Dexcom, Inc.

Functionalized exendin-4 derivatives

the present invention relates to exendin-4 derivatives and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake.. .
Sanofi

Use of dehydroeburicoic acid from antrodia camphorata in the treatment or prevention of diabetes and hyperlipidemia

the present invention provides a method for treating type 1 diabetes, hyperlipidemia or hepatic lipid accumulation by using dehydroeburicoic acid, as well as a method for decreasing levels of blood glucose, plasma total cholesterol, and triglyceride, and increasing insulin levels; and a method for decreasing hepatic balloon degeneration; and increasing expression levels of membrane glut4 and phospho-akt in myotubes; and enhancing expression levels of membrane glucose transporter 4 (glut4) in skeletal muscle, and phospho-ampk in both skeletal muscle and liver tissue using dehydroeburicoic acid.. .

Phenoxy acetic acids and phenyl propionic acids as ppar delta agonists

phenoxy acetic acids and phenyl propionic acids and their use in treating type i diabetes, type ii diabetes, impaired glucose tolerance, insulin resistance, or obesity are provided herein. The present compounds are activators of pparδ and may be useful for treating conditions mediated by the same..
Vtv Therapeutics Llc

Aldose reductase inhibitors and uses thereof

the present invention relates to novel compounds and pharmaceutical compositions thereof, and methods for promoting healthy aging of skin, the treatment of skin disorders, the treatment of cardiovascular disorders, the treatment of renal disorders, the treatment of angiogenesis disorders, such as cancer, treatment of tissue damage, such as non-cardiac tissue damage, the treatment of evolving myocardial infarction, and the treatment of various other disorders, such as complications arising from diabetes with the compounds and compositions of the invention. Other disorders can include, but are not limited to, atherosclerosis, coronary artery disease, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, infections of the skin, peripheral vascular disease, stroke, and the like..
The Trustees Of Columbia University In The City Of New York

Aldose reductase inhibitors and uses thereof

the present invention relates to novel compounds and pharmaceutical compositions thereof, and methods for promoting healthy aging of skin, the treatment of skin disorders, the treatment of cardiovascular disorders, the treatment of renal disorders, the treatment of angiogenesis disorders, such as cancer, treatment of tissue damage, such as non-cardiac tissue damage, the treatment of evolving myocardial infarction, and the treatment of various other disorders, such as complications arising from diabetes with the compounds and compositions of the invention. Other disorders can include, but are not limited to, atherosclerosis, coronary artery disease, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, infections of the skin, peripheral vascular disease, stroke, and the like..
The Trustees Of Columbia University In The City Of New York

Compositions for treating or preventing obesity and insulin resistance disorders

provided herein are methods and compositions for modulating the activity or level of a sirtuin, thereby treating or preventing obesity or an insulin resistance disorder, such as diabetes in a subject. Exemplary methods comprise contacting a cell with a sirtuin activating compound or an inhibitory compound to thereby increase or decrease fat accumulation, respectively..
The General Hospital Corporation D/b/a Massachusetts General Hospital

Methods of treating diabetes by administering a glucagon receptor antagonist in combination with a cholesterol absorption inhibitor

use of a glucagon receptor antagonist in combination with a cholesterol absorption inhibitor for the treatment of diabetes and related conditions is disclosed.. .
Merch Sharp & Dohme Corp.

Glucagon antagonists

provided herein are compounds, including enantiomerically pure forms thereof, and pharmaceutically acceptable salts or co-crystals and prodrugs thereof which have glucagon receptor antagonist or inverse agonist activity. Further, provided herein are pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucagon receptor antagonist is indicated, including type i and ii diabetes, insulin resistance and hyperglycemia.
Ligand Pharmaceuticals, Inc.

Veroscience Llc

. .

Screening and monitoring the progression of type 2 diabetes by the molecular identification of human gut flora using fta as a faecal collection device

disclosed is a method for detecting and quantifying gut flora derived from human faeces, comprising acquiring a solid support containing human faeces; optionally amplifying nucleic acid from the human faeces; and detecting and quantifying the presence of gut flora of interest. Also disclsoed is a method for assessing whether a person has type-2 diabetes as well as a kit for detecting and quantifying gut flora from human faeces, comprising a solid support for collecting human faeces; and primer pairs for amplifying 16s rrna sequence from bacteria of interest..
Ge Healthcare Uk Limited

High-purity galactooligosaccharide compositions, preparations, and applications thereof

provided is a method of preparing a high-purity galactooligosaccharide composition by fermentation of a low-purity galactooligosaccharide mixture with a yeast strain, kluyveromyces lactis atcc 8585. The high-purity galactooligosaccharide composition includes at least 99% of galactooligosaccharides selected from the group consisting of galactotriose, galactotetrose, galactooligosaccharides with five or more sugar units, and combinations thereof and lower than 1% of monosaccharides and disaccharides.
King-prebiotics Biotechnology (tw) Co., Ltd.

[5,6]-fused bicyclic antidiabetic compounds

novel compounds of the structural formula (i), and the pharmaceutically acceptable salts thereof, are agonists of g-protein coupled receptor 40 (gpr40) and may be useful in the treatment, prevention and suppression of diseases mediated by the g-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia..
Merck Sharp & Dohme Corp.

Deutero-phenformin derivatives

the present disclosure is directed to novel phenformin derivatives, and their pharmaceutically acceptable salts, solvates, or stereoisomers thereof. This disclosure also provides compositions and the use of such compositions in method of treating cancer, diabetes, or polycystic ovarian syndrome..
Enlibrium Inc

A peptide therapy to counteract insulin resistance and type 2 diabetes

compositions comprising an antagonist of pancreastatin are provided. The beneficial use of the compositions for treating insulin resistance, diabetes, especially type ii diabetes, inflammation, obesity, non-alcoholic fatty liver disease, atherosclerosis and cardiovascular diseases is described as well..
Indian Institute Of Technology Madras

Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes

in another aspect, the present invention is directed to a method for treating a patient suffering from a metabolic disorder such as the metabolic syndrome, type 2 diabetes, obesity, or prediabetes, and the metabolic sequale of these diseases including cardiovascular, cerebrovascular, renal and hepatic diseases, comprising the step of: administering to a patient suffering from the metabolic syndrome, type 2 diabetes, obesity, or prediabetes a pharmaceutical composition comprising (1) at least one compound that stimulates an increase in central dopaminergic neuronal activity level in the subject, and (2) at least one compound that stimulates a decrease in central noradrenergic neuronal activity level in the subject. The present invention is also directed to pharmaceutical compositions that include the above compounds and a pharmaceutically acceptable carrier..

Socs1-derived peptide for use in chronic complications of diabetes

the present invention relates to a socs1-derived peptide for use in chronic complications of diabetes, particularly ocular, renal, nerve and vascular complications, as well as compositions containing same and isolated polynucleotides encoding same. The present invention also relates to the socs1-derived peptide for topical use in the treatment and/or prevention of neurodegenerative diseases of the retina, particularly in the early stages of diabetic retinopathy and other diseases of the retina in which neurodegeneration plays an essential role..
Universidad Autónoma De Madrid

Composition for treating obesity and diabetes and for increasing muscle mass and improving capacity for exercise, comprising extracts of piper retrofractum vahl. fruits as active ingredients

the present invention relates to a food composition, and to a pharmaceutical composition, which exhibit anti-obesity effects by means of a thermogenesis produced by an activity of a ucp of fat cells, which exhibit anti-diabetes effects by means of an improved insulin resistance, increase muscle mass, and improve capacity for exercise. More particularly, the present invention relates to a novel use of a composition containing extracts of piper retrofractum, and to the food composition or pharmaceutical composition which exhibit anti-obesity effects by means of decreased body weight and body fat, exhibit anti-diabetes effects by means of ameliorated insulin resistance through the reduction of blood glucose and blood insulin, increase muscle mass by increasing an energy source being supplied to the muscles, and improve the capacity for exercise including increased endurance..
Industry-academic Cooperation Foundation, Yonsei University

A combination of kynurenine and antigen presenting cells (apc) as therapeutics and methods for their use in immune modulation

this invention provides combinations of kynurenine and antigen presenting cells (apc) for modulating immune tolerance, wherein the combinations may be used to modulate an autoimmune response, which may be of use in the treatment of type 1 diabetes (t1d) or alopecia areata (aa). Uses of kynurenine and antigen presenting cells (apc) as an immune modulator for the treatment of t1d or aa are also provided..
The University Of British Columbia

Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of diabetes

the present invention concerns the use of compounds for preventing and/or treating diabetes, for modulating glucose, insulin, and/or triglyceride levels; for reducing blood glucose level; for maintaining or increasing insulin level; for increasing insulin secretion; increasing insulin sensitivity; or decreasing insulin resistance in a subject. These novel uses have been found for compounds represented by formula i and pharmaceutically acceptable salts.
Prometic Pharma Smt Limited

Biguanide compositions and methods of treating metabolic disorders

provided herein are methods for treating certain conditions, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administrating a composition comprising a a biguanide or related heterocyclic compound, e.g., metformin. Also provided herein are biguanide or related heterocyclic compound compositions, and methods for the preparation thereof for use in the methods of the present invention.
Elcelyx Therapeutics, Inc.

Biochemical markers for use in determining risk of diabetes

a method for predicting risk of gestational diabetes mellitus (gdm) in a pregnant individual includes measuring one or more biochemical markers in a blood sample obtained from the pregnant individual to determine one or more biomarker levels, where the one or more measured biochemical markers includes at least one of amylin, 17β-estradiol, and lipocalin-2, identifying, for each of the one or more measured biochemical markers, a difference between the measured biomarker level and a corresponding predetermined control level, and, responsive to the identifying, determining a prediction corresponding to a relative risk of the pregnant individual having or developing gdm.. .
Wallac Oy

Goodpasture antigen binding protein detection and inhibition and its use in diabetes

disclosed herein are methods for treating type 2 diabetes, limiting development of type 2 diabetes, and treating a pre-diabetic state by administering to a subject in need thereof a gpbp inhibitor. Also disclosed herein are methods for diagnosing a pre-diabetic state and for diagnosing a propensity to develop type 2 diabetes by determining an amount of gpbp in a sample from a subject and comparing to control..
Fibrostatin, S.l.

Method of designing a peptide and/or peptide derivative for modulating gamma-c-cytokine activity

the γc-family cytokines, interleukin-2 (il-2), interleukin-4 (il-4), interleukin-7 (il-7), interleukin-9 (il-9), interleukin-15 (il-15), and interleukin-21 (il-21), are associated with important human diseases, such as leukemia, autoimmune diseases, collagen diseases, diabetes mellitus, skin diseases, degenerative neuronal diseases and graft-versus-host disease (gvhd). Thus, inhibitors of γc-cytokine activity are valuable therapeutic and cosmetic agents as well as research tools.
Bioniz, Llc

Preparation and use of crystalline beta-d-nicotinamide riboside

provided herein are crystalline beta-d-nicotinamide riboside chloride compositions and methods of preparation and use thereof. Also provided are related pharmaceutical compositions and methods of use thereof.
Glaxosmithkline Intellectual Property (no.2) Limited

Adjusting insulin delivery rates

a method may include delivering insulin, using an insulin pump and a controller, over a first diurnal time period based on a baseline basal insulin rate stored in memory. The controller may receive blood glucose data to control delivery of insulin via the insulin pump in amounts variable from the baseline basal insulin rate to control blood glucose levels for a person with diabetes (pwd).
Bigfoot Biomedical, Inc.

Diabetes management system

a variety of location-based and/or proximity-based features related to diabetes management systems can be used to improve maintenance compliance and/or to provide important information to pwd designated assistance entities (e.g., family, friends, givers, hcps, emergency medicine providers) under certain conditions. In some cases, a user's location can be tracked or determined to trigger and/or time alerts about upcoming maintenance tasks in a way that will increase the likelihood that the pwd will immediately perform the designated maintenance task.
Bigfoot Biomedical, Inc.

Compositions comprising cyclocarya paliurus extract and preparation method and uses thereof

compositions and preparation method thereof, said compositions comprise an extract from a mixture comprising cyclocarya paliurus leaves and one or more herbs selected from the group consisting of mori cortex, dendrobii caulis and citri reticulatae pericarpium, said compositions can treat diabetes, hyperglycemia, hypertension and/or hyperlipidemia.. .
Infinitus (china) Company Ltd

Small molecule inhibitors of stat3 with anti-tumor activity

the present invention concerns compounds, compositions containing these compounds, and methods of using these compounds and compositions as inhibitors of stat3 signaling, stat3 dimerization, stat3-dna binding, stat5-dna binding, and/or aberrant cell growth in vitro or in vivo, e.g., as anti-cancer agents for treatment of cancer, such as breast cancer. The compounds of the invention include, but are not limited to, nsc 74859 (s3i-201), nsc 42067, nsc 59263, nsc 75912, nsc 11421, nsc 91529, nsc 263435, and pharmaceutically acceptable salts and analogs of the foregoing.
University Of Central Florida Research Foundation.

Biguanide compositions and methods of treating metabolic disorders

provided herein are methods for treating certain conditions, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administrating a composition comprising a biguanide or related heterocyclic compound, e.g., metformin. Also provided herein are biguanide or related heterocyclic compound compositions, and methods for the preparation thereof for use in the methods of the present invention.
Elcelyx Therapeutics, Inc.

Surrogates of post-translationally modified proteins and uses thereof

the present invention provides compounds that are surrogates of post-translationally modified proteins and uses thereof. Numerous diseases are associated with post-translationally modified proteins that are difficult to obtain in homogenous form and in quantities needed for immunization and use as convenient standards, calibrators, and/or reference compounds that facilitate the detection and analysis of endogenous post-translationally modified proteins.
Dummen Group B.v.

User interface for diabetes management system

a diabetes management system including a pump for dispensing a medicant and a control device for controlling the pump includes a user interface for controlling functions of the pump and providing information related to operation of the pump and other information. The user interface can display blood glucose information and insulin dosing data such that a user can appropriately act on the information and/or gain confidence that the diabetes management system is operating appropriately to manage the disease.
Bigfoot Biomedical, Inc.

Methods of treating diabetes and compositions capable of same

a composition of matter is disclosed which comprises isolated oligomers of human islet amyloid polypeptide (iapp). Antibodies recognizing same are also disclosed.
Ramot At Tel-aviv University Ltd.

Agonists of the apelin receptor and methods of use thereof

provided herein are small molecule agonists of the apelin receptor for the treatment of disease. The compounds disclosed herein are useful for the treatment of a range of cardiovascular, renal and metabolic conditions.
Sanford-burnham Medical Research Institute

Ultrashort peptides as exogenous second harmonic probes for bioimaging applications

various aspects of the present invention relate to a peptide based biomaterial for visualization by shg microscopy. In particular the invention relates to the use of short peptides as a non-linear optical (nlo) material for second harmonic generation (shg) microscopy.
Agency For Science, Technology And Research

Composition for treating diabetes mellitus comprising insulin and a glp-1/ glucagon dual agonist

a composition for preventing or treating diabetes mellitus includes insulin and a glp-1/glucagon dual agonist. The composition can inhibit the weight gain and reduce the danger of hypoglycemia due to the administration of insulin, lower the administration dose and greatly improve the compliance of drugs through a combined administration of a long-acting insulin conjugate and a long-acting glp-1/glucagon dual agonist conjugate.
Hanmi Pharm. Co., Ltd.

Enhancement of glucose-stimulated insulin secretion by cells through induction of cellular senescence

methods for increasing glucose induced insulin secretion in an insulin secreting cell by inducing senescence in the cell are provided. Further, methods for treating diabetes, by providing cells with increased glucose induced insulin secretion to a subject, as well as a population of modified insulin secreting cells are provided..
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.

Compositions and methods of treating diabetic retinopathy

a method of treating diabetic retinopathy in a subject in need thereof includes administering to the subject a therapeutically effective amount of one or more agents that act as a trap of reactive aldehydes and/or inhibit diabetes-induced superoxide generation and capillary degeneration regulated by gpcr signaling pathways.. .
Case Western Reserve University

Tgr5 agonist complexes for treating diabetes and cancer

provided herein are complexes of metformin or metformin analogues and a tgr5 ligand that are useful in treating diseases including diabetes, cardiovascular disease, and cancer.. .
City Of Hope

Heterocyclic gsk-3 allosteric modulators

the present invention relates to heterocyclic substituted quinoline derivatives as allosteric inhibitors of the glycogen synthase kinase-3 (gsk-3) enzyme. Therefore, these compounds are useful for the manufacturing of a medicament designed for the treatment and/or prevention of diseases wherein gsk-3 is involved, such as neurodegenerative diseases, inflammatory diseases, cancer, diabetes, and to promote various regenerative processes..
Consejo Superior De Investigaciones Cientificas (csic)

Glsxosmithkline Intellectual Property (no.2) Limited

. .

Omniblend Innovation Pty Ltd.

. .

Ex vivo browning of adipose tissue therapy for reversal of obesity and type ii diabetes

provided are methods, apparatus, pharmaceutical compositions, and kits for treatment of a metabolic condition, including obesity and type 2 diabetes, by administration to a subject of a therapeutically effective amount of a cell or tissue preparation such as brown adipose microtissues or brown adipose tissue directly converted from white adipose tissue. Modified approaches to creating brown adipose tissue involve differentiation of explanted white adipose tissue and direct browning of white adipose tissue in a bioreactor rather than isolation and expansion of adipose stems cells or endothelial cells and formation and differentiation of 3d cell aggregates..
The Trustees Of Columbia University In The City Of New York

Compositions for selective reduction of circulating bioactive soluble tnf and methods for treating tnf-mediated disease

an isolated or synthetic antibody or ligand is provided that specifically binds to an epitope of a dissociated monomer of human tnf. Such binding disrupts assembly of the monomer into bioactive trimeric human stnf.
Thymon, Llc

Alpha1 -antitrypsin compositions and methods of treating autoimmune diseases

the specification provides compositions comprising chimeric proteins comprising aat conjugated to an fc region of an immunoglobulin. Methods for treating autoimmune disease, e.g., diabetes, e.g., type 1 and type 2 diabetes, are also provided..
Beth Israel Deaconess Medical Center, Inc.

Novel glucagon analogues

the present invention relates to novel peptide compounds which have a protracted profile of action and improved solubility and stability, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of hyperglycemia, diabetes and obesity, as well as a variety of diseases or conditions associated with hyperglycemia, diabetes and obesity..
Novo Nordisk A/s

Pyridine derivative

provided is a pyridine derivative represented by formula (i), a prodrug thereof, a pharmaceutically acceptable salt of the pyridine derivative or the prodrug, or a solvate of the pyridine derivative, the prodrug or the pharmaceutically acceptable salt, which is useful for treatment or prophylaxis of diseases associated with urat1 such as gout, hyperuricemia, hypertension, kidney diseases such as interstitial nephritis, diabetes, arteriosclerosis and lesch-nyhan syndrome.. .
Teijin Pharma Limited

Exendin-4 analogue pegylated with polyethylene glycol or derivative thereof, preparation method thereof, and pharmaceutical composition for preventing or treating diabetes, containing same as active ingredient

the present disclosure relates to an exendin-4 analogue pegylated with polyethylene glycol or a derivative thereof, a preparation method, and a pharmaceutical composition for prevention or treatment of diabetes containing the same as an active ingredient. According to the present invention, the yield of an exendin-4 analogue can be increased via the selective pegylation by using exendin-4 in which a cysteine is introduced into #40 site of the c-terminal, and treatment effect of medications can be increased, so that the exendin-analogue can be usefully applied as a composition for prevention or treatment of diseases caused by insulin hypersecretion..
Theraly Pharmaceuticals Inc.

Bacteroides cect 7771 and the use thereof in the prevention and treatment of excess weight, obesity and metabolic and immunological alterations

the invention relates to a strain of bacteroides uniformes with registration number cect 7771, and to the cellular constituents, metabolites and/or secreted molecules thereof. The invention also relates to a composition (nutritional or pharmaceutical) comprising at least one of the previous products.
Consejo Superior De Investigaciones Cientificas

Transgenic pig islets and uses thereof for treating diabetes

the present invention relates to an isolated transgenic pig beta cell wherein the pkc and the pka pathway are constitutively activated; to a transgenic pig islet comprising said transgenic pig beta cell; and to a transgenic pig comprising said transgenic pig beta cell or said transgenic pig islet. Another object of the invention is a device comprising a transgenic pig beta cell or a transgenic pig islet of the invention.
UniversitÉ Catholique De Louvain

Methods for treating insulin resistance and for sensitizing patients to glp1 agonist therapy

methods for treatment of insulin resistance and type ii diabetes by administration of inhibitors of the pki pathway are provided. In some aspects, inhibitors of the pki pathway, such as inhibitors of pikb, hif1 and/or mtor, can be used to treat subject having insulin resistance who are refractory to glp1 agonist therapy..
Research Development Foundation

Combination therapy with sglt-2 inhibitors and their pharmaceutical compositions

the present invention is directed to a pharmaceutical composition comprised of one or more sglt-2 inhibitor compound(s) in combination with one or more therapeutic agents which is suitable for the treatment of metabolic disorders including type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance, hyperglycemia, postprandial hyperglycemia, overweight, obesity, including class i obesity, class ii obesity, class iii obesity, visceral obesity and abdominal obesity, and metabolic syndrome.. .
Boehringer Ingelheim International Gmbh

Solid oral formulation of fenretinide

amorphous solid dispersions suitable for oral delivery comprising fenretinide or an analog thereof and at least one matrix polymer, and processes for making the dispersions, are disclosed. Also disclosed are solid oral formulations comprising the amorphous solid dispersions, as well as uses thereof for the prevention and/or treatment of diseases or conditions treatable by fenretinide, including but not limited to cancers, conditions associated with a lipid imbalance, cystic fibrosis, osteoporosis, conditions associated with inflammation or opportunistic infections, and other diseases such as diabetes, obesity, dry-form age-related macular degeneration..
Laurent Pharmaceuticals

Pharmaceutical composition comprising rimeporide for treating diseases associated with insulin resistance and beta-cell dysfunction

the invention relates to a pharmaceutical composition comprising as active ingredient an effective amount of 2-methyl-4,5-di-(methylsulfonyl)-benzoyl-guanidine, or derivatives thereof, for the prophylaxis and therapy of type ii diabetes mellitus, the metabolic syndrome, diabetic nephropathy and/or neuropathy. Another object of the invention concerns the use of 2-methyl-4,5-di-(methylsulfonyl)-benzoyl-guanidine, or derivatives thereof, for the enhancement of insulin sensitivity and the preservation or increase of β-cell compensation..
Merck Patent Gmbh

Composition and management of diabetes or pre-diabetes

wherein the drink exhibits shear banding when subject to the shear banding test herein described.. .

System for screening and diagnosis of diabetes

this invention relates to the means for detection of molecular and chemical matter utilizing multiple techniques covering electronics, optics, and imaging techniques. More particularly, this invention is related to detecting levels of certain molecules inside the body through non-invasive contact or non-contact with the body.
Banpil Photonics, Inc.

Human antigen binding proteins that bind to a complex comprising beta-klotho and an fgf receptor

the present invention provides compositions and methods relating to or derived from antigen binding proteins capable of inducing b-klotho, and or fgf21-like mediated signaling. In embodiments, the antigen binding proteins specifically bind to a complex comprising β-klotho and at least one of (i) fgfr1c, (ii) fgfr2c and (iii) fgfr3c.
Amgen Inc.

Oxyntomodulin analogue

provided is an oxyntomodulin analogue. The analogue comprises gcgr and glp-1r dual agonist activity, improved enzymolysis stability and biological activity, and no adverse reactions.

N-hydroxy bicyclic hydantoin carbamates as tools for indetification of serine hydrolase targets

provided herein are n-hydroxy bicyclic hydantoin carbamates and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful as modulators of serine hydrolases.
The Scripps Research Institute

Systemic delivery of virus vectors encoding urocortin-2 and related genes to treat diabetes-related cardiac dysfunctions and congestive heart failure

in alternative embodiments, provided are methods for treating, ameliorating or protecting (preventing) congestive heart failure (chf) or a diabetes-related cardiac dysfunction, comprising: providing a urocortin 2-encoding and/or a urocortin 3-encoding nucleic acid, transcript or message, or gene, operatively linked to a transcriptional regulatory sequence, optionally contained in an expression vehicle or a vector such as an adeno-associated virus (aav), e.g., an aav8 serotype; and administering to an individual or a patient in need thereof, such as a type 2 diabetic (t2dm), e.g., by iv administration, thereby treating, ameliorating or protecting against (preventing) the t2dm and/or the diabetes-related cardiac dysfunction in the individual or patient.. .
The Regents Of The University Of California

Agent for preventing or ameliorating diabetes

an object of the present invention is to find a component that is safe and is capable of effectively exerting various effects such as prevention or amelioration of diabetes, prevention or amelioration of metabolic syndrome, amelioration of insulin resistance, inhibition of an increase in a postprandial blood sugar level, and inhibition of α-glucosidase activity. The present invention provides agents for preventing or ameliorating diabetes or the like, the agents including a component of a hybrid plant of camellia sinensis and camellia taliensis as an active ingredient.
Kyushu University National University Corporation

Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes

the present invention provides novel, diastereomeric pyrazolines that are useful as cannabinoid receptor blockers and pharmaceutical compositions thereof and methods of using the same for treating obesity, diabetes, inflammatory disorders, cardiometabolic disorders, hepatic disorders, and/or cancers.. .
Jenrin Discovery

Modulators of gtpases and their use

the present invention relates to molecules which function as modulators (i.e., inhibitors and agonists) of the ras-homologous (rho) family of small gtpases (e.g. Rac, cdc42 and rho gtpases) and their use to treat diseases, including cancers (including solid tumors-medulloblastoma, ovarian, breast, head and neck, testicular, prostate among others and hematologic malignancies-b cell lymphoma, where these gtpases are overexpressed or hyperactivated), sporadic and genetic diseases where activation of rho gtpases plays a pivotal role (menkes disease, rheumatoid arthritis, atherosclerosis, diabetes (type i), huntington's disease and alzheimer's disease) which are mediated through these proteins.
Stc.unm

Ardelyx, Inc.

. .

Methods of obtaining islet cells

the present invention provides methods and materials relating to obtaining or expanding populations of islet cells, and uses of the islet cells obtained by these methods, for example in the treatment of diabetes. The invention uses transcription factors in a process of expansion and de-differention, followed by redifferentiation..
Lothian Health Board

Compositions comprising cyclocarya paliurus extract and preparation method and uses thereof

compositions and preparation method thereof, said compositions comprise herb extract from a mixture comprising cyclocarya paliurus leaf and one or two herbs selected from the group consisting of puerariae lobatae radix and polygonati odorati rhizoma, said compositions can treat diabetes, hyperglycemia, hypertension and/or hyperlipidemia.. .
Infinitus (china) Company Ltd

Tea composition comprising cyclocarya paliurus and preparation method and uses thereof

compositions and preparation method thereof, said compositions comprise cyclocarya paliurus leaf and one or more herbs selected from the group consisting of green tea, mori folium, siraitiae fructus, broadleaf holly leaf and polygonati odorati rhizoma, and their preparation method. Said compositions can treat diabetes, hyperglycemia, hypertension and/or hyperlipidemia..
Infinitus (china) Company Ltd

Novel combination of naturally occurring compounds to assist with suspected mycobacterial infections related to autoimmune conditions

the novel aspect of this invention is that it is a unique formulation of naturally occurring compounds with a unique intention to assist the concerns associated with autoimmune conditions, mainly inflammatory bowel disease (collectively crohn's, ulcerative colitis, irritable bowel syndrome), type 1 diabetes, multiple sclerosis, psoriasis and the suspected infection of the pathogen mycobacterium avium sub-species paratuberculosis (map). Furthermore, its intent is to address the lack of treatment options available for those with aforementioned autoimmune conditions.

Apoptosis signal-regulating kinase inhibitors

wherein variables are as defined above. The compounds have apoptosis signal-regulating kinase (“ask1”) inhibitory activity, and are thus useful in the treatment of ask1-mediated conditions, including autoimmune disorders, inflammatory diseases, cardiovascular diseases, diabetes, diabetic nephropathy, cardio-renal diseases, including kidney disease, fibrotic diseases, respiratory diseases, copd, idiopathic pulmonary fibrosis, acute lung injury, acute and chronic liver diseases, and neurodegenerative diseases..

Antidiabetic medications

methods of using antidiabetic medications which are suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance, and hyperglycemia, among others.. .
Boehringer Ingelheim International Gmbh

Methods and devices for the diagnosis and treatment of diabetes

methods and devices for the diagnosis and treatment of diabetes are disclosed in which an analyte concentration within a peritoneal fluid of a human subject may be determined by implanting an analyte sensor apparatus in the subject where the apparatus may comprise a housing and a flexible sensing catheter which has a lumen with a plurality of apertures and an exterior surface with an analyte sensor affixed thereto. The catheter may comprise a proximal end attached to the housing and the remaining end may be positioned freely within the peritoneal space to contact peritoneal fluid where an analyte concentration in the peritoneal fluid may be sensed.
Theranova, Llc

In vitro process for the quantification of carboxymethyl and carboxyethyl level of albumin in a sample

an in vitro method for the identification and quantification of glycated human serum albumin to assess the extent of diabetic complications in diseased individuals. Further, a diagnostic kit for identifying the extent of diabetes in a diseased individual by estimating glycated serum albumin levels in such individuals..
Council Of Scientific & Industrial Research

Esculentin-2cha peptide and analogues thereof

the present invention relates to an esculentin-2cha peptide and analogues thereof, and the use each thereof in the treatment of diabetes, for example type 2 diabetes; insulin resistance; obesity, and/or hypercholesterolemia. Also disclosed is a pharmaceutical composition comprising peptides and analogues according to the present invention; use of peptides and analogues according to the present invention for the manufacture of a medicament for the treatment of diabetes, insulin resistance, obesity, and/or hypercholesterolemia; and methods of treating diabetes, insulin resistance, obesity, and/or hypercholesterolemia..
University Of Ulster

Antidiabetic substituted heteroaryl compounds

the present invention relates to a compound represented by formula (i): and pharmaceutically acceptable salts thereof. The compounds of formula i are agonists of g-protein coupled receptor 40 (gpr40) and may be useful in the treatment, prevention and suppression of diseases mediated by the g-protein-coupled receptor 40.
Merck Sharp & Dohme Corp.

O-glcnac transferase (ogt) inhibitors and uses thereof

the present invention provides inhibitors of o-glcnac transferase. Typically, the inhibitors are quinolinone-6-sulfonamides.
The United States Of America, As Represented By The Secretary, Department Of Health And Human

Process for the preparation of dapagliflozin

dapagliflozin compounds and process for dapagliflozin preparation are described. Pharmaceutical compositions comprising dapagliflozin or solvates of dapagliflozin, for the treatment of diabetes are also described..
Cadila Healthcare Limited

Compositions and methods for treating diabetes and liver diseases

compounds, compositions, and methods are described herein for treating diabetes, fatty liver diseases, fibrotic diseases, such as liver and pulmonary fibrosis, and hepatocellular carcinoma.. .
Cempra Pharmaceuticals, Inc.

Heteroaromatic compounds and their use as dopamine d1 ligands

and pharmaceutically acceptable salts thereof and n-oxides thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds (n-oxides thereof or or pharmaceutically acceptable salts of the compound or the n-oxides) and the uses of such compounds (n-oxides thereof or or pharmaceutically acceptable salts of the compound or the n-oxides) for the treatment of d1-mediated (or d1-associated) disorders including cognitive and motivational impairments and negative symptoms associated with illnesses such as schizophrenia, depression, bipolar disorder, parkinson's disease, mild cognitive impairment (mci), alzheimer's disease, lupus, huntington's disease, parkinson's, dyskinesia, adhd, post-traumatic stress disorder, autism spectrum disorder, treatment-resistant depression, major depressive disorder (mdd), drug dependence, tourette's syndrome, tardive dyskinesias as well as impairments associated with age, chronic stress, sleep deprivation, combat, chronic fatigue; endocrine or metabolic diseases such as hyperglycemia, dislipidemia, diabetes, obesity, and sepsis; and cardiovascular disorder such as hypertension. The present invention further provides a d1 agonist with reduced d1r desensitization, a d1 agonist with a reduced β-arrestin recruitment activity relative to dopamine, a d1 agonist interacting significantly with the ser188 but not significantly with the ser202 of a d1r when binding to the d1r, a d1 agonist interacting less strongly the asp103 and interacting less strongly with the ser198 of a d1r when binding to the d1r, and their uses..

Mutation for type i diabetes mellitus and animal model

the invention relates to a mutation in the dock8 encoding gene that is causative for type 1 diabetes mellitus at least in the rat (rattus norvegicus) or mouse, the rat or mouse preferably having an mhc predisposing towards type 1 diabetes mellitus and/or a mutation in the von willebrand factor vwa2. Embodiments of the invention comprise a process for generating a non-human mammal by genetic manipulation to contain at least heterozygously, preferably homozygously, the mutation causative for type 1 diabetes mellitus, preferably in combination with an mhc predisposing for type 1 diabetes mellitus and/or with a mutation in the von willebrand factor vwa2..
Medizinische Hochschule Hannover

Means and methods for determining risk of type-1 diabetes by serum protein biomarkers

the present invention relates to methods for predicting a risk of a subject for type 1 diabetes (t1d) on the basis of expression levels of protein markers in a sample obtained from the subject. The present invention also relates to in vitro kits for use in said methods..
Turun Yliopisto

High load enzyme immobilization by crosslinking

methods of cross-linking polypeptide molecules are provided, where such methods include combining a cross-linking agent and polypeptide molecules in a solution under conditions suitable for a cross-linking reaction to occur. Also provided are preparations of cross-linked polypeptide molecules, where the polypeptide molecules are cross-linked by essentially unbranched cross-linking groups of at least 40 contiguous atoms.
Roche Diabetes Care, Inc.

Novel compound, pharmaceutically acceptable salt or optical isomer thereof, preparing the same, and pharmaceutical composition for prevention or treatment of viral diseases containing same as active ingredient

the present invention relates to a novel compound, to a pharmaceutically acceptable salt or optical isomer thereof, to a method for preparing same, and to a pharmaceutical composition for the prevention or treatment of viral diseases containing same as an active ingredient. The novel compound according to the present invention not only has low cytotoxicity but also has excellent antiviral activity against picornavirus such as coxsackievirus, enterovirus, echovirus, poliovirus and rhinovirus, and thus can be effectively used as a pharmaceutical composition for the prevention or treatment of viral diseases such as infantile paralysis, acute hemorrhagic conjunctivitis, viral meningitis, hand-foot-and-mouth disease, vesicular disease, hepatitis a, myitis, myocarditis, pancreatitis, diabetes, epidemic myalgia, encephalitis, cold, herpangina, foot-and-mouth disease, asthma, chronic obstructive pulmonary disease, pneumonia, sinus infection, or otitis media..
Katholieke Universiteit Leuven K.u. Leuven R & D

Co-crystal of dapagliflozin with citric acid

the present invention relates to a dapagliflozin-citric acid co-crystal, processes for its preparation, and its use for the treatment of type 2 diabetes mellitus. A dapagliflozin citric acid co-crystal.
Sun Pharmaceutical Industries Limited

Method for producing 4,4,7-trifluoro-1,2,3,4-tatrahydro-5h-1-benzazepine compound and intermediate used in the method

the present invention provides a method for producing a 4,4,7-trifluoro-1,2,3,4-tetrahydro-5h-1-benzazepine compound which has an superior agonistic activity to an arginine vasopressin v2 receptor and is useful as an active ingredient for a pharmaceutical composition for preventing and/or treating urinary frequency, urinary incontinence, enuresis, central diabetes insipidus, nocturia, nocturnal enuresis, or the like; and useful intermediates for use in the methods. The production method of the present invention is suitable for the industrial production of a medicament, because of a smaller number of steps, a higher yield, and a lower cost, as compared with the methods in the related art..
Tacurion

Methods for inducing insulin production and uses thereof

the invention relates to methods of inducing insulin production in delta-cells and/or converting delta-cells into insulin producing cells, as well as methods of preventing and/or treating diabetes and agents and compositions useful in said methods.. .
Universite De Geneve

Early prediction markers of diabetic nephropathy

the present invention concerns a method for the in vitro detection of an increased risk of diabetic nephropathy in a subject suffering from diabetes and being normoalbuminuric. Another aspect of the invention pertains to a method for the in vitro identification of a marker for prediction of diabetic nephropathy.
Chu Montpellier

Inhibitors of the farnesoid x receptor and uses in medicine

disclosed are inhibitors of the farnesoid x receptor, for example of formula (i), wherein r1, r2, r4, x, y, z, m, and n are as defined herein, which are useful in treating or preventing obesity, type 2 diabetes/insulin resistance and non-alcoholic fatty liver disease in a mammal in need thereof. Also disclosed is a composition comprising a pharmaceutically suitable carrier and at least one compound of the invention, a method of method of inhibiting a farnesoid x receptor in a mammal, and a method of treating or preventing obesity in a mammal..
The Penn State Research Foundation

Crystalline solvate forms of a pharmaceutical

the invention provides and describes solid state 17α-ethynyl-androst-5-ene-3β,7β,17β-triol including amorphous and crystalline forms and specific polymorphic forms thereof. Anhydrates and solvates of 17α-ethynyl-androst-5-ene-3β,7β,17β-triol include form i anhydrate and form iv and form v solvates.
Neurmedix, Inc.

Pyrazine derivatives

provided is a novel pyrazine derivative represented by the following formula (i) or a pharmaceutically acceptable salt thereof, or a solvate thereof which is useful for treating or preventing diseases in which urat1 is involved, including gout, hyperuricemia, hypertension, renal diseases such as interstitial nephritis and the like, diabetes, arteriosclerosis, lesch-nyhan syndrome, and the like.. .
Teijin Pharma Limited

Compositions and methods for treating obesity and related disorders by characterizing and restoring mammalian bacterial microbiota

the present invention relates to characterizing changes in mammalian intestinal microbiota associated with associated with high-fat and low-fat diets and with diets containing hydroxypropylmethylcellulose (hpmc) and related methods for diagnosing, preventing and treating obesity and related conditions such as metabolic syndrome and diabetes mellitus. Therapeutic methods of the invention involve the use of probiotics, and/or prebiotics, and/or narrow spectrum antibiotics/anti-bacterial agents that are capable of restoring healthy mammalian bacterial intestinal microbiota..
New York University

Systems and methods of diabetes management

presented herein are one or more software applications to help a user manager their diabetes. Embodiments and descriptions of the various applications are provided below in conjunction with an analyte measurement device..

Glp-1 derivatives

the invention relates to a derivative of a glp-1 peptide, which peptide has two lys residues, namely a first and a second lys residue, and a maximum of eight amino acid changes as compared to glp-1(7-37) (seq id no: 3), which derivative comprises two protracting moieties attached to the epsilon amino group of said first and second lys residue, respectively, via a linker, wherein the protracting moiety is selected from chem. 15: hooc—(ch2))x—co—*, and chem.

Canagliflozin monohydrate and its crystalline forms, preparation methods and uses thereof

the present invention relates to canagliflozin monohydrate and its crystalline forms. Compared to the prior art, canagliflozin monohydrate and its crystalline forms have higher stability in water or aqueous system, is more suitable for wet granulation processes or suspension preparations and have good storage stability.

Crystalline forms and processes for the preparation of cannabinoid receptor modulators

the present invention relates to crystalline forms of (1as,5as)-2-(4-oxy-pyrazin-2-yl)-1a,2,5,5a-tetrahydro-1h-2,3-diaza-cyclopropa[a]pentalene-4-carboxylic acid ((s)-1-hydroxymethyl-2,2-dimethyl-propyl)-amide (compound 1) and pharmaceutical compositions thereof that modulate the activity of the cannabinoid cb2 receptor and are therefore useful in the treatment of cb2 receptor-mediated disorders, for example, osteoarthritis; pain; hyperalgesia; allodynia; inflammatory hyperalgesia; neuropathic hyperalgesia; acute nociception; osteoporosis; multiple sclerosis-associated spasticity; autoimmune disorders; allergic reactions; cns inflammation for example; atherosclerosis; undesired immune cell activity, and inflammation associated with a disorder selected from: osteoarthritis, anaphylaxis, behcet's disease, graft rejection, vasculitis, gout, spondylitis, viral disease, bacterial disease, lupus, inflammatory bowel disease, autoimmune hepatitis, and type 1 diabetes mellitus; age-related macular degeneration; cough; leukemia; lymphoma; cns tumors; prostate cancer; alzheimer's disease; stroke-induced damage; dementia; amyotrophic lateral sclerosis; and parkinson's disease.. .

Velocity-weighting model predictive control of an artificial pancreas for type 1 diabetes applications

methods, devices, algorithms, and systems controlling insulin delivery employ velocity-weighting. Predicted glucose outcomes are penalized with a cost modulated by a factor that is a function of the glucose velocity, wherein glucose outcomes are penalized increasingly less for increasingly negative glucose velocities, when glucose level is high, and/or wherein a hyperglycemic glucose value that is already converging to the euglycemic zone results in less corrective action by the controller than were the hyperglycemic state steady..

Rituximab induction therapy followed by glatiramer acetate therapy

the present invention provides a method of treating a subject afflicted with a form of multiple sclerosis or presenting a clinically isolated syndrome comprising periodic administration of an amount of rituximab at least twice to the subject followed by periodic administration of an amount of glatiramer acetate to the subject, wherein the amounts are effective to treat the subject. The present invention also provides a method of treating a subject afflicted with an immune disease, comprising periodic administration of an amount of rituximab at least twice to the subject followed by periodic administration of an amount of glatiramer acetate to the subject wherein the amounts are effective to treat the subject, and wherein the immune disease is an autoimmune disease, an arthritic condition, a demyelinating disease, an inflammatory disease, multiple sclerosis, relapsing-remitting multiple sclerosis, diabetes mellitus, psoriasis, rheumatoid arthritis, inflammatory bowel disease, crohn's disease, or systemic lupus erythematosus..

Composition for treating diabetes comprising long-acting insulin analogue conjugate and long-acting insulinotropic peptide conjugate

the present invention relates to a composition for the prevention or treatment of diabetes including a long-acting insulin conjugate and a long-acting insulinotropic peptide conjugate, and a method for treating diabetes. More specifically, combination administration of the long-acting analogue conjugate and the long-acting insulinotropic peptide conjugate inhibits weight gain due to administration of insulin, and vomiting and nausea due to administration of the insulinotropic peptide, and also reduces the required doses of insulin, thereby remarkably improving drug compliance.

Pharmaceutical combination for use in glycemic control in diabetes type 2 patients

the present invention refers to a pharmaceutical combination for use in glycemic control in diabetes type 2 patients.. .

Calcitonin mimetics for treating diseases and disorders

calcitonin mimetic peptides having an amino acid sequence in accordance with seq id no:8 or seq id no:53, each of which may be carboxylated at its n-terminal or otherwise modified to reduce the positive charge of the first amino acid and independently of that may be amidated at its c-terminal, and in each of which the 1 and 7 position cysteine residues may together be replaced by α-aminosuberic acid (asu) are useful as medicaments for treating diabetes (type i and/or type ii), excess bodyweight, excessive food consumption, metabolic syndrome, rheumatoid arthritis, non-alcoholic fatty liver disease, osteoporosis, or osteoarthritis, poorly regulated blood glucose levels, poorly regulated response to glucose tolerance tests, or poorly regulated of food intake.. .

Modulation of cellular stress

disclosed are compositions and methods for modulating oxidative and/or endoplasmic reticulum (oer) stress. More particularly, the present invention discloses compositions and methods that target oer stress inhibitors to pancreatic cells for treating diseases associated with oxidative and/or oer stress, including metabolic disorders such as diabetes..

Aav mediated exendin-4 gene transfer to salivary glands to protect subjects from diabetes or obesity

the invention relates to a gene transfer-based method to protect a subject from diabetes or obesity. The method comprises administering to a salivary gland of the subject an aav virion comprising an aav vector that encodes an exendin-4 protein.

Calcium folate (cafolate) and therapeutic methods based thereon

disclosed herein are methods for the treatment of cancer and inflammatory-based diseases and disorders, such as hepatitis b virus infection, tuberculosis and type 2 diabetes based upon the administration of cafolate. In one embodiment is a method of treating cancer comprising administration of cafolate.

Compositions and methods for improving mitochondrial function and treating neurodegenerative diseases and cognitive disorders

provided are compositions comprising compounds or precursors to compounds which may be used for a variety of therapeutic applications including, for example, treating and/or preventing a disease or disorder related to reduced or inadequate mitochondrial activity, including aging or stress, diabetes, obesity, and neurodegenerative diseases. The compounds relate generally to urolithins and precursors thereof, including but not limited to ellagitannins and urolithin a.

Compositions and methods for improving mitochondrial function and treating neurodegenerative diseases and cognitive disorders

provided are compositions comprising compounds or precursors to compounds which may be used for a. Variety of therapeutic applications including, for example, treating and/or preventing a disease or disorder related to reduced or inadequate mitochondrial activity, including aging or stress, diabetes, obesity, and neurodegenerative diseases.

Effect of lipophilic nutrients on diabetic eye diseases

compositions containing molecular dispersions of lipophilic nutrients and methods thereof are provided for delaying the development and maturation of eye related complications of diabetes by administering a composition containing lipophilic nutrients. More particularly, methods relate to delaying the development and maturation of eye related complications of diabetes by administering a composition containing lutein and its isomers, lutein ester, zeaxanthin isomers, turmeric extract, curcumin or curcuminoids, derived from plant extract/oleoresin containing xanthophylls/xanthophylls esters which are safe for human consumption and are particularly useful as dietary supplements for nutrition and health promoting benefits..

Device and method to detect diabetes in a person using pulse palpation signal

a device and method is provided for the detection of diabetes in a person using pulse palpation signals. The pulse palpation signal is captured from the radial artery of the person using a photo-plethysmograph (ppg) sensor.

Sanofi-aventis Deutschland Gmbh

. .

Apoiii and the treatment and diagnosis of diabetes

the present invention provides methods of identifying candidate compounds for the treatment of type i diabetes comprising contacting pancreatic β cells with an amount of apolipoprotein ciii (“apociii”) effective to increase intracellular calcium concentration, in the presence of one or more test compounds, and identifying those test compounds that inhibit an apociii-induced increase in intracellular calcium concentration in the pancreatic β cells. The present invention also provides methods for treating patients with type i diabetes comprising administering to the patient an amount effective of an inhibitor of apociii to reduce apociii-induced increase in intracellular calcium concentration in pancreatic β cells..
Biocrine Ab

Organic compositions to treat apoc3-related diseases

the present disclosure relates to compositions and methods for treating apoc3-related diseases such as: hypertriglyceridemia (e.g., type v hypertriglyceridemia), abnormal lipid metabolism, abnormal cholesterol metabolism, atherosclerosis, hyperlipidemia, diabetes, including type 2 diabetes, obesity, cardiovascular disease, and coronary artery disease, among other disorders relating to abnormal metabolism or otherwise, using a therapeutically effective amount of a rnai agent to apoc3.. .
Arrowhead Pharmaceuticals, Inc.

Compositions and methods for treating diabetes

compositions containing an fkbp 11 peptide (i.e., fkbp11 polypeptide, a variant or a fragment thereof), a fusion protein containing an fkbp11 peptide, or a nucleic acid encoding an fkbp 11 peptide are disclosed. Also disclosed are methods of reducing blood glucose levels, improving glucose tolerance, decreasing hepatic gluconeogenic activity and/or improving insulin sensitivity in a subject, by administering a composition containing an fkbp 11 peptide or a fusion protein containing an fkbp11 peptide.
The Children's Medical Center Corporation

Vaccines and monoclonal antibodies targeting truncated variants of osteopontin and uses thereof

the present invention provides monoclonal antibodies specific for one or more truncated variants of human osteopontin and vaccines comprising at least one isolated osteopontin peptide, as well methods for manufacturing said antibodies and vaccines. Furthermore, a diagnostic method making use of said antibodies is provided.
Affiris Ag

Treatment of chronic kidney disease and other renal dysfunction using a gdf15 modulator

the invention provides methods and compositions for treating a subject having a renal-related disorder, such as chronic kidney disease (ckd), end stage renal failure, diabetes, insulin resistance, kidney hypertrophy, kidney hypotrophy, polycystic kidney disease, proteinuria, hyperglycemia, hyperuricemia, gout, kidney stones, hypertension or hypertensive nephropathy, dyslipidemia, anemia and/or reduced erythropoietin production, iron deficiency or hyperfiltration. The methods and compositions use or contain a composition that reduces or inhibits gdf15 activity..
Aveo Pharmaceuticals, Inc.

Long-acting single-chain insulin analogues

a single-chain insulin analogue containing a basic side chain at position a8 (arginine, histidine, lysine, or ornithine), a basic side chain at position b29 (arginine, histidine, lysine, or ornithine), and a foreshortened c-domain of length 6-11 residues is provided. Residues c1 and c2 of the c-domain have a net negative charge of −1 or −2; c3 is chosen from a group consisting of gly, ala, pro, or ser; and the remaining c-domain segment is successively derived from the c-domain of igf-ii (rrsr, srrsr, vsrrsr, rvsrrsr, or srvsrrsr; seq id no: 13).
Case Western Reserve University

Peptide yy (pyy) analogues

analogues of peptide yy (pyy), which are useful in treating disorders such as diabetes and obesity and also for inducing cosmetic weight loss, related compositions, formulations, uses and methods.. .
Imperial Innovations Limited

Insulin-containing prolonged-action preparation

the invention relates to the field of biotechnology and medicine, and specifically to insulin-containing injectable formulations used, in particular, for treating diabetes mellitus. The present formulation comprises insulin and a pharmacologically acceptable polymer having a hydrodynamic diameter of more than 4.5+/−0.5 nanometers.
Obschestvo S Ogranchennoj Otvetctvennostu "biosabtek"

Methods of treatment using a pentapeptide derived from the c-terminus of glucagon-like peptide 1 (glp-1)

methods of treating obesity, metabolic syndrome, hepatic and non-hepatic steatosis, and diabetes using a pentapeptide, lvkgramide, derived from the c-terminus of glucagon-like peptide 1 (glp-1).. .
The General Hospital Corporation

Method of treatment of diabetes type 2 comprising add-on therapy to insulin glargine and metformin

to a subject in need thereof.. .

Anti-glycation methods and compositions

the present invention comprises compositions that provide anti-glycation activity comprising a mineral extract composition or a mogroside/mineral extract composition or a mogroside composition. Such compositions are useful for methods of preventing, treating and inhibiting the effects of glycation in the body.
Core Intellectual Properties Holdings, Llc

Pharmaceutical compositions of berberine with epa and dha, and methods thereof

the invention provides various novel compositions of berberine in combination with pharmacologically active epa and dha, and related methods of their use in treating various diseases or disorders. The pharmaceutical compositions of the invention are useful in treating and/or preventing various diseases or disorders, including metabolic diseases or disorders such as dyslipidemia, hyperglycemia, hypertriglyceridemia, hyperlipidemia, diabetic dyslipidemia, diabetic hyperlipidemia, dyslipidemia in statin-intolerance patients, diabetes, diabetic complications, hypercholesterolemia, or obesity.
Shenzhen Hightide Biopharmaceutical, Ltd.

Method for suppressing glucagon secretion of an sglt2 inhibitor

methods are provided for avoiding an increase in glucagon secretion associated with the administration of a sodium glucose co-transporter 2 (sglt2) inhibitor via the co-administration of a dipeptidyl peptidase iv (dpp iv) inhibitor. Additionally, methods are provided for normalizing the glucagon secretion associated with the administration of a sodium glucose co-transporter 2 (sglt2) inhibitor via the co-administration of a dipeptidyl peptidase iv (dpp iv) inhibitor.
Astrazeneca Ab

Systems using fingerprint images as diagnostic detection systems for type 2 diabetes

method and kits for determining a propensity to develop type 2 diabetes mellitus (t2dm) in an individual by measuring an asymmetry of a captured fingerprint from the individual are described.. .
Ohio University

Human antibodies to the glucagon receptor

the present invention provides antibodies that bind to the human glucagon receptor, designated gcgr and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human gcgr.
Regeneron Pharmaceuticals, Inc.

Aminosteroids for the treatment of a ptp1b associated disease

this application is directed to the use of aminosteroid compounds for the selective inhibition of the enzyme ptp1b in a mammal for the treatment of diabetes.. .
Ohr Pharmaceutical, Inc.

Amide derivatives for gpr119 agonist

the present invention relates to novel amide derivatives, stereoisomers thereof or pharmaceutically acceptable salts thereof; methods for preparing the compound; and pharmaceutical compositions comprising the compound. The novel amide derivatives, according to the present invention, having an effect as gpr119 agonist can be used for treatment of metabolic disorders, including diabetes mellitus (especially type ii) and related disorders..
Chong Kun Dang Pharmaceutical Corp.

Non-aqueous glucagon formulations

the compositions can be used to treat subjects with very low blood sugar (severe hypoglycemia) that can happen in subjects who have diabetes and use insulin.. .

Co-encapsulation of live cells with oxygen-generating particles

microcapsules are described that comprise (a) a liquid aqueous or hydrogel core; (b) a semipermeable membrane surrounding said core; (c) live animal cells (e.g., pancreatic cells) in the core; and (d) oxygen-generating particles in said core, said oxygen-generating particles included in said microcapsules in an amount sufficient to lengthen the duration of viability of said animal cells in said microcapsules. Compositions comprising such microcapsules and uses thereof, such as in treating diabetes, are also described..
Wake Forest University Healthy Sciences

Cell implant for islet grafts and uses thereof

the present disclosure relates to a cell implant for islet grafts and uses thereof. More specifically, the present disclosure provides a method for treating or preventing diabetes including administering a composition comprising a spheroid and an islet cluster as active ingredients to a subject in need thereof, and a method for preparing the cell implant.
Samsung Life Public Welfare Foundation

Combination therapy for the treatment of diabetes

the present invention is directed to co-therapy and methods for the treatment and prevention of glucose-related disorders such as type 2 diabetes mellitus and syndrome x. The present invention is further directed to pharmaceutical compositions for the co-therapy and methods described herein..
Janssen Pharmaceutica N.v.

Anti-intussusception ileal stent and its use as an anti-hyperglycemic method

selected diabetic patients reveal significant glycemic control after bariatric surgical or endoscopic duodenal bypass. This controlling effect appears to occur partly because of an enhanced glucagon-like peptide 1 (glp1) release from intestinal l-cells.

Integrated physical activity level (i-pal) measurement and tracking in adolescents and older teenagers

described are systems that include at least one sub-system to track, measure, monitor and reward adolescents and young adults for performing daily physical activities, which include before-school, in-school, after-school, sports and activities of daily living. The system offers adolescents the opportunity to track their integrated physical activity level (i-pal) scores over their adolescent years.

Substituted aromatic n-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (mnk1) and 2 (mnk2)

disclosed are substituted aromatic n-heterocyclic compounds. The disclosed compounds typically exhibit kinase inhibition activity, for example, and inhibit mnk1 kinase and/or mnk2 kinase.
Northwestern University

Selective androgen receptor modulators

this invention provides compounds of formula (ii), or (iia) and or salts thereof, pharmaceutical compositions comprising a compound of formula (ii), or (iia) and a pharmaceutically acceptable excipient, processes for making compounds for formula (ii), or (iia) and intermediates useful in the preparation of same; and methods of modulating the androgen receptor, methods of treating diseases beneficially treated by an androgen receptor modulator (e.g., sarcopenia, prostate cancer, contraception, type ii diabetes related disorders or diseases, anemia, depression, and renal disease) using compounds of formula (i), (ii), or (iia).. .
Radius Health, Inc.

Ppar modulators

the present application relates to amorfrutin analogs and uses as ppar modulators for the treatment of metabolic syndrome, obesity, hyperlipidemia, elevated fasting blood glucose, elevated blood pressure, low hdl cholesterol, type 2 diabetes, cardiovascular disease, a neurodegenerative disease, malaria or irritable bowel syndrome.. .
FundaÇao Universidade De BrasÍlia

Amino sphingoglycolipid analogues

the invention relates to amino sphingoglycolipid analogues and peptide derivatives thereof, compositions comprising these compounds and methods of treating or preventing diseases or conditions using such compounds, especially diseases or conditions relating to cancer, infection, atopic disorders, autoimmune disease or diabetes.. .

Administration routes of insulin, insulin analogs or derivatives of insulin

an insulin, insulin analog or derivative of insulin for use in the treatment of diabetes. The use comprises new administration routes of insulin analogs..
Sanofi

Use of ave0010 for the treatment of diabetes mellitus type 2

the present invention refers to the use of lixisenatide or/and a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment of diabetes mellitus type 2, for inducing weight loss in diabetes type 2 patients or/and for preventing weight gain in diabetes type 2 patients.. .
Sanofi-aventis Deutschland Gmbh

Scaffolds for inhibitors of menin-mll interactions

disclosed herein are methods and compositions for treating, as well as identifying potential therapeutics for, cancers or diabetes, with compounds that inhibit the activity of menin, preferably the compounds are capable of inhibiting mll binding to menin.. .
The Trustees Of The University Of Pennsylvania

Lanthionine synthetase c-like 2-based therapeutics

provided are compounds that target the lanthionine synthetase c-like protein 2 pathway. The compounds can be used to treat a number of conditions, including infectious disease, autoimmune disease, diabetes, and a chronic inflammatory disease..
Biotherapeutics, Inc.

Compounds influencing fatty acid uptake and metabolism and the production of inflammatory agents and methods of isolating them from cocoa products

the invention provides compounds and plant extract compositions that inhibit pancreatic enzymes, such as lipases and amylases, and most particularly pancreatic lipase and phospholipase a2 (pla2), and cox-2 enzyme, and improve the inflammatory state or response conditions in animals. The compounds and plant extracts can be used in methods and administration regimens to treat animals for obesity-related conditions, diabetes and related conditions, metabolic syndrome, metabolic endotoxemia, and inflammatory conditions.
The Hershey Company

Biopolymer-encapsulated glycosyl transferase inhibitor compositions and methods for treating diabetes and cardiac indications

the present invention relates to compositions comprising a biopolymer-encapsulated glycosyltransferase inhibitor and methods for treating and reducing a symptom of atherosclerosis or cardiac hypertrophy and/or diabetes using said compositions.. .
The Johns Hopkins University

Highly protonated hydronium and peroxymonosulfuric acid as a sanitizing solution

a water-based, alcohol-free, skin and hard surfaces sanitizing solution with a natural skin softener, where the nature of the biocidal enhancer used in the process of making the solution significantly increases efficacy while simultaneously enabling much more economical manufacturing, processing and transportation of the product. As the present solution is water-based, no further moisturizing additives are required, and those with sensitive skin, diabetes, allergies or religious beliefs are able to use the product without concern..

Predicting rapid decline in renal function in diabetes

methods of predicting rapid decline in renal function in diabetes employing panels of biomarkers. The methods are useful for predicting risk of decline of renal function in individual subject and also for selecting subjects for clinical trials..
University Of Dundee

Breath analyser and detection methods

a measurement device for measuring a concentration of a component of a gas mixture includes a chamber that contains the gas mixture, a light source that emits light into the chamber, the emitted light having a wavelength between 230 nm and 320 nm, and a light sensor that detects a portion of the light from the light source that has propagated through the gas mixture. A processor is configured to determine the concentration of the component of the gas mixture based on the portion of the light emitted from the light source that is detected by the light sensor.
Sharp Kabushiki Kaisha

Use of tgf-beta antagonists of treat type-2 diabetes

method and compositions for treating type-2 diabetes in a subject are provided comprising administering to the subject an amount of an inhibitor of a tgf-beta.. .
Albert Einstein College Of Medicine, Inc.

Double-acylated glp-1 compounds

the invention relates to a derivative of a glp-1 peptide, which peptide comprises a first lys residue at a position corresponding to position 36 of glp-1(7-37) (seq id no:1), a second lys residue at a position corresponding to position 37 of glp-1(7-37) (seq id no: 1), and a maximum of seven amino acid changes as compared to glp-1(7-37) (seq id no: 1); which derivative comprises two protractors attached to said first and second lys residue, respectively, each via a linker; wherein the protractor is selected from: chem. 1: hooc—c6h4-0-(ch2)y—co—*, and chem.
Novo Nordisk A/s

Engineered polypeptides having enhanced duration of action

compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens including oral administration. The compounds are engineered polypeptides which incorporate an albumin binding domain in combination with one or more biologically active polypeptides.
Astrazeneca Pharmaceuticals Lp

Cyclohexene derivative, preparation method therefor, and pharmaceutical composition for preventing or treating metabolic diseases, containing same as active ingredient

the present invention relates to: a cyclohexene derivative; a preparation method therefor; and a pharmaceutical composition for preventing or treating metabolic diseases, containing the same as an active ingredient. The cyclohexene derivative according to the present invention increases the intracellular activity of cyclic adenosine monophosphate (camp) by activating g protein-coupled receptor 119 (gpr-119) and simultaneously exhibits weight loss and hypoglycemic effects by inducing the release of glucagon-like peptide-1 (glp-1), which is a neuroendocrine protein, and thus can be useful as a pharmaceutical composition for preventing or treating metabolic diseases such as obesity, type 1 diabetes, type 2 diabetes, inadequate glucose tolerance, insulin resistance, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, dyslipidemia and syndrome x..
Hyundai Pharm Co., Ltd.

Ethynyl derivatives

it has been surprisingly been found that the compounds of general formula i are positive allosteric modulators (pams) of metabotropic glutamate receptor 4 (mglur4), useful for the treatment of parkinson's disease, anxiety, emesis, obsessive compulsive disorder, autism, neuroprotection, cancer, depression and diabetes type 2.. .
Hoffmann-la Roche Inc.

3-dimensional large capacity cell encapsulation device assembly

disclosed herein are implantable 3-dimensional large capacity device assemblies, specifically, large capacity device assemblies for encapsulating pancreatic progenitor cells for treatment of diabetes.. .
Viacyte, Inc.

Pharmaceutical formulations

good bioavailability of desmopressin can be obtained by means of an orodispersible pharmaceutical dosage form. Preferred dosage forms comprise desmopressin and an open matrix network which is an inert water-soluble or water-dispersible carrier material.
Ferring B.v.

Magnesium compositions and uses thereof for neurological disorders

a composition for administration to a subject, such as oral administration to a subject, for example, has been provided. Such a composition may comprise at least one magnesium-counter ion compound.
Neurocentria, Inc.

Algin oligosaccharides and the derivatives thereof as well as the manufacture and the use of the same

the invention provides an alginate oligosaccharide and its derivatives with the degree of polymerization ranging from 2 to 22. The alginate oligosaccharide is composed of β-d-mannuronic acid linked by 1,4 glycosidic bonds.
Ocean University Of China

Solid formulations containing omega-3 and resveratrol

the present application relates to invention a solid composition comprising omega-3 polyunsaturated fatty acids (n-3 pufa), or their alkyl esters, and resveratrol, adsorbed on an inert substrate and wherein the recovery of omega-3 is at least 96% after 6 months at 25° c. The composition according to the present invention can be formulated as food supplement or medicament for preventing or treating cardiovascular diseases due to lipid metabolism disorders and increased platelets aggregation; damages due to free radicals selected from the group consisting of atherosclerosis, cancer, inflammatory joint disease, asthma, diabetes, senile dementia and degenerative eye disease; and/or viral diseases..
Sigma-tau Industrie Farmaceutiche Riunite S.p.a.

Methods of treatment of inflammation of the gut

described herein are methods of improving immune homeostasis in the gut of a subject suffering from an autoimmune disease characterized by inflammation of the gut by administering, e.g., orally administering, to the subject an effective amount of a cannabinoid receptor agonist to improve immune homeostasis in the gut of the subject. Exemplary cannabinoid receptor ligands include anandamide.
The University Of Connecticut

Methods and reagents for the assessment of gestational diabetes

the invention involves assays, diagnostics, kits, and assay components for determining levels of glycated cd59 in the assessment of gestational diabetes mellitus and/or related disorders and/or conditions.. .
Agricultural Research Council

Computerized system, device, method and program product for medical treatment automation

a computerized system and method that automates diagnosing and prescribing treatment plans for patients with medical conditions, such as: dermatological (e.g. Acne, dark spots, anti-aging), high blood pressure, diabetes, pre and post-surgical care, pain management, simple infections, and other medical conditions with standardized treatment protocols.

Peptide agonists of glp-1 activity

novel peptide agonists of glp-1 activity useful for lowering blood glucose levels. The novel peptides comprise variants of the glp-1 or the exendin-4 polypeptide sequence and are pharmacologically active and stable.
Zealand Pharma A/s

Insulin dosage proposal system

a device for proposing an insulin dosage for a diabetes patient, wherein the device comprises an input interface configured for receiving patient glucose level data indicative of glucose level information of the patient, a processor configured for determining the insulin dosage in an interactive time-dependent manner based on applying the received patient glucose level data to at least only predefined insulin dosage determining criterion, and an output interface configured for outputting a result of the determining as a proposal for the insulin dosage indicative of doses and assigned times of the day according to which insulin is to be administered to the diabetes patient.. .
Medizinische Universität Graz

Treatment of immune disorders

the present disclosure relates to stem cells which express high levels of angeopoetin-1 (ang1) and uses thereof in inhibiting m1-type macrophage production and treating inflammatory disease such as diabetes.. .
Mesoblast International Sarl

Magnesium compositions and uses thereof for neurological disorders

a composition for administration to a subject, such as oral administration to a subject, for example, has been provided. Such a composition may comprise at least one magnesium-counter ion compound.
Neurocentria, Inc.

Treatment of non-alcoholic fatty liver disease or non-alcoholic steatohepatitis with delayed-release 6-mercaptopurine

methods of treating patients suffering from non-alcoholic fatty liver disease (nafld) and non-alcoholic steatohepatitis (nash), including those also suffering front type ii diabetes mellitus (t2dm), with a delayed release pharmaceutical composition comprising 6-mercaptopurine are disclosed.. .
Hadasit Medical Research Services And Development Ltd.

Heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders

compounds and methods are provided for the treatment of, inter alia, type ii diabetes and other diseases associated with poor glycemic control. The compounds of the invention are orally active..
Cymabay Therapeutics, Inc.

Activation of amp-protein activated kinase by oxaloacetate compounds

the present invention relates to oxaloacetate compounds that activate amp-activated protein kinase (ampk), including the preparation of the compounds, compositions containing the compounds, preserving said compounds and the use of the compounds in the prevention or treatment of disorders such as diabetes, metabolic syndrome, obesity, cardiovascular disease, alzheimer's disease, and cancer.. .

Method for suppressing diabetes and/or hepatic lipids using tormentic acid

provided is a method for suppressing diabetes and/or hepatic lipids in a mammal to lower blood glucose levels and hepatic total lipids and triacylglycerol contents by increasing amp-activated protein kinase (ampk) phosphorylation in both skeletal muscle and liver tissue, and akt phosphorylation and membraneprotein levels of glucose transporter 4 (glut4) in skeletal muscle. The method comprises administrating to the mammal an effective amount of tormentic acid or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier..

Treatments for diabetes mellitus and obesity

methods of treatment in subjects suffering from diabetes mellitus or obesity are provided. The methods comprise ablation of a region of the small intestine in the subject, in particular ablation of a region of the duodenum.

Daicel Corporation

. .

Compositions and methods for making alpha-(1,2)-branched alpha-(1,6) oligodextrans

compositions for improving the health of a subject comprise alpha-(1,2)-branched alpha-(1,6) oligodextrans, preferably with an average molecular weight between about 10 kda and 70 kda, between about 10% and 50% alpha-(1,2)-osidic side chains, and having at least partial indigestibility in the subject. Methods for improving the health of a subject comprise administering the composition to a subject in an amount effective to improve gut health, or to prevent or treat a gastrointestinal disorder, a cholesterol-related disorder, diabetes, or obesity.
Tate & Lyle Ingredients France Sas

Glp-1/glucagon receptor co-agonists for medical use

the present invention relates to novel glucagon derivatives which are glp-1/glucagon receptor co-agonists, and to the use of said glucagon derivatives in medicine, such as in the treatment of diabetes, obesity and related diseases and conditions.. .
Novo Nordisk A/s

Modulating gamma-c-cytokine activity

embodiments relate to peptide antagonists of γc-family cytokines, which is associated with important human diseases, such as leukemia, autoimmune diseases, collagen diseases, diabetes mellitus, skin diseases, degenerative neuronal diseases and graft-versus-host disease (gvhd). Thus, inhibitors of γc-cytokine activity are valuable therapeutic and cosmetic agents as well as research tools.
Bioniz, Llc

Chimeric fibroblast growth factor 19 proteins and methods of use

the present invention relates to a chimeric protein that includes an n-terminus coupled to a c-terminus, where the n-terminus includes a portion of a paracrine fibroblast growth factor (“fgf”) and the c-terminus includes a c-terminal portion of an fgf 19 molecule. The portion of the paracrine fgf is modified to decrease binding affinity for heparin and/or heparan sulfate compared to the portion without the modification.
New York University

Thienopyranones as kinase and epigenetic inhibitors

the invention relates to methods of treating diseases including but not limited to, cancer, non-cancer proliferative disease, sepsis, autoimmune disease, viral infection, atheroscleosis, type 1 or 2 diabetes, obesity, inflammatory disease, or myc-depenent disorder including by modulating biological processes by the inhibition of pi3 kinase and/or bromodomain protein binding to substrates comprising the administration of a compound(s) of formula i-ix (or pharmaceutically acceptable salts thereof) as defined herein.. .
Signalrx Pharmaceuticals, Inc.

Sweetness receptor antagonist

wherein each symbol is described herein, are useful for the prophylaxis or treatment of metabolic syndrome, diabetes, obesity and the like.. .

Human antibodies to human tnf-like ligand 1a (tl1a)

a fully human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits human tnf-like ligand 1a (htl1a) is provided. The human anti-htl1a antibodies are useful in treating diseases or disorders associated with tl1a, such as inflammatory diseases or disorders, e.g., inflammatory bowel diseases, including ulcerative colitis and crohn's disease, rheumatoid arthritis, and the like; autoimmune diseases or disorders, such as multiple sclerosis, diabetes, and the like; and allergic reactions, such as asthma and allergic lung inflammation..
Regeneron Pharmaceuticals, Inc.

Peptide analogs for treating diseases and disorders

provided herein are peptides, that in combination with metformin, are effective for the treatment of type i diabetes, type ii diabetes, metabolic syndrome, or obesity, or of appetite suppression, or for mitigating insulin resistance, or for reducing an undesirably high fasting serum glucose level, or for reducing an undesirably high peak serum glucose level, or for reducing an undesirably high peak serum insulin level, or for reducing an undesirably large response to a glucose tolerance test in synergistic combination with metformin. The peptides are selected from sequences seq id no: 11, seq id no: 12, seq id no: 13, seq id no: 14, seq id no: 15, seq id no: 16, seq id no: 17, seq id no: 19, seq id no: 20, seq id no: 21, seq id no: 22, seq id no: 23, and seq id no: 24..
Keybioscience Ag

Chimeric fgf21 proteins with enhanced binding affinity for beta-klotho for the treatment of type ii diabetes, obesity, and related metabolic disorders

the present invention relates to chimeric proteins that include an n-terminus coupled to a c-terminus, where the n-terminus includes an n-terminal portion of fibroblast growth factor 21 (“fgf21”) and the c-terminus includes a c-terminal portion of fibroblast growth factor 19 (“fgf19”). The present invention also relates to pharmaceutical compositions including chimeric proteins according to the present invention, as well as methods for treating a subject suffering from diabetes, obesity, or metabolic syndrome, methods of treating a subject in need of increased fgf21-βklotho-fgf receptor complex formation, methods of causing increased fgf21 receptor agonist-βklotho-fgf receptor complex formation, and methods of screening for compounds with enhanced binding affinity for the βklotho-fgf receptor complex involving the use of chimeric proteins of the present invention..
New York University

Inhibition of gliadin peptides

novel compounds and methods for the inhibition of biological barrier permeability and for the inhibition of peptide translocation across biological barriers are identified. Assays for determining modulators of biological barrier permeability and for peptide translocation across biological barriers are provided.
Alba Therapeutics Corporation

Novel activators of glucokinase

the present invention provides for novel compounds of formulas i and ii and pharmaceutically acceptable salts and co-crystals thereof which have glucokinsae activator activity. The present invention further provides for pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucokinase activator is indicated, including type 1 and 2 diabetes, impaired glucose tolerance, insulin resistance and hyperglycemia.
Metabasis Therapeutics, Inc.

Nitroxides for use in treating or preventing diabetes and obesity

pharmaceutical compositions are provided that are useful in treating diabetes. The compositions comprise a pharmaceutically acceptable carrier, and an effective therapeutic or prophylactic amount of a nitroxide antioxidant that alters the expression of genes related to diabetes.
Mitos Pharmaceuticals, Inc.

Gilead Sciences, Inc.

. .

Methods and apparatus to reduce the impact of user-entered data errors in diabetes management systems

embodiments provide systems, methods, and apparatus for reducing the impact of user-entered data errors in a data management system (dms) such as for diabetes. Embodiments include storing user-entered data received from a user into a primary dms database; storing secondary data received from a source other than the user into a secondary tracking database; associating the secondary data with one or more events described by the user-entered data; cross-checking the user-entered data against the associated secondary data; evaluating user-entered data based on the cross-checking results; presenting for review evaluated user-entered data; treating user-entered data in the primary dms database based on review results; and determining a diabetes management plan based on the treated user-entered data.
Ascensia Diabetes Care Holdings Ag

Uses of mito-ob transgenic mice

the mito-ob obese mouse model overexpresses the mitochondrial protein prohibitin (phb). Mito-ob male mice develop insulin resistance in addition to obesity and they do not develop overt diabetes.
University Of Manitoba

Fibronectin based scaffold domain proteins that bind to myostatin

the present invention relates to fibronectin-based scaffold domain proteins that bind to myostatin. The invention also relates to the use of these proteins in therapeutic applications to treat muscular dystrophy, cachexia, sarcopenia, osteoarthritis, osteoporosis, diabetes, obesity, copd, chronic kidney disease, heart failure, myocardial infarction, and fibrosis.
Bristol-myers Squibb Company

Glycoproteins having lipid mobilizing properties and therapeutic uses thereof

the invention provides formulations and methods for ameliorating symptoms associated with metabolic disorders, such as cachexia, hypoglycemia, obesity, diabetes, and the like by administering zn-α2-glycoproteins or a functional fragment thereof, alone or in combination with additional agents, such as β adrenergin receptor agonists, β adrenergin receptor antagonists, and/or glycemic control agents.. .
Aston University

Benzo-fused heterocyclic derivatives useful as agonists of gpr120

the present invention is directed to benzo-fused heterocyclic derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by gpr120. More particularly, the compounds of the present invention are agonists of gpr120, useful in the treatment of, such as for example, type ii diabetes mellitus..
Janssen Pharmaceutica Nv

Superior control of blood glucose in diabetes treatment

methods related to the treatment of diabetes and improving the control of blood glucose levels are provided. In particular, methods are provided for effectively reducing postprandial glucose excursions while reducing the incidence of clinically significant late postprandial hypoglycemia by administered an insulin composition in a form suitable for pulmonary administration.
Mannkind Corporation

Use of overground part of hedychium coronarium koenig in reducing blood glucose; extracts and compositions of overground part of hedychium coronarium koenig and their uses

the present invention is related to the use of an overground part of hedychium coronarium koenig in lowering blood glucose, increasing insulin levels and treating and/or preventing diabetes without overly reducing blood glucose in a subject; i.e., not reducing blood glucose in a fasting subject. The present invention also relates to an extract and composition of the overground part of hedychium coronarium koenig and its use in lowering blood glucose, increasing insulin levels and treating and/or preventing diabetes..
Development Center For Biotechnology

Composition for treating or preventing metabolic disease, containing, as active ingredient, extracellular vesicles derived from akkermansia muciniphila bacteria

the present invention relates to a pharmaceutical and food composition for treating, preventing, or alleviating a metabolic disease, containing, as an active ingredient, extracellular vesicles derived from akkermansia muciniphila. The composition of the present invention can be used as a pharmaceutical/food composition and the like for treating, preventing, or alleviating metabolic diseases, in particular metabolic diseases such as obesity, diabetes, hyperlipidemia, arteriosclerosis, and hypertension, occurring or exacerbated due to a high fat diet.
Md Healthcare Inc.

Methods of isolating distinct pancreatic cell types

methods of isolating distinct specific cell types within mixed populations of cells. Methods of isolating specific cell types among pancreatic cells, particularly from human islets of langerhans.
Yeda Research And Development Co. Ltd.

Compositions and methods for treating type 1 and type 2 diabetes and related disorders

the invention features compositions comprising in vitro generated beta cells capable of glucose-stimulated insulin secretion, methods of inducing beta cell maturation from embryonic or induced pluripotent stem cell-derived beta-like cells, and methods of using in vitro generated beta cells for the treatment of type 1 diabetes, type 2 diabetes, or a related disorder.. .
Salk Institute For Biological Studies

Sodium glucose co-transporter inhibitors and methods of their use

sulfanyl-tetrahydropyran-based compounds, pharmaceutical compositions comprising them, and methods of their use for the treatment of diseases and disorders such as diabetes and obesity are disclosed.. .
Lexicon Pharmaceuticals, Inc.

Furo[3,4-b]pyran compounds and pharmaceutical uses

furo[3,4-b]pyran compounds similar in chemical structure to the natural product known as tan-2483b and their use for treating cancer, osteoporosis, type 2 diabetes, or immune diseases.. .
Victoria Link Limited

Nutritional compositions comprising a lipophilic active ingredient

disclosed embodiments provide methods and compositions for improving the metabolic health of consumers. Bovine beta-casein, a major component of milk from cattle, has many genetic variants.
Abbott Laboratories

Sanofi-aventis Deutschland Gmbh

. .

A novel soluble biomarker for insulin resistance

the present invention relates to a novel soluble biomarker for insulin resistance: 1-methyl nicotinamide (mna). The invention relates to methods of determining the degree of insulin resistance in a patient.
UniversitÄt Leipzig

Treatment of diabetes

glycated hemoglobin (hba1c) levels and other characteristics of diabetes are reduced by administering to a human subject a pharmaceutical composition that includes a pharmaceutically acceptable carrier and a therapeutically effective amount of an agent that selectively binds il-1α.. .
Xbiotech, Inc.

Novel compounds as diacylglycerol acyltransferase inhibitors

this invention relates to novel compounds which are inhibitors of acyl coenzyme a: diacylglycerol acyltransferase 1 (dgat-1), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination with weight management therapies or other triglyceride lowering therapy for the prevention or treatment of diseases related to dgat-1 dysfunction or where modulation of dgat-1 activity may have therapeutic benefit including but not limited to obesity, obesity related disorders, genetic (type 1, type 5 hyperlipidemia) and acquired forms of hypertriglyceridemia or hyperlipoproteinemia-related disorders, caused by but not limited to lipodystrophy, hypothyroidism, medications (beta blockers, thiazides, estrogen, glucocorticoids, transplant) and other factors (pregnancy, alcohol intake), hyperlipoproteinemia, chylomicronemia, dyslipidemia, non-alcoholic steatohepatitis, diabetes, insulin resistance, metabolic syndrome, cardiovascular outcomes, angina, excess hair growth (including syndromes associated with hirsutism), nephrotic syndrome, fibrosis such as myocardial, renal and liver fibrosis, hepatitis c virus infection and acne or other skin disorders.. .
Glaxosmithkline Llc

Antidiabetic tricyclic compounds

novel compounds of the structural formula (i), and the pharmaceutically acceptable salts thereof, are agonists of g-protein coupled receptor 40 (gpr40) and may be useful in the treatment, prevention and suppression of diseases mediated by the g-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia..
Merck Sharp & Dohme Corp.

Prevention of hypoglycemia in diabetes mellitus type 2 patients

(b) metformin or/and a pharmaceutically acceptable salt thereof, to a subject in need thereof.. .

Combination of biologically active substances for treatment of hyperglycaemic disorders

the present invention relates to a synergistic composition which comprises (a) phlorizin, and (b) at least one further defined inhibitor of the enzyme lactase-phlorizin hydrolase. In particular, the present invention relates to such a composition for the treatment and/or prophylaxis of a hyperglycemic disease such as obesity, diabetes or a secondary disease associated with diabetes.
Bioactive Food Gmbh

Therapy for complications of diabetes

a method for enhancing glycemic control and/or insulin sensitivity to a human subject having diabetic nephropathy and/or metabolic syndrome comprises administering to the subject a selective endothelin a (eta) receptor antagonist in a glycemic control and/or insulin sensitivity enhancing effective amount. A method for treating a complex of comorbidities in an elderly diabetic human subject comprises administering to the subject a selective eta receptor antagonist in combination or as adjunctive therapy with at least one additional agent that is (i) other than a selective eta receptor antagonist and (ii) effective in treatment of diabetes and/or at least one of said comorbidities other than hypertension.
Abbvie Deutschland Gmbh & Co. Kg

Insulin sensitisers and methods of treatment

the present invention relates generally to the field of therapy. The invention particularly relates to insulin sensitisers and methods of regulating glucose homeostasis and to the therapeutic or prophylactic treatment of diseases and associated conditions, in which impaired glucose uptake due to insulin resistance is involved or implicated, such as diabetes, syndrome x, hyperglycaemia, vascular disease and kidney disease.
Naia Metabolic, Inc.

Composition for reducing new-onset diabetes

a medical composition for reducing the rate of new-onset diabetes caused by administration of a statin or for inhibiting an increase in blood glucose level by administration of a statin, the composition containing at least one ingredient selected from the group consisting of icosapentaenoic acid and pharmaceutically acceptable salts or esters thereof as an inactive ingredient.. .
Mochida Pharmaceutical Co., Ltd.

Diabetes and hypertension screening by assessment of arterial stiffness and autonomic function

the present invention provides methods and apparatuses to assess vascular stiffness of a subject, and to assess diabetes or hypertension from the assessment of vascular stiffness. Example embodiments comprise determining arrival at a peripheral site of a blood pressure wave as a function of time relative to the cardiac cycle of the subject at a plurality of measurement conditions, wherein at least two of the conditions are characterized by at least one of: (a) different central transmural pressure, (b) different peripheral transmural pressure; assessing vascular stiffness from the determinations at the plurality of measurement conditions..
Medici Technologies, Llc

Antagonists of slc38a9 and their use in therapy

the present invention relates to an antagonist or modulator of slc38a9 for use in treating a disease associated with mtorc1 activation, like a proliferative disease (e.g. A cancerous disease or benign proliferative disease), a metabolic disorder, a disorder of the immune system, a disorder causing premature aging, an ophthalmic disorder or a neurological disorder.
Cemm - Forschungzentrum Fuer Molekulare Medizin Gmbh

Neo-islets comprising stem and islet cells and treatment of diabetes mellitus therewith

described are neo-islets comprising: a) dedifferentiated islet cells and mesenchymal and/or adipose stem cells; or b) redifferentiated islet cells and mesenchymal and/or adipose stem cells where the cells have been treated so as to facilitate redifferentiation. Further described herein are methods of generating neo-islets, the methods comprising: culturing a) dedifferentiated islet cells and mesenchymal and/or adipose stem cells; or b) redifferentiated islet cells and mesenchymal and/or adipose stem cells; on a surface that promotes the formation of cell clusters.
Symbiocelltech, Llc

Compositions and methods for the treatment of diabetes and pre-diabetes

the invention relates to the compounds and compositions of formula i, formula ii, formula iii, formula iv, formula v, formula vi or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprises a salt of dipeptidyl peptidase-4 inhibitor and the methods for treating or preventing metabolic syndrome, prediabetes and diabetes may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection.

Compositions and methods for regulating pancreatic beta cell function using adipsin

the present invention provides compositions and methods for regulating pancreatic beta cell function through modulation of adipsin activity and/or expression. Also provided are methods for preventing, treating, diagnosing, and prognosing metabolic disorders, such as diabetes, in a subject through modulation or detection of adipsin activity and/or expression..
Dana-farber Cancer Institute, Inc.

Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders

the present invention is directed to the use of co-therapy comprising administration of canagliflozin and phentermine for the treatment of obesity and obesity related disorders. More particularly, the present invention is directed to co-therapy for treating obesity, for promoting weight loss and/or for suppressing appetite; for treating, delaying, slowing the progression of and/or preventing metabolic disorders (including for example type 2 diabetes mellitus); for treating, delaying, slowing the progression of and/or preventing renal or fatty liver disorders (including for example nash, nafld, etc.); for treating, delaying, slowing the progression of and/or preventing sleep disorders (including for example sleep apnea); for providing cardiovascular protection; for treating, delaying, slowing the progression of and/or preventing cardiovascular events (including major adverse cardiac events (mace) such as myocardial infarction, unstable angina, cardiovascular death, revascularization, fatal or non-fatal cerebrovascular accident, peripheral arteriopathy, aortic events, hospitalization due to congestive heart failure, etc.); and/or for extending or prolonging life span..
Janssen Pharmaceutica Nv

Ciclopirox for use in modulation of glucose homeostasis

modulation of glucose homeostasis by administration of ciclopirox (6-cyclohexyl-1-hydroxy-4-methylpyridin-2(1h)-one) is described. Methods can be utilized in treatment of conditions that involve loss of glucose homeostasis, such as diabetes, and in one particular embodiment type ii diabetes.
University Of South Carolina

International Nutrition Research Company

. .

Advanced Neuroregenerative Therapies, Llc

. .

Method and system to derive glycemic patterns from clustering of glucose data

described are methods and systems for determining clusters of glucose data that can be utilized to provide insights to the person with diabetes, such as, for example, when a certain number of measurements during a predetermined time period is less than a predetermined threshold so that the subject is notified that the number of glucose measurements is less than optimum for management of diabetes.. .
Lifescan, Inc.

Novel insulin analogs and use thereof

the present invention relates to a novel insulin analog, and more specifically, to an insulin analog with an improved in vitro effect compared with native insulin, a nucleic acid encoding the same, an expression vector including the nucleic acid, a transformant introduced with the expression vector, a method of producing the insulin analog from the transformant, a pharmaceutical composition for treating diabetes containing the insulin analog as an active ingredient, and a method for treating diabetes using the insulin analog or the pharmaceutical composition.. .
Hanmi Pharm. Co., Ltd.

Apelin analogues

the invention relates to a peptide analogue comprising at least residues 2-13 of seq id no: 1 and further comprising at least a substitution or modification at residue 13 of seq id no: 1. The invention also relates to a pharmaceutical composition comprising the peptide analogue of the present invention and methods of treatment of diabetes, stimulating insulin release and moderating blood glucose excursions comprising administering the peptide analogue of the present invention to a patient in need thereof..
University Of Ulster

Bicyclic derivatives and pharmaceutical composition including the same

the present invention relates to a novel bicyclic derivative that has an inhibitory activity against sodium-glucose linked transporters (sglts) present in the intestines and kidneys, or a pharmaceutically acceptable salt, isomer, hydrate or solvate thereof, and a pharmaceutical composition including the same as an active ingredient, which effectively inhibit the sglt activity, and thus can be used as a therapeutic agent to treat diseases caused by hyperglycemia, such as diabetes including insulin-dependent diabetes (type i diabetes mellitus) and non-insulin-dependent diabetes (type ii diabetes mellitus), diabetic complications, and obesity.. .
Hanmi Pharm. Co., Ltd.

Controlled inhaler for distributing inhalant according to inhalation velocity

an inhaler is provided that includes a controller, a driver, an atomizer and one or more sensors for detecting information about a velocity of inhalation of a user of the inhaler. The controller is configured to dispense an inhalant from the inhaler during an inhalation of the user based on information about the velocity of inhalation of the user.
Incube Labs, Llc

Composition for imaging atherosclerosis and diagnosing atherosclerosis by using same

the present disclosure relates to a composition for imaging atherosclerosis and a method for diagnosing atherosclerosis using the same. The composition for imaging atherosclerosis according to the present disclosure shows excellent atherosclerosis diagnosis accuracy, enables diagnosis of atherosclerosis even for a person with diseases of glucose metabolism such as diabetes and enables effective diagnosis even for atherosclerosis occurring in the brain and heart.
Seoul National University R&db Foundation

Compositions containing alpha-1-antitrypsin and methods for use

methods and compositions for treating patients (e.g., patients who are insulin resistant, patients who have diabetes, or are at risk for developing diabetes) are disclosed herein. The methods can include administration of an al antitrypsin (aat) polypeptide or an agent, such as a nucleic acid molecule or organic compound, that promotes the expression or activity of α1-antitrypsin..
The General Hospital Corporation

Treatment of diabetes using g-csf

e. Exposing the patient to a stem cell proliferation agent for a third treatment period; whereby the patient's blood glucose level begins trending lower subsequent to initiation of treatment and continues to trend lower after active treatment has ended..

Methods of treating metabolic disorders associated with lipodystrophies and defects in insulin production or signaling

the invention relates to the identification of new therapeutic methods for the fgf21 polypeptide or protein, or mutants, variants, and fusions thereof, for instance, in treating metabolic diseases associated defects in insulin signaling (e.g. Insulin receptor mutation disorders (insr disorders) and/or autoimmune insulin receptor disorders (type b insulin resistance)), defects in insulin production such as type 1 diabetes mellitus, mixed dyslipidemia, nonalcoholic fatty liver disease (nafld), and other metabolic disorders, and various lipodystrophies such as hiv-haart induced partial-lipodystrophy, and in reducing the mortality and morbidity of critically ill patients..
Novartis Ag

Non-reducing end unsaturated mannuronic acid oligosaccharides and compositions containing same as active ingredient

disclosed is a non-reducing end unsaturated mannuronic acid oligosaccharide having a molecular weight of 100-3000 da, which is obtained by lysing polymannuronate as a substrate with alginate lyase, and provided are: a non-reducing end unsaturated mannuronic acid oligosaccharide; and pharmaceutical compositions for alleviating, preventing, or treating obesity, diabetes, and climacteric syndrome, and probiotics for promoting intestinal beneficial bacteria, the compositions and probiotics containing, as an active ingredient, the non-reducing end unsaturated mannuronic acid oligosaccharide, so that the antiobesity and antidiabetic effects, estrogen activity, and intestinal microflora controlling effect of the non-reducing end unsaturated mannuronic acid oligosaccharides are remarkably excellent as compared with non-reducing end saturated mannuronic acid oligosaccharides.. .
Industry Foundation Of Chonnam National University

Activated soy pod fiber

the present disclosure encompasses, among other things, compositions and methods of enhancing glyceollin content of soybean tissue as well as methods of large-scale production of soybean tissues comprising elevated glyceollin content. The present disclosure further encompasses administration of food products comprising glyceollins in the treatment or prevention (i.e., delay of onset) of overweight, obesity, prediabetes, diabetes, ibd, and gastrointestinal dysbiosis..
Microblome Therapeutics Llc

Induced expression of brain derived neurotrophic factor (bdnf) for treatment of neuromuscular, neurodegenerative, autoimmune, developmental and/or metabolic diseases

a method of treating a host of neuromuscular, neurodegenerative, developmental, autoimmune and metabolic diseases/disorders related to aging, such as traumatic injury, stroke, huntington's disease, epilepsy, multiple sclerosis (ms), lupus, type-1 and type-2 diabetes, maturity onset diabetes of the young (mody), myasthenia gravis (mg), rheumatoid arthritis (ra), graves' disease, guillain-barré syndrome (gbs), metabolic syndrome, muscular dystrophy or duchenne muscular dystrophy (dmd), severe burns, aging, amyotrophic lateral sclerosis (als), friedreich's ataxia, batten disease, alzheimer's disease, optic neuritis, leber's hereditary optic neuropathy (lhon), autism, rett syndrome, batten disease, angelman's syndrome, leigh disease, fragile-x syndrome, depression, parkinson's disease, mitochondrial diseases, developmental disorders, metabolic disease disorders and/or autoimmune disorders by inducing endogenous bdnf expression with dnp treatment to protect from neuromuscular dysfunction/disorders and/or neurodegeneration and/or muscle wasting. Dnp was administered to mice daily over a range of doses, and subsequently bdnf expression in the brain showed a dose dependent and non-linear increase in expression..
Mitochon Pharmaceuticals, Inc.

Double-acylated glp-1 derivatives

the invention relates to a derivative of a glp-1 analogue, which analogue comprises a first k residue at a position corresponding to position 27 of glp-1(7-37) (seq id no: 1); a second k residue at a position corresponding to position t of glp-1(7-37), where t is an integer in the range of 7-37 except 18 and 27; and a maximum of ten amino acid changes as compared to glp-1(7-37); wherein the first k residue is designated k27, and the second k residue is designated kt; which derivative comprises two albumin binding moieties attached to k27 and kt, respectively, via a linker, wherein the albumin binding moiety comprises a protracting moiety selected from hooc—(ch2)x—co— and hooc—c6h4—o—(ch2)y—co—; in which x is an integer in the range of 6-16, and y is an integer in the range of 3-17; wherein the linker comprises an element of the formula —nh—(ch2)2—(o—(ch2)2)k—o—(ch2)n—co—, wherein k is an integer in the range of 1-5, and n is an integer in the range of 1-5; or a pharmaceutically acceptable salt, amide, or ester thereof. The invention also relates to the pharmaceutical use thereof, for example in the treatment and/or prevention of all forms of diabetes and related diseases, as well as to corresponding novel glp-1 analogues.
Novo Nordisk A/s

Peptides hormone analogues derivable from preproglucagon

peptide hormone analogues of the formula x-v are provided herein, wherein x is a glucagon analogue or a glp1 analogue, and v is a c-terminal extension amino acid sequence comprising at least four amino acid residues, at least three of said residues being his. Also provided herein are pharmaceutical compositions comprising said analogues, and methods of using said analogues for the treatment of conditions such as obesity and diabetes..
Imperial Innovations Limited

Phenyl c-glucoside derivative containing deoxyglucose structure, preparation method and use thereof

the present invention provides a phenyl c-glucoside derivative containing a deoxyglucose structure as represented by formula i, preparation method thereof, a pharmaceutical composition comprising the same, and uses thereof in the preparation of medicaments for treating diabetes, wherein substituents r1-r7 are as defined in the specification. The present invention also provides a method for synthesizing the phenyl c-glucoside derivative containing a deoxyglucose structure and an intermediate product.
Tianjin Institute Of Pharmaceutical Research

Heteroaromatic compounds and their use as dopamine d1 ligands

and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating d1-mediated (or d1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, ad, pd, or pharmacotherapy therapy), adhd, impulsivity, compulsive gambling, overeating, autism spectrum disorder, mcl, age-related cognitive decline, dementia, rls, parkinson's disease, huntington's chorea, anxiety, depression, mdd, trd, bipolar disorder, chronic apathy, anhedonia, chronic fatigue, post-traumatic stress disorder, seasonal affective disorder, social anxiety disorder, post-partum depression, serotonin syndrome, substance abuse and drug dependence, drug abuse relapse, tourette's syndrome, tardive dyskinesia, drowsiness, excessive daytime sleepiness, cachexia, inattention, sexual dysfunction, migraine, sle, hyperglycemia, atherosclerosis, dislipidemia, obesity, diabetes, sepsis, post-ischemic tubular necrosis, renal failure, hyponatremia, resistant edema, narcolepsy, hypertension, congestive heart failure, postoperative ocular hypotonia, sleep disorders, and pain.. .

Substituted pyridazines as prostacyclin receptor modulators

cyclohexane derivatives of formula ia and pharmaceutical compositions thereof that modulate the activity of the pgi2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (pah) and related disorders; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack; angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation in an angioplasty or coronary bypass surgery individual or in an individual suffering from atrial fibrillation; atherosclerosis; atherothrombosis; asthma or a symptom thereof; a diabetic-related disorder such as diabetic peripheral neuropathy, diabetic nephropathy or diabetic retinopathy; glaucoma or other disease of the eye with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (sle); ulcerative colitis; ischemia-reperfusion injury; restenosis; atherosclerosis; acne; type 1 diabetes; type 2 diabetes; sepsis; and chronic obstructive pulmonary disorder (copd)..
Arena Pharmaceuticals, Inc.

Method of using dihydro-resveratrol or its stilbenoid derivatives and/or chemical variants in treatments of fibrotic and diabetic conditions

a polyphenol derivative of the stilbenoid family, namely trans-3,5,4′-trihydroxybibenzyl, also known as dihydro-resveratrol, is disclosed as a remedial agent. In particular, the usage of dihydro-resveratrol as an anti-fibrotic agent in suppressing the activation of pancreatic stellate cells (pscs) is presented.
Hong Kong Baptist University

System, method, and computer readable medium for dynamic insulin sensitivity in diabetic pump users

a technique for treating diabetes that recognizes patient insulin sensitivity is a time-varying physiological parameter. The described techniques for treating diabetes include measuring interstitial fluid glucose concentration, reading insulin delivery data, determining patient insulin sensitivity based on the interstitial fluid glucose concentration and insulin delivery data, and a time-varying physiological parameter, and dispensing an insulin dose from an insulin delivery device based on the determined patient insulin sensitivity..
University Of Virginia Patent Foundation

Compositions and methods for treating diabetes

the present disclosure is a compound, a method of making the compound and method of using such compound preferably in the form of a dietary supplement that, when administered, is capable of treating prediabetes, diabetes, insulin resistance or metabolic syndrome. The unique combination of the composition is preferably administered orally.

Methods and compositions comprising ursolic acid and/or resveratrol for treating diabetes, or cancer

certain embodiments are directed to methods and compositions for treating obesity, diabetes, and/or cancer with a combination of ursolic acid and resveratrol.. .
The Board Of Regents Of The University Of Texas System

Method of using dopamine reuptake inhibitors and their analogs for treating diabetes symptoms and delaying or preventing diabetes-associated pathologic conditions

method of using dopamine reuptake inhibitors, e.g., sydnonimine derivatives, for the management of diabetic symptoms and associated complications or conditions, such as hyperglycemia and diabetic neuropathy.. .
Caliper Life Sciences, Inc.

Ghrelin o-acyltransferase inhibitors

small molecule ghrelin o-acyltransferase inhibitors found using an assay to detect ghrelin o-acyltransferase activity using an acrylodan-labeled peptide mimic of ghrelin that provides for high-throughput screening for ghrelin o-acyltransferase inhibitors and detection via high performance liquid chromatography. The newly discovered class of synthetic triterpenoids efficiently inhibits ghrelin acylation by goat and function as covalent reversible inhibitors of goat.
Syracuse University

Dapagliflozin compositions

the present invention relates to pharmaceutical compositions comprising a solid dispersion of dapagliflozin and one or more pharmaceutically acceptable excipients, and processes for their preparation. It further relates to a method of treating diabetes using said pharmaceutical compositions..
Sun Pharmaceutical Industries Limited

Foldover sensors and methods for making and using them

the invention disclosed herein includes sensors having three dimensional configurations that allow expansive “360°” sensing (i.e. Sensing analyte from multiple directions) in the environments in which such sensors are disposed.
Medtronic Minimed, Inc.

Methods of inhibiting the ghrelin/growth hormone secretatogue receptor pathway and uses thereof

the invention provides methods for treatment, prevention or management of obesity, obesity related disorders, diabetes mellitus, and metabolic syndrome in a subject by administering a ghrelin o-acyltransferase (goat) inhibitor and/or a ghrelin receptor antagonist to the subject. The invention also provides ghrelin receptor antagonists of formula (vii): a11-a12-a13-gly-ser-a14-phe-leu-a15-a16-a17-a18, wherein each of a11, a12, and a13 is independently absent, an amino acid, or an amino protecting group; each of a15, a16, a17, and a18 is independently absent or an amino acid; and a14 is a serine conjugated with a —c(o)c1-c20alky or a diaminopropionic acid conjugated with a —c(o)c1-c20alkyl group, provided that at least one of a11, a12, or a13 is present..
Ball Horticultural Company

Combined non invasive blood glucose monitor device

this patent is a combined non-invasive method of monitoring glucose level. Monitoring the concentration of glucose level in human blood and tissue was developed by a combined non-invasive technique.
Ball Horticultural Company

Management and prioritization of the delivery of glycemic insight messages

a computer-implemented system and related method of managing use of a diabetes management device are presented here. An embodiment of the method obtains a number of glycemic insight messages for delivery to a user device associated with a user of the diabetes management device, each of the glycemic insight messages conveying information regarding a relationship between an insight event derived from patient-specific historical input data and a glycemic outcome.
Medtronic Minimed, Inc.

Diabetes management therapy advisor

a method includes obtaining training data for a plurality of patients of a patient population. The training data includes training blood glucose history data including treatment doses of insulin administered by the patients of the patient population and one or more outcome attributes associated with each treatment dose.
Aseko, Inc.

Data analytics and reporting of glucose-related information

a computer-implemented system and related method of reporting glucose information for a user of a diabetes management device are presented here. An embodiment of the method obtains input data for the user of the diabetes management device, and identifies a glycemic response event based on an analysis of the obtained input data.
Medtronic Minimed, Inc.

Data analytics and insight delivery for the management and control of diabetes

a computer-implemented system and related method of managing use of a diabetes management device are presented here. An embodiment of the method obtains input data for a user of the diabetes management device, and compares the input data against historical event/outcome combinations maintained for the user.
Medtronic Minimed, Inc.

Novel glucagon analogues

the present invention relates to novel peptide compounds which have a protracted profile of action and improved solubility and stability, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of hyperglycemia, diabetes and obesity, as well as a variety of diseases or conditions associated with hyperglycemia, diabetes and obesity..
Novo Nordisk A/s

New compounds

the invention relates to a compound of formula (i) wherein the variables have the meaning as indicated in the claims; in free form and in salt form; and optionally the enantiomers and geometrical isomers thereof. The compounds of formula (i) are useful as therapeutic agent for organ transplants, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, type i diabetes and complications from diabetes, cancer, asthma, atopic dermatitis, autoimmune thyroid disorders, ulcerative colitis, inflammatory bowel diseases, crohn's disease, alzheimer's disease, leukemia, osteoarthritis, control of pruritus, chronic respiratory disease or keratoconjunctivitis in mammals..
Novartis Tiergesundheit Ag

Aromatic heterocyclic compound

the compound represented by the general formula: wherein ring a is benzene which may be substituted and the like; ring b is benzene which may be substituted and the like; x is a single bond and the like; y is alkyl which may be substituted and the like; z is cr1 or nitrogen atom; r1 is hydrogen and the like; r2 is alkyl which may be substituted and the like or a pharmaceutically acceptable salt thereof is useful as a prevention/treatment agent of obesity, diabetes, and the like.. .
Mitsubishi Tanabe Pharma Corporation

Infusion pump with program key

a wearable infusion pump allows a user to insert a program key into the device housing to select a continuous dosage rate. The program keys are shaped to close contacts on a printed circuit board within the housing to communicate the selected dosage to a microprocessor.
Becton, Dickinson And Company

Mitochondrial-derived peptide mots3 regulates metabolism and cell survival

mots3 is a novel polypeptide. Methods of treating diseases such as diabetes, obesity, fatty liver, and cancer using mots3 and pharmaceutical compositions thereof are disclosed herein..
The Regents Of The University Of California

Hepatocyte growth factor mimics as therapeutic agents

small molecule, peptidic hepatocyte growth factors mimics, which act as both mimetics and antagonists, have been generated. These molecules have been shown or predicted to have therapeutic potential for numerous pathologies including dementia, neurodegenerative disease, diabetes and metabolic syndrome, cancer, and defective wound healing..
Washington State University

Inhibitor of inflammatory conditions

the invention relates to boswellia frereana and particularly an extract of same for treating a range of inflammatory disorder or conditions selected from the group comprising: inflammatory bowel disease (ibd), all forms of muscular dystrophy especially duchenne muscular dystrophy, sepsis, sepsis syndrome, osteoporosis, ischemic injury, graft vs. Host disease, reperfusion injury, asthma, diabetes, cancer, myelogenous and other leukemias, psoriasis and cachexia, alzheimer's disease, demyelinating neurological disorders including multiple sclerosis, acetylcholinesterase mediated disorders, retinal disorders, neurological, retinal, and muscular disorders..
Compton Developments Ltd.

Pdia4 protein as a target for diagnosis, monitoring and treatment of diabetes

a pdia4 inhibitor for use in preventing, alleviating and/or treating diabetes and/or diabetes-related complications in a subject in need thereof is disclosed, wherein the pdia4 inhibitor does not comprise cytopiloyene. A pdia4 inhibitor and one other anti-diabetic agent for use in combination therapy in preventing, alleviating, treating diabetes and diabetes-related complications, and/or reversing diabetes in a subject in need thereof is also disclosed, wherein the pdia4 inhibitors for use in combination therapy may comprise cytopiloyene.
Academia Sinica

Derivatives of ergostatrien-3-beta-ol from antrodia camphorata and antiglycemic, antihyperlipidemic and decreasing hepatic fat use thereof

the present invention provides a method for treating diabetes, hyperlipidemia or hepatic total lipids by using ergostatrien-3β-ol and its derivatives, as well as a method for decreasing blood glucose and hba1c levels and reducing blood total cholesterol and triglyceride levels, whereas increasing blood hdl-c levels; and a method for decreasing hepatic total lipid and triacylglycerol levels; and increasing expression levels of membrane glucose transporter 4 (glut4) and phospho-akt in skeletal muscle tissue, and phospho-ampk in both skeletal muscle and liver tissue using ergostatrien-3β-ol and its derivatives.. .

Methods and compositions for increasing fertility and/or inhibiting pregnancy failure and restoring glucose tolerance

methods and compositions for enhancing fertility and/or inhibiting pregnancy failure, restoring glucose tolerance and/or preventing glucose intolerance and/or maintaining glucose homeostasis and/or increasing insulin sensitivity and/or preventing weight gain and/or inducing or enhancing weight loss, treating dyslipidemia, treating hypertestosteronism or hyperandrogenism, and/or treating type 2 diabetes in an individual in need thereof are provided.. .
Queens University At Kingston

Data analytics and generation of recommendations for controlling glycemic outcomes associated with tracked events

a computer-implemented system and related method of reporting glucose information for a user of a diabetes management device are presented here. An embodiment of the method obtains input data for the user of the diabetes management device, and identifies a tracked glycemic response event.
Medtronic Minimed, Inc.

Enzo Therapeutics, Inc.

. .

Method and means for the non-invasive diagnosis of type ii diabetes mellitus

the invention relates to a method and means for the non-invasive diagnosis of type ii diabetes mellitus. The glycation state is determined in at least one glycation position of selected plasma proteins..
Ohio University

Methods of measuring antigen-specific t cells

provided herein are methods and kits for assaying antigen-specific t cell responses, such as rare autoantigen-specific t cell responses, by measuring a level of ip-10 in a sample from a subject having or suspected of having an autoimmune disease, an allergy, an infectious disease or condition, or an adverse immune condition caused by administration of an isolated, recombinant or synthetic protein or peptide. Also provided herein are methods and kits for assaying a t cell response to an antigen peptide, such as an islet autoantigen peptide, such as measuring a t cell response to at least one antigen peptide, such as an islet autoantigen peptide, in a sample from a subject, such as one having or suspected of having type 1 diabetes (tid), celiac disease or both..
Immusant, Inc.

Genetic alterations on chromosome 16 and methods of use thereof for the diagnosis and treatment of type 1 diabetes

compositions and methods for the detection and treatment of t1d are provided.. .
The Children's Hospital Of Philadelphia

Compositions and methods for treating fatty tissue buildup

the present disclosure is directed to the treatment of diseases or conditions involving the buildup of fatty tissues, such as obesity, metabolic syndrome, type ii diabetes, etc. A composition containing a monoclonal antibody directed against gastric inhibitory polypeptide is administered.
The Metrohealth System

Gpr40 agonists for the treatment of type ii diabetes

wherein r1c, r2c, r4c, wc, yc, zc, and gc, are defined herein.. .

Gpr40 agonists for the treatment of type ii diabetes

wherein r1b, r2b, r4b, wb, xb, yb, and gb, are defined herein.. .

Gpr40 agonists for the treatment of type ii diabetes

wherein r1, r2, r4, w, x, y, and g, are defined herein.. .

Tetra-o-substituted butane-bridge modified ndga derivatives, their synthesis and pharmaecutical use

the present invention relates to nordihydroguaiaretic acid derivative compounds, namely, butane bridge modified nordihydroguaiaretic acid (ndga) compounds and butane bridge modified tetra-o-substituted ndga compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them and kits including them for the treatment of diseases and disorders, in particular, diseases resulting from or associated with a virus infection, such as hiv infection, hpv infection, or hsv infection, an inflammatory disease, such as various types of arthritis and inflammatory bowel diseases, metabolic diseases, such as diabetes and hypertension, or a proliferative disease, such as diverse types of cancers.. .
Erimos Pharmaceuticals Llc

2,2'-tandem dithiazole compound, preparation method therefor, and use thereof

the present invention relates to a thiazole-based compound, a preparation method therefor, and a use thereof. More specifically, the present invention relates to a 2,2′-bis-thiazole-based compound, a preparation method therefor, and a use of 2,2′-bis-thiazole-based compound a histone deacetylase inhibitor in the preparation of an antitumor medicament, a medicament for treating autoimmune diseases, a medicament for treating type ii diabetes mellitus and complication thereof, or a medicament for treating neurodegenerative diseases..
Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences

Treatment of diabetes type 1 using glp-1 and anti-il-21

the present invention relates to use of a glp-1 agonist and an anti-il-2 antibody in treatment and/or prevention of type 1 diabetes.. .
Novo Nordisk A/s

Mangifera indica as a sirtuin 1 activating agent

the invention relates to a mangifera (mango) indica preparation as sirtuin 1 activating agent for in vivo and in vitro applications. The preparation may be used to reduce the risk of developing obesity, type ii diabetes, elevated blood lipid levels, artheriosclerosis and cardiovascular diseases, as well as a cell and dna protector..
Vital Solutions Swiss Ag

Modulation of fat storage in a subject by altering population levels of christensenellaceae in the gi tract

disclosed herein are compositions that have substantially purified christensenellaceae bacteria, and uses of these compositions to alter the microbiome of an individual. The addition of christensenellaceae bacteria, such as christensenella, to the microbiome of an individual can treat or prevent weight gain, reduce body weight, inhibit fat accumulation, reduce excess adiposity, and reduce a high body mass index (bmi), and can also treat or prevent conditions correlating with excess weight and fat and a high bmi, such as insulin sensitivity, metabolic syndrome, excess adiposity, and diabetes..
Cornell University

Pancreatic islets of transgenic lea29y animals for treating diabetes

the present invention relates to methods of treating diabetes in a human subject comprising the use of pancreatic islets or of embryonic pancreatic tissue of a transgenic animal, wherein said transgenic animal contains a polynucleotide sequence encoding a ctla4 peptide-immunoglobulin fusion, preferably lea29y, and expresses said ctla4 peptide-immunoglobulin fusion in a tissue-specific manner in pancreatic islets.. .
Mwm Biomodels Gmbh

Glycoside derivatives and uses thereof

wherein the variables are defined as herein above, which are useful for treating diseases and conditions mediated by the sodium d-glucose co-transporter (sglt), e.g. Diabetes.

Sitagliptin tannate complex

the present invention provides for a sitagliptin tannate complex or a pharmaceutical compositions or a pharmaceutically acceptable intermediates comprising said complex. This invention also relates to a processes to prepare the sitagliptin tannate complex as well as to methods of using the sitagliptin tannate complex to treat diabetes, obesity and high blood pressure..
Merck Sharp & Dohme Corp.

Anti-human il-21 antibodies

monoclonal antibodies are identified that bind the il-21 protein. These antibodies are used to identify regions of the il-21 protein to where binding neutralizes il-21 activity.
Zymogenetics, Inc.

Methods for treating and/or limiting development of diabetes

provided herein are methods and compositions for limiting development of and/or treating diabetes, involving compounds of formula a-b, wherein a is a pancreatic β cell targeting moiety, and b is an inhibitor of expression and/or activity of apolipoprotein ciii (apociii), protein kinase a (pka), src kinase, and/or β1 integrin.. .
Biocrine Ab

Compositions and methods for treating metabolic disorders

the disclosure features compositions and methods for treating a metabolic disorder, including diabetes, conditions associated with inhibition of insulin secretion, or for increasing longevity. In some embodiments, the methods comprise administering an anti-cgrp antagonist antibody..
Labrys Biologics, Inc.

Heteroaryl compounds and methods of use thereof

provided herein are heteroaryl compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. In one embodiment, the compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as cns disorders and metabolic disorders, including, but not limited to, e.g., neurological disorders, psychosis, schizophrenia, obesity, and diabetes..
Sunovion Pharamaceuticals Inc.

Berberine salts, ursodeoxycholic salts and combinations, methods of preparation and application thereof

the invention provides various novel compositions of berberine in combination with pharmacologically active organic acids, and related methods of their use in treating various diseases or disorders. The invention further provides various novel compounds prepared from berberine and pharmacologically active organic acids and prepared from ursodeoxycholic acid and pharmacologically active organic bases, and pharmaceutical compositions thereof, and methods of their preparation and therapeutic use in treating and/or preventing various diseases or disorders.
Shenzhen Hightide Biopharmaceutical, Ltd.

Indanylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof

wherein the groups r, r1, r2, r3, m and n are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the gpr40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.

Methods and compositions for treating nephrogenic diabetes insipidus

disclosed are compositions and methods for treating nephrogenic diabetes insipidus and for induction of diuretic effect.. .

Methods of upregulating irs function

this invention is directed to a general method for the chronic treatment, potential cure, or prevention of various metabolic and related diseases in people, including diabetes, by modulating irs2 activity in cells and tissues in the body. Irs1 and irs2 are part of the insulin or insulin-like growth factor signaling pathway.
Hmi Medical Innovations, Llc

Novel lactic acid bacterium and use thereof

a new lactobacillus mali that can be used for preventing or treating a metabolic syndrome is provided. A method for preventing or treating obesity, diabetes or a complication of diabetes by using the lactobacillus mali is also provided..
National Taiwan University

Composition of dietary supplements based on apoptosis that support optimal health

this invention clearly identifies the current agriculture-based diseases facing united states citizens such as, heart disease, stroke, cancer, diabetes and other degenerative diseases that did not exist in our hunter-gatherer ancestors. The united states government has established the dietary guidelines advisory committee (dgac) to solve the problem.

Methods and diets to protect against chemotoxicity and age related illnesses

a method of improving longevity and/or alleviating a symptom of aging or preventing age related diseases is provided. The method includes a step in which the subject's average and type of daily protein intake, igf-i, and igfbp1 levels, and risk factors for overall mortality, cancer and diabetes are determined.
University Of Southern California

Stimulation via tlr4/md-2 to reverse type 1 diabetes

disclosed are methods and compositions for treating type i diabetes in a subject. Agents selected from a tlr4 agonist, a tlr4/md-2 agonist, or a combination thereof may be used in the disclosed methods and compositions.
University Of Cincinnati

Chimeric fibroblast growth factor 21 proteins and methods of use

the present invention relates to a chimeric protein that includes an n-terminus coupled to a c-terminus, where the n-terminus includes a portion of a paracrine fibroblast growth factor (“fgf”) and the c-terminus includes a c-terminal portion of an fgf21 molecule. The portion of the paracrine fgf is modified to decrease binding affinity for heparin and/or heparan sulfate compared to the portion without the modification.
New York University

Phenyl-triazolo-pyridine compounds

the present invention provides a compound of the formula (i) below: wherein r1 is selected from the group consisting of h, ch3, cn, —ch2cn, —c(ch3)2cn, f, cl, and br; r2 is selected from the group consisting of h, —o(c1-c3alkylene)r4, —ch2cn, cn, —och3, cf2, —c(ch3)2cn, —c(ch3)2, —s(o)2ch3, —s(o)2nh2, and —ocf2; r3 is selected from the group consisting of h, ch3, and —och3; and r4 is selected from the group consisting of h, —c(ch3)2cn, —och3, —s(o)2ch3, cn, and —c(ch3)2oh; or a pharmaceutical salt thereof, methods of treating type two diabetes using the compound and a process for preparing the compound.. .
Eli Lily And Company

Substituted indanone compounds as gpr119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders

the present invention relates to indanone compounds. The indanone compounds are gpr119 modulators and useful for the prevention and/or treatment of diabetes, obesity, dyslipidemia and related disorders.
Sanofi

Swallowable capsule and stimulating incretin production within the intestinal tract

embodiments of the invention provide apparatus and methods for stimulating l cells in the intestinal tract to produce incretins for the treatment of conditions including diabetes and obesity. Many embodiments provide a method and apparatus for the treatment of diabetes by electrically stimulating l-cells to secrete incretins to stimulate or otherwise modulate the production of insulin.
Incube Labs, Llc

Novel fast acting insulin preparations

the invention relates to a soluble preparation for injection in humans, characterized in that the preparation (1) contains human insulin or a monomeric insulin analog, (2) has a lower concentration of insulin-bound zinc than about 1.8 ions per hexamer of insulin, (3) contains nicotinamide, (4) has a lower conductivity than 5 msi/cm. The concentration of insulin-bound zinc ions is less than 0.02 ions per hexamer of insulin and the conductivity less than 0.2 msi/cm.

Dietary compositions for reducing blood glucose levels and for weight management

the present invention provides dietary compositions comprising mulberry extract, coffee extract, bean extract, optionally, dietary fibers, and a nutraceutically acceptable carrier. The present invention further provides methods for preventing the increase in postprandial hyperglycemia and hypoglycemia, hyperinsulinemia and diseases and disorders associated therewith, including, endothelial dysfunction, inflammatory conditions, oxidative stress, hyperlipidemia, and consecutive pathologies like insulin resistance, diabetes, visceral obesity, hypertension and cardiovascular diseases..
Marmar Investment Sp. Z O.o.

Medical use of artemisinin compounds and gephyrin agonists

the invention refers to btbd9 binders and gephyrin binders for medical use and in particular an artemisinin compound of general formula i for use in the treatment of a diabetes patient, as well as a method of identifying suitable lead candidates.. .
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh

Exendin-4 peptide analogues as dual glp-1/glucagon receptor agonists

the present invention relates to exendin-4 derivatives and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake. .
Greenleaf Nursery Company

Surrogates of post-translationally modified proteins and uses thereof

the present invention provides compounds that are surrogates of post-translationally modified proteins and uses thereof. Numerous diseases are associated with post-translationally modified proteins that are difficult to obtain in homogenous form and in quantities needed for immunization and use as convenient standards, calibrators, and/or reference compounds that facilitate the detection and analysis of endogenous post-translationally modified proteins.
President And Fellows Of Harvard College

C1-phostphonate analogue of udp-glcnac for inhibition of o-glcnac transferase

a novel c1-phosphate analogue of uridine-5′-diphosphate (udp)-glcnac as an effective ogt (o-linked n-acetylglucosamine (o-glcnac) transferase) inhibitor, and a preparation method for the same provides a compound having an ogt inhibitory effect that can be used as a useful tool in the studies on various vital phenomena in association with the protein modification by o-glcnac within cells and furthermore as a candidate substance in the treatment or research of diseases related to the protein modification by o-glcnac, such as cancers, diabetes, or degenerative neurological diseases.. .
Soonchunhyang University Industry Academy Cooperation Foundation

Substituted fused heterocycles as gpr119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders

the substituted fused heterocyclic compounds are gpr119 modulators and useful for the prevention and/or treatment of diabetes, obesity, dyslipidemia and related disorders. The invention furthermore relates to the use of substituted fused heterocyclic compounds as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them..

Isoindolinone compounds as gpr119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders

the present invention relates to isoindolinone compounds. The isoindolinone compounds are gpr119 modulators and useful for the prevention and/or treatment of diabetes, obesity, dyslipidemia and related disorders.
Sanofi

Combination therapy for the treatment of autoimmune diseases

the present invention pertains to compounds and their combination for use in the prevention or therapy of a subject suffering from an autoimmune disease such as diabetes type 1. Provided are antagonists of t-cells that are used in combination with antagonists of the cytokine cxcl10, sequentially or concomitantly, in a subject suffering from an autoimmune disease, in particular diabetes type 1..
Fraunhofer-gesellschaft Zur Förderung Der Angewandten Forschung E.v.

Potassium-binding agents for treating hypertension and hyperkalemia

the present invention generally relates to methods of treating hypertension (htn) in patients in need thereof wherein the patient optionally further suffers from chronic kidney disease (ckd) or type ii diabetes mellitus (t2dm). The invention also relates to methods of treating hyperkalemia in a patient in need thereof, wherein the patient suffers from ckd, t2dm or htn and are optionally being treated with an effective amount of a renin-angiotensin-aldosterone system (raas) agent.
Relypsa, Inc.

Pharmaceutical composition, methods for treating and uses thereof

the invention relates to the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia using a sglt-2 inhibitor. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions..
Boehringer Ingelheim International Gmbh

Bromocriptine formulations

the present application describes pharmaceutical formulations of bromocriptine mesylate and methods of manufacturing and using such formulations. The formulations are useful for improving glycemic control in the treatment of type 2 diabetes..
Veroscience Llc

Treatment for diabetes in patients inappropriate for metformin therapy

the present invention relates to the finding that certain dpp-4 inhibitors are particularly suitable for treating and/or preventing metabolic diseases, particularly diabetes, in patients for whom metformin therapy is inappropriate due to intolerability or contraindication against metformin.. .
Boehringer Ingelheim International Gmbh

Chemosensory receptor ligand-based therapies

provided herein are methods for treating conditions associated with a chemosensory receptor, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administrating a composition comprising a chemosensory receptor ligand, such as a bitter receptor ligand. Also provided herein are chemosensory receptor ligand compositions, including bitter receptor ligand compositions, and methods for the preparation thereof for use in the methods of the present invention.
Elcelyx Therapeutics, Inc.

Volant Holdings Gmbh

. .

Human antigen binding proteins that bind betta-klotho, fgf receptors and complexes thereof

the present invention provides compositions and methods relating to or derived from antigen binding proteins activate fgf21-mediated signaling. In embodiments, the antigen binding proteins specifically bind to (i) β-klotho; (ii) fgfr1c, fgfr2c, fgfr3c or fgfr4; or (iii) a complex comprising β-klotho and one of fgfr1c, fgfr2c, fgfr3c, and fgfr4.
Amgen Inc.

Enolase 1 (eno1) compositions and uses thereof

the invention provides compositions comprising eno1 and a muscle targeting peptide, e.g, as a fusion protein, for delivery of eno1 to a muscle. The eno1 may contain one or more added cysteine residues which are covalently attached to a biocompatible polymer (e.g.
Berg Llc

Methods of use for therapeutics targeting the pathogen porphyromonas gingivalis

the invention relates to compositions, formulations, vaccines and antibodies for the prevention and/or treatment of aging and brain disorders, including alzheimer's disease, diabetes, cardiovascular disease, retinal disorders and arthritis. The invention also provides methods of treatment of aging disorders, brain disorders, including alzheimer's disease, diabetes, cardiovascular disease, retinal disorders, and arthritis by administering compositions, formulations, vaccines and antibodies described in the specification.
Cortexyme, Inc.

Oral formulations mimetic of roux-en-y gastric bypass actions on the ileal brake; compositions, methods of treatment, diagnostics and systems for treatment of metabolic syndrome manifestations including insulin resistance, fatty liver disease, hyperlipidemia, and type 2 diabetes.

in other aspects, the invention provides ileal brake hormone releasing compositions, methods of treatment, diagnostics, and related systems useful in selective control of appetite, stabilizing blood glucose and insulin levels, and treating gastrointestinal disorders in a similar manner to rygb surgery, but having at least 20% of the potency to stimulate the hormonal response of the ileal brake of humans.. .

Compositions and methods for reducing chronic low-level inflammation

the invention relates to compositions and methods for reducing chronic low-level inflammation associated with chronic conditions. Specifically, the invention relates to compositions of hydrophobic derivatives of aspirin and/or hydrophobic derivatives of sesamol in combination with eicosapentaenoic acid (epa) and docosahexaenoic acid (dha), and their methods for reducing chronic low-level inflammation associated with chronic conditions including obesity, metabolic syndrome, diabetes, cardiovascular disease, cancer, auto-immune disorders, ocular and neurological disorders in a mammal..

Methods of assessing diabetes treatment protocols based on protocol complexity levels and patient proficiency levels

embodiments of methods of assessing a diabetes treatment protocol comprise determining a protocol complexity level corresponding to a degree of difficulty of completing the diabetes treatment protocol by utilizing the processor, determining a patient proficiency level corresponding to a skill set of the patient in conducting the diabetes treatment protocol by utilizing the processor, comparing the protocol complexity level to the patient proficiency level via the processor, and providing an output based on the comparison.. .
Roche Diabetes Care, Inc.

Compositions and methods for detecting snp(s) associated with diabetes

in one aspect, provided herein are set of primers and use of the same for the detection of snps associated with diabetes. In certain embodiments, the primers used to detect snp sites associated with diabetes comprise primer set 1 to primer set 47.
Shanghai Sixth People's Hospital

Guided differentiation of induced pluripotent stem cells

this document provides methods and materials related to making and using differentiated induced pluripotent stem cells. For example, methods and materials for making differentiated induced pluripotent stem cells (e.g., insulin-producing cells) that do not form cancer cells within a mammal (e.g., a human), cells that underwent guided differentiation from induced pluripotent stem cells, compositions containing cells that underwent guided differentiation from induced pluripotent stem cells, and methods for using cells that underwent guided differentiation from induced pluripotent stem cells (e.g., methods for using such cells to treat diabetes or to repair cardiovascular tissue) are provided..
Mayo Foundation For Medical Education And Research

Novel insulin derivatives and the medical uses hereof

the present invention is in the therapeutic fields of drugs for medical conditions relating to diabetes. More specifically the invention relates to novel acylated derivatives of human insulin analogues.
Novo Nordisk A/s

Exendin-4 derivatives as selective peptidic dual glp-1/glucagon receptor agonists

the present invention relates to dual glp-1/glucagon receptor agonists and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as for reduction of excess food intake.. .
Sanofi

Therapeutic compounds

the invention provides compounds and compositions that are useful for treating conditions including alzheimer's disease, parkinson's disease, diabetes, cancer, and psychotic disorders such as schizophrenia.. .
Arizona Board Of Regents On Behalf Of Arizona State University

Ethynyl derivatives

the present invention relates to compounds useful for the treatment of parkinson's disease, anxiety, emesis, obsessive compulsive disorder, autism, neuroprotection, cancer, depression and diabetes type 2.. .
Hoffmann-la Roche Inc.

Quinoline compounds

the present invention relates to quinoline compounds as defined by formula i below. Such quinoline compounds have been shown to inhibit the formation of amyloid deposits (e.g., amyloid oligomers, fibrils or plaques).
Oxford University Innovation Limited

Infusion of insulin into a patient and diabetes mellitus medical methods based on the patients monitored analyte concentration

medical data provided by a physiological parameter sensor is used for management of the patient's medical condition. Analytes that may be monitored and managed include, but are not limited to, acetyl choline, amylase, bilirubin, cholesterol, chorionic gonadotropin, creatine kinase (e.g., ck-mb), creatine, glucose, glutamine, growth hormones, hormones, ketones, lactate, oxygen, peroxide, prostate-specific antigen, prothrombin, thyroid stimulating hormone, and troponin..
Abbott Diabetes Care Inc.

Compositions and methods for treating diabetes

the present invention relates to the field of diabetes mellitus. More specifically, the present invention provides compositions and methods useful for treating diabetes.
The Johns Hopkins University

Treatment of inflammatory diseases using placental stem cells

provided herein are methods of treatment of individuals having an immune-related disease, disorder or condition, for example, inflammatory bowel disease, graft-versus-host disease, multiple sclerosis, rheumatoid arthritis, psoriasis, lupus erythematosus, diabetes, mycosis fungoides (alibert-bazin syndrome), or scleroderma using placental stem cells or umbilical cord stem cells.. .
Anthrogenesis Corporation

Methods of manipulating alginate microcapsule size and permeability

methods and apparatuses are disclosed for the treatment of diabetes using artificial islets of langerhans. In one example, the artificial islet of langerhans include islets or stem cells (but can also include hepatocytes or even any biological cell type) encapsulated in alginate microcapsules.
The Regents Of The University Of California

Composition to mitigate spikes in blood sugar

compositions comprising therapeutically effective amounts of quercetin, myricetin and chlorogenic acid are improved by the addition of one or multiple additional components, for mitigating blood sugar spikes in general and for treating diabetes specifically. Certain other additives produce additional benefits..
Panacea Scientific, Inc.

Small molecule inhibitors of xbp1 splicing

small molecule inhibitors of xbp1 splicing by ire1α are provided, as well as methods for their use in treating or preventing cancer (e.g., endocrine resistant breast cancer), diabetes, and obesity.. .
Georgetown University

Use of composition containing iron (ii) amino acid chelate in preparation of drug for ameliorating diabetes

the present invention provides a use of a composition containing a ferrous amino acid chelate for the preparation of a pharmaceutical used in diabetes improvement. The pharmaceutical comprise an effective amount of the composition containing the ferrous amino acid chelate and pharmaceutically acceptable carriers to improve diabetes.
Profeat Biotechnology Co., Ltd.

Gi-endocrine drug delivery device and use

shown are a device, system and method that improve the diabetes care of a patient that has undergone gastric surgery. The device provides continuously or intermediate monitoring at various intervals before and after meals of several sensors to perceive, among other things, the blood glucose level, ekg/heart rate and volume of meals a patient has consumed.
Hamilton Scientific, Ltd.

Protein and lipid biomarkers providing consistent improvement to the prediction of type 2 diabetes

the invention relates to biomarkers associated with diabetes, including protein and lipid metabolite biomarkers, methods of using the biomarkers to determine the risk that an individual will develop diabetes, and methods of screening a population to identify persons at risk for developing diabetes and other pre-diabetic conditions.. .
True Health Diagnostics, Llc

Nmr measurements of nmr biomarker glyca

biomarkers and/or risk assessments identify patients having an increased risk of certain clinical disease states including, for example, chd, type 2 diabetes, dementia, or all-cause death (acd) using nmr signal to measure a level of “glyca” in arbitrary units or in defined units (e.g., μmol/l) that can be determined using a defined single peak region of proton nmr spectra. The glyca measurement can be used as an inflammation biomarker for clinical disease states .
Liposcience, Inc.

Compositions and methods of using islet neogenesis peptides and analogs thereof

the invention provides peptides and analogs of ingap and hip peptides. The peptides and analogs can be used in methods for treating various diseases and conditions.
Shenzhen Hightide Biopharmaceutical, Ltd.

Inhibitors of mitochondrial pyruvate dehydrogenase kinase isoforms 1-4 and uses thereof

the present disclosure relates to the identification of pdk inhibitors and their use in the treatment of diseases such as diabetes, cardiovascular disease and cancer. The invention relates to the development of robust pdk inhibitors that can be used to improve glucose metabolism and correct metabolic dysfunction in vivo.
The Board Of Regents Of The University Of Texas System

4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide derivatives as potent and selective inhibitors of 12-lipoxygenase

human lipoxygenases (loxs) are a family of iron-containing enzymes involved in catalyzing the oxidation of polyunsaturated fatty acids to provide the corresponding bioactive hydroxyeicosatetraenoic acid (hete) metabolites. These eicosanoid signaling molecules are involved in a number of physiologic responses such as platelet aggregation, inflammation, and cell proliferation.
Thomas Jefferson University

Non-invasive in vivo imaging and methods for treating type i diabetes

the present invention provides novel drug discovery platforms and methods for treating type i diabetes.. .
Biocrine Ab

Dna vaccines encoding heat shock proteins

a method of treating a t cell-mediated inflammatory autoimmune disease by administering to an individual in need thereof an immunogenic composition comprising a recombinant construct of a nucleic acid sequence encoding heat shock protein 90 (hsp 90), or an active fragment thereof, wherein the nucleic acid sequence is operatively linked to one or more transcription control sequences. The disease is other than insulin dependent diabetes mellitus (iddm) or rheumatoid arthritis.
Alma Bio Therapeutics

New target for diabetes treatment and prevention

the present invention relates to the identification of alms1 as the missing player involved in the regulation of the insulin-mediated glucose uptake through glut4 sorting vesicles, and to the down-regulation of alms1 by αpkc. Accordingly, the present invention relates to a molecule capable of preventing the binding of αpkc on alms1 for use for treating or preventing diabetes, in particular type 2 diabetes.
Vaxine Pty Ltd

Dietary supplements and formulations

provided are dietary supplements, formulations, kits and methods for administration to an individual with type ii diabetes or at risk of developing type ii diabetes. Provided herein are formulations, kits and methods useful for treating, preventing, supporting, controlling, restoring, and/or maintaining blood sugar levels in individuals with type ii diabetes or at risk of developing the same.
Eastern Vision Limited

Fasting condition as dietary treatment of diabetes

a method of alleviating symptoms of, or treating, pancreatic beta-cell damage in a subject includes a step of identifying a subject having pancreatic beta-cell damage. Multiple cycles of a diet protocol are administered to the subject.
University Of Southern California

Nutritional compositions with phospholipids

the present invention relates to a nutritional composition such as an infant formula comprising phospholipids in an amount of at least 300 mg/l. Bioactive compounds may preferably be added to the nutritional composition.
Nestec S.a.